CA2605295A1 - 6-11 bridged oxime erythromycin derivatives - Google Patents
6-11 bridged oxime erythromycin derivatives Download PDFInfo
- Publication number
- CA2605295A1 CA2605295A1 CA002605295A CA2605295A CA2605295A1 CA 2605295 A1 CA2605295 A1 CA 2605295A1 CA 002605295 A CA002605295 A CA 002605295A CA 2605295 A CA2605295 A CA 2605295A CA 2605295 A1 CA2605295 A1 CA 2605295A1
- Authority
- CA
- Canada
- Prior art keywords
- substituted
- group
- unsubstituted
- compound
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- -1 oxime erythromycin derivatives Chemical class 0.000 title claims description 72
- 150000001875 compounds Chemical class 0.000 claims abstract description 166
- 238000000034 method Methods 0.000 claims abstract description 39
- 239000000651 prodrug Substances 0.000 claims abstract description 28
- 229940002612 prodrug Drugs 0.000 claims abstract description 28
- 150000003839 salts Chemical class 0.000 claims abstract description 16
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 14
- 238000011282 treatment Methods 0.000 claims abstract description 14
- 208000035143 Bacterial infection Diseases 0.000 claims abstract description 11
- 208000022362 bacterial infectious disease Diseases 0.000 claims abstract description 11
- 150000002148 esters Chemical class 0.000 claims abstract description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 26
- 239000001257 hydrogen Substances 0.000 claims description 24
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 23
- 125000001072 heteroaryl group Chemical group 0.000 claims description 21
- 229920006395 saturated elastomer Polymers 0.000 claims description 21
- 125000003118 aryl group Chemical group 0.000 claims description 19
- 125000001931 aliphatic group Chemical group 0.000 claims description 17
- 125000000623 heterocyclic group Chemical group 0.000 claims description 15
- 125000006239 protecting group Chemical group 0.000 claims description 15
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 14
- 201000003883 Cystic fibrosis Diseases 0.000 claims description 12
- 125000002723 alicyclic group Chemical group 0.000 claims description 12
- 125000000217 alkyl group Chemical group 0.000 claims description 12
- 229910052799 carbon Inorganic materials 0.000 claims description 12
- 125000002252 acyl group Chemical group 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- 229910052760 oxygen Inorganic materials 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 8
- 150000002367 halogens Chemical class 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- 108020001305 NR1 subfamily Proteins 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 6
- 101100277337 Arabidopsis thaliana DDM1 gene Proteins 0.000 claims description 6
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical compound [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 claims description 6
- 150000001721 carbon Chemical group 0.000 claims description 6
- 101150113676 chr1 gene Proteins 0.000 claims description 6
- 229910000077 silane Inorganic materials 0.000 claims description 6
- 229910052717 sulfur Inorganic materials 0.000 claims description 6
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 claims description 5
- HCUOEKSZWPGJIM-YBRHCDHNSA-N (e,2e)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N/O)\C(N)=O HCUOEKSZWPGJIM-YBRHCDHNSA-N 0.000 claims description 4
- 101001109689 Homo sapiens Nuclear receptor subfamily 4 group A member 3 Proteins 0.000 claims description 4
- 101000598778 Homo sapiens Protein OSCP1 Proteins 0.000 claims description 4
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 101001067395 Mus musculus Phospholipid scramblase 1 Proteins 0.000 claims description 4
- 102100022673 Nuclear receptor subfamily 4 group A member 3 Human genes 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 3
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims description 2
- 229910052770 Uranium Inorganic materials 0.000 claims description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 2
- 229910052805 deuterium Inorganic materials 0.000 claims description 2
- 101150009274 nhr-1 gene Proteins 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims 8
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 7
- 230000008569 process Effects 0.000 abstract description 6
- 230000003115 biocidal effect Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 description 48
- 208000015181 infectious disease Diseases 0.000 description 47
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 40
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 39
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 30
- 239000000243 solution Substances 0.000 description 24
- 239000002904 solvent Substances 0.000 description 20
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 19
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 18
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 17
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 17
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 15
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
- 238000006243 chemical reaction Methods 0.000 description 14
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- 239000003120 macrolide antibiotic agent Substances 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- 238000002360 preparation method Methods 0.000 description 10
- 239000007787 solid Substances 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 241000251468 Actinopterygii Species 0.000 description 9
- 241000283690 Bos taurus Species 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 9
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 9
- 239000012267 brine Substances 0.000 description 9
- 125000004432 carbon atom Chemical group C* 0.000 description 9
- 239000003795 chemical substances by application Substances 0.000 description 9
- 230000000694 effects Effects 0.000 description 9
- 239000000546 pharmaceutical excipient Substances 0.000 description 9
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 9
- 208000024891 symptom Diseases 0.000 description 9
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 8
- 239000007832 Na2SO4 Substances 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 239000002253 acid Substances 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- 125000004400 (C1-C12) alkyl group Chemical group 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 101150041968 CDC13 gene Proteins 0.000 description 6
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 6
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 6
- 125000004429 atom Chemical group 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 208000035475 disorder Diseases 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 229940041033 macrolides Drugs 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 150000002923 oximes Chemical class 0.000 description 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 5
- 229910019142 PO4 Inorganic materials 0.000 description 5
- 150000007513 acids Chemical class 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 5
- 239000002552 dosage form Substances 0.000 description 5
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 5
- 235000021317 phosphate Nutrition 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 5
- 230000002685 pulmonary effect Effects 0.000 description 5
- 238000000746 purification Methods 0.000 description 5
- 125000006413 ring segment Chemical group 0.000 description 5
- 239000000725 suspension Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 4
- GQHTUMJGOHRCHB-UHFFFAOYSA-N 2,3,4,6,7,8,9,10-octahydropyrimido[1,2-a]azepine Chemical compound C1CCCCN2CCCN=C21 GQHTUMJGOHRCHB-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 241000588724 Escherichia coli Species 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 241000193996 Streptococcus pyogenes Species 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 4
- 235000010443 alginic acid Nutrition 0.000 description 4
- 229920000615 alginic acid Polymers 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 239000000010 aprotic solvent Substances 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- XMIIGOLPHOKFCH-UHFFFAOYSA-N beta-phenylpropanoic acid Natural products OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000011203 carbon fibre reinforced carbon Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 235000019698 starch Nutrition 0.000 description 4
- 239000000454 talc Substances 0.000 description 4
- 235000012222 talc Nutrition 0.000 description 4
- 229910052623 talc Inorganic materials 0.000 description 4
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 4
- 239000001993 wax Substances 0.000 description 4
- 125000006710 (C2-C12) alkenyl group Chemical group 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 3
- OISVCGZHLKNMSJ-UHFFFAOYSA-N 2,6-dimethylpyridine Chemical compound CC1=CC=CC(C)=N1 OISVCGZHLKNMSJ-UHFFFAOYSA-N 0.000 description 3
- OZAIFHULBGXAKX-UHFFFAOYSA-N 2-(2-cyanopropan-2-yldiazenyl)-2-methylpropanenitrile Chemical compound N#CC(C)(C)N=NC(C)(C)C#N OZAIFHULBGXAKX-UHFFFAOYSA-N 0.000 description 3
- 229960000549 4-dimethylaminophenol Drugs 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- 241000193403 Clostridium Species 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 241000606768 Haemophilus influenzae Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 241000606856 Pasteurella multocida Species 0.000 description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 150000001408 amides Chemical class 0.000 description 3
- 150000001412 amines Chemical class 0.000 description 3
- 229940024606 amino acid Drugs 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 125000000539 amino acid group Chemical group 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 239000004599 antimicrobial Substances 0.000 description 3
- 125000003710 aryl alkyl group Chemical group 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 125000004122 cyclic group Chemical group 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000029142 excretion Effects 0.000 description 3
- 239000000945 filler Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 150000002430 hydrocarbons Chemical group 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 239000003835 ketolide antibiotic agent Substances 0.000 description 3
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 3
- 235000019341 magnesium sulphate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 3
- 239000010452 phosphate Substances 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 239000011541 reaction mixture Substances 0.000 description 3
- 230000035484 reaction time Effects 0.000 description 3
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 3
- 235000012239 silicon dioxide Nutrition 0.000 description 3
- 239000000377 silicon dioxide Substances 0.000 description 3
- 206010040872 skin infection Diseases 0.000 description 3
- 229910000104 sodium hydride Inorganic materials 0.000 description 3
- 239000007909 solid dosage form Substances 0.000 description 3
- 239000008247 solid mixture Substances 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 3
- 229910052720 vanadium Inorganic materials 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- MQVISALTZUNQSK-UHFFFAOYSA-N 2-pyridin-2-ylacetic acid;hydrochloride Chemical compound Cl.OC(=O)CC1=CC=CC=N1 MQVISALTZUNQSK-UHFFFAOYSA-N 0.000 description 2
- 229920001817 Agar Polymers 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000416162 Astragalus gummifer Species 0.000 description 2
- 241000271566 Aves Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 241001148536 Bacteroides sp. Species 0.000 description 2
- 206010006474 Bronchopulmonary aspergillosis allergic Diseases 0.000 description 2
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 description 2
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- 241001647372 Chlamydia pneumoniae Species 0.000 description 2
- 241000606153 Chlamydia trachomatis Species 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010065152 Coagulase Proteins 0.000 description 2
- 241000186216 Corynebacterium Species 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 2
- 241000194033 Enterococcus Species 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 239000007821 HATU Substances 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- 241001502334 Mycobacterium avium complex bacterium Species 0.000 description 2
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 2
- LFTLOKWAGJYHHR-UHFFFAOYSA-N N-methylmorpholine N-oxide Chemical compound CN1(=O)CCOCC1 LFTLOKWAGJYHHR-UHFFFAOYSA-N 0.000 description 2
- 229910002651 NO3 Inorganic materials 0.000 description 2
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- 241000191992 Peptostreptococcus Species 0.000 description 2
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 206010039705 Scleritis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 206010062255 Soft tissue infection Diseases 0.000 description 2
- 241000191967 Staphylococcus aureus Species 0.000 description 2
- 241000191963 Staphylococcus epidermidis Species 0.000 description 2
- 241000193985 Streptococcus agalactiae Species 0.000 description 2
- 241000193998 Streptococcus pneumoniae Species 0.000 description 2
- 241001312524 Streptococcus viridans Species 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 125000004423 acyloxy group Chemical group 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 235000010419 agar Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 125000000304 alkynyl group Chemical group 0.000 description 2
- 208000006778 allergic bronchopulmonary aspergillosis Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 238000011203 antimicrobial therapy Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 235000012216 bentonite Nutrition 0.000 description 2
- SESFRYSPDFLNCH-UHFFFAOYSA-N benzyl benzoate Chemical compound C=1C=CC=CC=1C(=O)OCC1=CC=CC=C1 SESFRYSPDFLNCH-UHFFFAOYSA-N 0.000 description 2
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
- 125000002619 bicyclic group Chemical group 0.000 description 2
- 229920002988 biodegradable polymer Polymers 0.000 description 2
- 239000004621 biodegradable polymer Substances 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000006172 buffering agent Substances 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical group 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940110456 cocoa butter Drugs 0.000 description 2
- 235000019868 cocoa butter Nutrition 0.000 description 2
- 235000012343 cottonseed oil Nutrition 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 2
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 2
- 229940043264 dodecyl sulfate Drugs 0.000 description 2
- 238000012377 drug delivery Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 125000004185 ester group Chemical group 0.000 description 2
- MMXKVMNBHPAILY-UHFFFAOYSA-N ethyl laurate Chemical compound CCCCCCCCCCCC(=O)OCC MMXKVMNBHPAILY-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940047650 haemophilus influenzae Drugs 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 125000004446 heteroarylalkyl group Chemical group 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 2
- 150000002443 hydroxylamines Chemical class 0.000 description 2
- 239000003701 inert diluent Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007972 injectable composition Substances 0.000 description 2
- 239000002054 inoculum Substances 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 230000007794 irritation Effects 0.000 description 2
- 239000012948 isocyanate Substances 0.000 description 2
- 150000002576 ketones Chemical class 0.000 description 2
- 150000002596 lactones Chemical group 0.000 description 2
- 239000008297 liquid dosage form Substances 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 description 2
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 2
- 125000004092 methylthiomethyl group Chemical group [H]C([H])([H])SC([H])([H])* 0.000 description 2
- 239000004530 micro-emulsion Substances 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 125000002950 monocyclic group Chemical group 0.000 description 2
- 239000000346 nonvolatile oil Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 230000003287 optical effect Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 229960004063 propylene glycol Drugs 0.000 description 2
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
- 125000001567 quinoxalinyl group Chemical group N1=C(C=NC2=CC=CC=C12)* 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000012552 review Methods 0.000 description 2
- 239000008159 sesame oil Substances 0.000 description 2
- 235000011803 sesame oil Nutrition 0.000 description 2
- WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229940031000 streptococcus pneumoniae Drugs 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 230000002194 synthesizing effect Effects 0.000 description 2
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 230000000699 topical effect Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 239000000196 tragacanth Substances 0.000 description 2
- 235000010487 tragacanth Nutrition 0.000 description 2
- 229940116362 tragacanth Drugs 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 238000000844 transformation Methods 0.000 description 2
- 238000011269 treatment regimen Methods 0.000 description 2
- DBGVGMSCBYYSLD-UHFFFAOYSA-N tributylstannane Chemical compound CCCC[SnH](CCCC)CCCC DBGVGMSCBYYSLD-UHFFFAOYSA-N 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 208000019206 urinary tract infection Diseases 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- LSPHULWDVZXLIL-UHFFFAOYSA-N (+/-)-Camphoric acid Chemical compound CC1(C)C(C(O)=O)CCC1(C)C(O)=O LSPHULWDVZXLIL-UHFFFAOYSA-N 0.000 description 1
- OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- 125000006711 (C2-C12) alkynyl group Chemical group 0.000 description 1
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- UKAUYVFTDYCKQA-UHFFFAOYSA-N -2-Amino-4-hydroxybutanoic acid Natural products OC(=O)C(N)CCO UKAUYVFTDYCKQA-UHFFFAOYSA-N 0.000 description 1
- 125000006033 1,1-dimethyl-2-propenyl group Chemical group 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical group C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 125000004972 1-butynyl group Chemical group [H]C([H])([H])C([H])([H])C#C* 0.000 description 1
- 125000000530 1-propynyl group Chemical group [H]C([H])([H])C#C* 0.000 description 1
- 125000000453 2,2,2-trichloroethyl group Chemical group [H]C([H])(*)C(Cl)(Cl)Cl 0.000 description 1
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 1
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 1
- ZMXYNJXDULEQCK-UHFFFAOYSA-N 2-amino-p-cresol Chemical compound CC1=CC=C(O)C(N)=C1 ZMXYNJXDULEQCK-UHFFFAOYSA-N 0.000 description 1
- RVHOBHMAPRVOLO-UHFFFAOYSA-N 2-ethylbutanedioic acid Chemical class CCC(C(O)=O)CC(O)=O RVHOBHMAPRVOLO-UHFFFAOYSA-N 0.000 description 1
- CFMZSMGAMPBRBE-UHFFFAOYSA-N 2-hydroxyisoindole-1,3-dione Chemical compound C1=CC=C2C(=O)N(O)C(=O)C2=C1 CFMZSMGAMPBRBE-UHFFFAOYSA-N 0.000 description 1
- XWKFPIODWVPXLX-UHFFFAOYSA-N 2-methyl-5-methylpyridine Natural products CC1=CC=C(C)N=C1 XWKFPIODWVPXLX-UHFFFAOYSA-N 0.000 description 1
- 229940080296 2-naphthalenesulfonate Drugs 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- BRMWTNUJHUMWMS-UHFFFAOYSA-N 3-Methylhistidine Natural products CN1C=NC(CC(N)C(O)=O)=C1 BRMWTNUJHUMWMS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- UOQHWNPVNXSDDO-UHFFFAOYSA-N 3-bromoimidazo[1,2-a]pyridine-6-carbonitrile Chemical compound C1=CC(C#N)=CN2C(Br)=CN=C21 UOQHWNPVNXSDDO-UHFFFAOYSA-N 0.000 description 1
- ZRPLANDPDWYOMZ-UHFFFAOYSA-N 3-cyclopentylpropionic acid Chemical compound OC(=O)CCC1CCCC1 ZRPLANDPDWYOMZ-UHFFFAOYSA-N 0.000 description 1
- XMIIGOLPHOKFCH-UHFFFAOYSA-M 3-phenylpropionate Chemical compound [O-]C(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-M 0.000 description 1
- BCJVBDBJSMFBRW-UHFFFAOYSA-N 4-diphenylphosphanylbutyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(C=1C=CC=CC=1)CCCCP(C=1C=CC=CC=1)C1=CC=CC=C1 BCJVBDBJSMFBRW-UHFFFAOYSA-N 0.000 description 1
- MBVFRSJFKMJRHA-UHFFFAOYSA-N 4-fluoro-1-benzofuran-7-carbaldehyde Chemical compound FC1=CC=C(C=O)C2=C1C=CO2 MBVFRSJFKMJRHA-UHFFFAOYSA-N 0.000 description 1
- GFBVUFQNHLUCPX-UHFFFAOYSA-N 5-bromothiophene-2-carbaldehyde Chemical compound BrC1=CC=C(C=O)S1 GFBVUFQNHLUCPX-UHFFFAOYSA-N 0.000 description 1
- BKLJUYPLUWUEOQ-UHFFFAOYSA-N 6-bromopyridin-2-amine Chemical compound NC1=CC=CC(Br)=N1 BKLJUYPLUWUEOQ-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- OZAIFHULBGXAKX-VAWYXSNFSA-N AIBN Substances N#CC(C)(C)\N=N\C(C)(C)C#N OZAIFHULBGXAKX-VAWYXSNFSA-N 0.000 description 1
- 241000606750 Actinobacillus Species 0.000 description 1
- 241000606748 Actinobacillus pleuropneumoniae Species 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 241000588986 Alcaligenes Species 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 235000003276 Apios tuberosa Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000010744 Arachis villosulicarpa Nutrition 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 244000075850 Avena orientalis Species 0.000 description 1
- 235000007319 Avena orientalis Nutrition 0.000 description 1
- 241000223836 Babesia Species 0.000 description 1
- 241001518086 Bartonella henselae Species 0.000 description 1
- 239000004342 Benzoyl peroxide Substances 0.000 description 1
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 241000588807 Bordetella Species 0.000 description 1
- 241000588832 Bordetella pertussis Species 0.000 description 1
- 241000180135 Borrelia recurrentis Species 0.000 description 1
- 241000589969 Borreliella burgdorferi Species 0.000 description 1
- 241001148534 Brachyspira Species 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 description 1
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Natural products CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000589876 Campylobacter Species 0.000 description 1
- 241000589875 Campylobacter jejuni Species 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000193468 Clostridium perfringens Species 0.000 description 1
- 241000224483 Coccidia Species 0.000 description 1
- 229940126062 Compound A Drugs 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 description 1
- 208000031973 Conjunctivitis infective Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 208000008953 Cryptosporidiosis Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- 241000605721 Dichelobacter nodosus Species 0.000 description 1
- SNRUBQQJIBEYMU-UHFFFAOYSA-N Dodecane Natural products CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 206010015084 Episcleritis Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000186811 Erysipelothrix Species 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- 241000186394 Eubacterium Species 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010016952 Food poisoning Diseases 0.000 description 1
- 208000019331 Foodborne disease Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 241000605909 Fusobacterium Species 0.000 description 1
- 241000605952 Fusobacterium necrophorum Species 0.000 description 1
- 201000000628 Gas Gangrene Diseases 0.000 description 1
- 208000005577 Gastroenteritis Diseases 0.000 description 1
- 241000206672 Gelidium Species 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Polymers OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 1
- NLDMNSXOCDLTTB-UHFFFAOYSA-N Heterophylliin A Natural products O1C2COC(=O)C3=CC(O)=C(O)C(O)=C3C3=C(O)C(O)=C(O)C=C3C(=O)OC2C(OC(=O)C=2C=C(O)C(O)=C(O)C=2)C(O)C1OC(=O)C1=CC(O)=C(O)C(O)=C1 NLDMNSXOCDLTTB-UHFFFAOYSA-N 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- LCWXJXMHJVIJFK-UHFFFAOYSA-N Hydroxylysine Natural products NCC(O)CC(N)CC(O)=O LCWXJXMHJVIJFK-UHFFFAOYSA-N 0.000 description 1
- PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- RHGKLRLOHDJJDR-BYPYZUCNSA-N L-citrulline Chemical compound NC(=O)NCCC[C@H]([NH3+])C([O-])=O RHGKLRLOHDJJDR-BYPYZUCNSA-N 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- UKAUYVFTDYCKQA-VKHMYHEASA-N L-homoserine Chemical compound OC(=O)[C@@H](N)CCO UKAUYVFTDYCKQA-VKHMYHEASA-N 0.000 description 1
- UCUNFLYVYCGDHP-BYPYZUCNSA-N L-methionine sulfone Chemical compound CS(=O)(=O)CC[C@H](N)C(O)=O UCUNFLYVYCGDHP-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001148567 Lawsonia intracellularis Species 0.000 description 1
- 241000589242 Legionella pneumophila Species 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000016604 Lyme disease Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 241001293418 Mannheimia haemolytica Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000010315 Mastoiditis Diseases 0.000 description 1
- 241000588622 Moraxella bovis Species 0.000 description 1
- 241000588655 Moraxella catarrhalis Species 0.000 description 1
- 241000186367 Mycobacterium avium Species 0.000 description 1
- 241000186364 Mycobacterium intracellulare Species 0.000 description 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 241001138504 Mycoplasma bovis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- JDHILDINMRGULE-LURJTMIESA-N N(pros)-methyl-L-histidine Chemical compound CN1C=NC=C1C[C@H](N)C(O)=O JDHILDINMRGULE-LURJTMIESA-N 0.000 description 1
- FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical class CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- RHGKLRLOHDJJDR-UHFFFAOYSA-N Ndelta-carbamoyl-DL-ornithine Natural products OC(=O)C(N)CCCNC(N)=O RHGKLRLOHDJJDR-UHFFFAOYSA-N 0.000 description 1
- 101100030361 Neurospora crassa (strain ATCC 24698 / 74-OR23-1A / CBS 708.71 / DSM 1257 / FGSC 987) pph-3 gene Proteins 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 101800001775 Nuclear inclusion protein A Proteins 0.000 description 1
- 240000007817 Olea europaea Species 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
- UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
- 206010031252 Osteomyelitis Diseases 0.000 description 1
- 206010033078 Otitis media Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N Pd(PPh3)4 Substances [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- LGRFSURHDFAFJT-UHFFFAOYSA-N Phthalic anhydride Natural products C1=CC=C2C(=O)OC(=O)C2=C1 LGRFSURHDFAFJT-UHFFFAOYSA-N 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- 241000233870 Pneumocystis Species 0.000 description 1
- 239000004952 Polyamide Substances 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000605861 Prevotella Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-N Propionic acid Chemical class CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 206010037294 Puerperal pyrexia Diseases 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 241000316848 Rhodococcus <scale insect> Species 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 235000019485 Safflower oil Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 206010040070 Septic Shock Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000191980 Staphylococcus intermedius Species 0.000 description 1
- 241001147691 Staphylococcus saprophyticus Species 0.000 description 1
- SSZBUIDZHHWXNJ-UHFFFAOYSA-N Stearinsaeure-hexadecylester Natural products CCCCCCCCCCCCCCCCCC(=O)OCCCCCCCCCCCCCCCC SSZBUIDZHHWXNJ-UHFFFAOYSA-N 0.000 description 1
- 241000862969 Stella Species 0.000 description 1
- 241000194042 Streptococcus dysgalactiae Species 0.000 description 1
- 241000194054 Streptococcus uberis Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000000491 Tendinopathy Diseases 0.000 description 1
- 206010043255 Tendonitis Diseases 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-M Thiocyanate anion Chemical compound [S-]C#N ZMZDMBWJUHKJPS-UHFFFAOYSA-M 0.000 description 1
- 206010044248 Toxic shock syndrome Diseases 0.000 description 1
- 231100000650 Toxic shock syndrome Toxicity 0.000 description 1
- 241000223996 Toxoplasma Species 0.000 description 1
- 241000589884 Treponema pallidum Species 0.000 description 1
- 241000224526 Trichomonas Species 0.000 description 1
- 241000223104 Trypanosoma Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 241000202921 Ureaplasma urealyticum Species 0.000 description 1
- 208000006374 Uterine Cervicitis Diseases 0.000 description 1
- 206010046793 Uterine inflammation Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 241000606834 [Haemophilus] ducreyi Species 0.000 description 1
- SORGEQQSQGNZFI-UHFFFAOYSA-N [azido(phenoxy)phosphoryl]oxybenzene Chemical compound C=1C=CC=CC=1OP(=O)(N=[N+]=[N-])OC1=CC=CC=C1 SORGEQQSQGNZFI-UHFFFAOYSA-N 0.000 description 1
- 206010000210 abortion Diseases 0.000 description 1
- 231100000176 abortion Toxicity 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 239000002250 absorbent Substances 0.000 description 1
- 230000002745 absorbent Effects 0.000 description 1
- 239000003655 absorption accelerator Substances 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000001252 acrylic acid derivatives Chemical class 0.000 description 1
- 201000001028 acute contagious conjunctivitis Diseases 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 238000012382 advanced drug delivery Methods 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 150000007933 aliphatic carboxylic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 125000003282 alkyl amino group Chemical group 0.000 description 1
- 208000002205 allergic conjunctivitis Diseases 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 239000012080 ambient air Substances 0.000 description 1
- 125000003368 amide group Chemical group 0.000 description 1
- 125000002344 aminooxy group Chemical group [H]N([H])O[*] 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 150000008378 aryl ethers Chemical class 0.000 description 1
- 125000005228 aryl sulfonate group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000024998 atopic conjunctivitis Diseases 0.000 description 1
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 1
- MQTOSJVFKKJCRP-BICOPXKESA-N azithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)N(C)C[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 MQTOSJVFKKJCRP-BICOPXKESA-N 0.000 description 1
- 229960004099 azithromycin Drugs 0.000 description 1
- 201000008680 babesiosis Diseases 0.000 description 1
- 229940092524 bartonella henselae Drugs 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 229940050390 benzoate Drugs 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000005872 benzooxazolyl group Chemical group 0.000 description 1
- 235000019400 benzoyl peroxide Nutrition 0.000 description 1
- 229960002903 benzyl benzoate Drugs 0.000 description 1
- 229940000635 beta-alanine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 150000004648 butanoic acid derivatives Chemical class 0.000 description 1
- 125000004369 butenyl group Chemical group C(=CCC)* 0.000 description 1
- JHIWVOJDXOSYLW-UHFFFAOYSA-N butyl 2,2-difluorocyclopropane-1-carboxylate Chemical compound CCCCOC(=O)C1CC1(F)F JHIWVOJDXOSYLW-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- WXMZPPIDLJRXNK-UHFFFAOYSA-N butyl(diphenyl)phosphane Chemical compound C=1C=CC=CC=1P(CCCC)C1=CC=CC=C1 WXMZPPIDLJRXNK-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- FATUQANACHZLRT-KMRXSBRUSA-L calcium glucoheptonate Chemical compound [Ca+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)C([O-])=O FATUQANACHZLRT-KMRXSBRUSA-L 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 150000001715 carbamic acids Chemical class 0.000 description 1
- 150000004653 carbonic acids Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000003857 carboxamides Chemical class 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 125000002843 carboxylic acid group Chemical group 0.000 description 1
- 150000001735 carboxylic acids Chemical class 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 239000003054 catalyst Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 206010008323 cervicitis Diseases 0.000 description 1
- 229960000541 cetyl alcohol Drugs 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 229940038705 chlamydia trachomatis Drugs 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 125000002668 chloroacetyl group Chemical group ClCC(=O)* 0.000 description 1
- 150000005827 chlorofluoro hydrocarbons Chemical class 0.000 description 1
- 229960002173 citrulline Drugs 0.000 description 1
- 235000013477 citrulline Nutrition 0.000 description 1
- 229960002626 clarithromycin Drugs 0.000 description 1
- AGOYDEPGAOXOCK-KCBOHYOISA-N clarithromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@](C)([C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)OC)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 AGOYDEPGAOXOCK-KCBOHYOISA-N 0.000 description 1
- 239000004927 clay Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000002385 cottonseed oil Substances 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 125000002704 decyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- YSMODUONRAFBET-UHFFFAOYSA-N delta-DL-hydroxylysine Natural products NCC(O)CCC(N)C(O)=O YSMODUONRAFBET-UHFFFAOYSA-N 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- WMKGGPCROCCUDY-PHEQNACWSA-N dibenzylideneacetone Chemical compound C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 WMKGGPCROCCUDY-PHEQNACWSA-N 0.000 description 1
- 150000001993 dienes Chemical class 0.000 description 1
- 238000003113 dilution method Methods 0.000 description 1
- PHBAAFDKJNNRNJ-UHFFFAOYSA-N dimethoxymethoxy(dimethoxy)methane Chemical compound COC(OC)OC(OC)OC PHBAAFDKJNNRNJ-UHFFFAOYSA-N 0.000 description 1
- MKRTXPORKIRPDG-UHFFFAOYSA-N diphenylphosphoryl azide Chemical compound C=1C=CC=CC=1P(=O)(N=[N+]=[N-])C1=CC=CC=C1 MKRTXPORKIRPDG-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
- POULHZVOKOAJMA-UHFFFAOYSA-M dodecanoate Chemical compound CCCCCCCCCCCC([O-])=O POULHZVOKOAJMA-UHFFFAOYSA-M 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- YSMODUONRAFBET-UHNVWZDZSA-N erythro-5-hydroxy-L-lysine Chemical compound NC[C@H](O)CC[C@H](N)C(O)=O YSMODUONRAFBET-UHNVWZDZSA-N 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- 229940093499 ethyl acetate Drugs 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003885 eye ointment Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 208000010801 foot rot Diseases 0.000 description 1
- 150000004675 formic acid derivatives Chemical class 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- YQEMORVAKMFKLG-UHFFFAOYSA-N glycerine monostearate Natural products CCCCCCCCCCCCCCCCCC(=O)OC(CO)CO YQEMORVAKMFKLG-UHFFFAOYSA-N 0.000 description 1
- SVUQHVRAGMNPLW-UHFFFAOYSA-N glycerol monostearate Natural products CCCCCCCCCCCCCCCCC(=O)OCC(O)CO SVUQHVRAGMNPLW-UHFFFAOYSA-N 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- MNWFXJYAOYHMED-UHFFFAOYSA-N heptanoic acid Chemical compound CCCCCCC(O)=O MNWFXJYAOYHMED-UHFFFAOYSA-N 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000003906 humectant Substances 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- ZMZDMBWJUHKJPS-UHFFFAOYSA-N hydrogen thiocyanate Natural products SC#N ZMZDMBWJUHKJPS-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- QJHBJHUKURJDLG-UHFFFAOYSA-N hydroxy-L-lysine Natural products NCCCCC(NO)C(O)=O QJHBJHUKURJDLG-UHFFFAOYSA-N 0.000 description 1
- 229960002591 hydroxyproline Drugs 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000002636 imidazolinyl group Chemical group 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 229940102213 injectable suspension Drugs 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000007919 intrasynovial administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 125000004628 isothiazolidinyl group Chemical group S1N(CCC1)* 0.000 description 1
- 125000003965 isoxazolidinyl group Chemical group 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 229940099584 lactobionate Drugs 0.000 description 1
- JYTUSYBCFIZPBE-AMTLMPIISA-N lactobionic acid Chemical compound OC(=O)[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O JYTUSYBCFIZPBE-AMTLMPIISA-N 0.000 description 1
- 229940099563 lactobionic acid Drugs 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 229940070765 laurate Drugs 0.000 description 1
- 229940115932 legionella pneumophila Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 239000006194 liquid suspension Substances 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 208000004396 mastitis Diseases 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 229940013390 mycoplasma pneumoniae Drugs 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
- OWIUPIRUAQMTTK-UHFFFAOYSA-M n-aminocarbamate Chemical compound NNC([O-])=O OWIUPIRUAQMTTK-UHFFFAOYSA-M 0.000 description 1
- 125000001298 n-hexoxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- KVBGVZZKJNLNJU-UHFFFAOYSA-M naphthalene-2-sulfonate Chemical compound C1=CC=CC2=CC(S(=O)(=O)[O-])=CC=C21 KVBGVZZKJNLNJU-UHFFFAOYSA-M 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 1
- 231100000344 non-irritating Toxicity 0.000 description 1
- 125000001400 nonyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000012044 organic layer Substances 0.000 description 1
- 229960003104 ornithine Drugs 0.000 description 1
- 125000001715 oxadiazolyl group Chemical group 0.000 description 1
- 125000000160 oxazolidinyl group Chemical group 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004043 oxo group Chemical group O=* 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 238000005192 partition Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L peroxydisulfate Chemical compound [O-]S(=O)(=O)OOS([O-])(=O)=O JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 125000005541 phosphonamide group Chemical group 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- OJMIONKXNSYLSR-UHFFFAOYSA-N phosphorous acid Chemical class OP(O)O OJMIONKXNSYLSR-UHFFFAOYSA-N 0.000 description 1
- 229910000073 phosphorus hydride Inorganic materials 0.000 description 1
- 229940075930 picrate Drugs 0.000 description 1
- OXNIZHLAWKMVMX-UHFFFAOYSA-M picrate anion Chemical compound [O-]C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O OXNIZHLAWKMVMX-UHFFFAOYSA-M 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- 125000003386 piperidinyl group Chemical group 0.000 description 1
- 229950010765 pivalate Drugs 0.000 description 1
- IUGYQRQAERSCNH-UHFFFAOYSA-N pivalic acid Chemical compound CC(C)(C)C(O)=O IUGYQRQAERSCNH-UHFFFAOYSA-N 0.000 description 1
- 201000000317 pneumocystosis Diseases 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920002647 polyamide Polymers 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 229920001184 polypeptide Chemical group 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- IUBQJLUDMLPAGT-UHFFFAOYSA-N potassium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([K])[Si](C)(C)C IUBQJLUDMLPAGT-UHFFFAOYSA-N 0.000 description 1
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 description 1
- 229910000105 potassium hydride Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 108090000765 processed proteins & peptides Chemical group 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 206010036784 proctocolitis Diseases 0.000 description 1
- 208000017048 proctosigmoiditis Diseases 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 125000004368 propenyl group Chemical group C(=CC)* 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 229940055019 propionibacterium acne Drugs 0.000 description 1
- 125000006308 propyl amino group Chemical group 0.000 description 1
- 239000003586 protic polar solvent Substances 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003072 pyrazolidinyl group Chemical group 0.000 description 1
- 125000002755 pyrazolinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 description 1
- 125000006513 pyridinyl methyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 125000001453 quaternary ammonium group Chemical group 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 210000000664 rectum Anatomy 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 239000003340 retarding agent Substances 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 235000005713 safflower oil Nutrition 0.000 description 1
- 239000003813 safflower oil Substances 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 150000004760 silicates Chemical class 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000005017 substituted alkenyl group Chemical group 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000004426 substituted alkynyl group Chemical group 0.000 description 1
- 125000003107 substituted aryl group Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 229940014800 succinic anhydride Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 150000003460 sulfonic acids Chemical class 0.000 description 1
- 239000011593 sulfur Chemical group 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 201000004415 tendinitis Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000001113 thiadiazolyl group Chemical group 0.000 description 1
- AYEKOFBPNLCAJY-UHFFFAOYSA-O thiamine pyrophosphate Chemical compound CC1=C(CCOP(O)(=O)OP(O)(O)=O)SC=[N+]1CC1=CN=C(C)N=C1N AYEKOFBPNLCAJY-UHFFFAOYSA-O 0.000 description 1
- 125000001984 thiazolidinyl group Chemical group 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 125000006168 tricyclic group Chemical group 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 1
- 125000002948 undecyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical class CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
- 235000014692 zinc oxide Nutrition 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
- C07H17/08—Hetero rings containing eight or more ring members, e.g. erythromycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Genetics & Genomics (AREA)
- Pain & Pain Management (AREA)
- Ophthalmology & Optometry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
The present invention discloses compounds of formula I, or pharmaceutically acceptable salts, esters, or prodrugs thereof (see formula I) which exhibit antibacterial properties. The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject in need of antibiotic treatment. The invention also relates to methods of treating a bacterial infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention. The invention further includes processes by which to make the compounds of the present invention.
Description
6-11 Bridged Oxime Erythromycin Derivatives RELATED APPLICATIONS
This application claims the benefit of U.S. Application No. 11/122,251, filed on May 4, 2005 and U.S. Provisional Application No. 60/677,675, filed on May 4, 2005. The entire teachings of the above application(s) are incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to novel semisynthetic macrolides having antibacterial activity and useful in the treatment and prevention of bacterial infections. More particularly, the invention relates to 6-11 bicyclic macrolide, ketolide, and anhydrolide derivatives, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
BACKGROUND OF THE INVENTION
Macrolide antibiotics play a therapeutically important role, particularly with the emergence of new pathogens. Structural differences are related to the size of the lactone ring and to the number and nature (neutral or basic) of the sugars.
Macrolides are classified according to the size of the lactone ring (12, 14, 15 or 16 atoms). The macrolide antibiotic family (14-, 15- and 16-membered ring derivatives) shows a wide range of characteristics (antibacterial spectrum, side-effects and bioavailability). Among the commonly used macrolides are erythromycin, clarithromycin, and azithromycin. Macrolides possessing a 3-oxo moiety in place of the 3-cladinose sugar are known as ketolides and have shown enhanced activity towards gram-negative bacteria and macrolide resistant gram-positive bacteria. Macrolides possessing a degree of unsaturation between carbons 2 and 3 or between carbons 3 and 4 of the erythromycin macrocycle are known as anhydrolides. The search for macrolide compounds which are active against MLSB-resistant strains (MLSB = Macrolides-Lincosamides-type B Streptogramines) has become a major goal, together with retaining the overall profile of the macrolides in terms of stability, tolerance and pharmacokinetics.
International Application WO 97/42205 of Elliott et al, published November 13, 1997, discloses 3-descladinose-2, 3-anhydroerythromycin derivatives having a cyclic carbamate and cyclic carbazate basic nuciear structure. rurtner aetaiis were also disclosed in J. Med Chein., 41, pp 1651-1659 (1998) and J. Med Chem., 41, pp 1660-1670 (1998) by Elliott et al, and by Griesgraber et al, respectively.
United States Patent 5,444,051 discloses certain 6-0-substituted-3-oxoerythromycin A derivatives. PCT application WO 97/10251, published March 20, 1997, discloses intermediates useful for preparation of 6-0-methyl3-descladinose erythromycin derivatives. United States Patent 5,631,355 discloses certain tricyclic 6-0-methyl3-oxo erythromycin derivatives. United States Patent 5,527,780 discloses certain bicyclic 6-0-methyl-3-oxo erythromycin A
derivatives (Agouridas, ROUSSEL) corresponding to EP application 596802, published May 11, 1994. United States Patents 5,866,549 and 6,075,011, and PCT application WO
00/78773, published December 28, 2000, disclose certain 6-0-substituted erythroinycin derivatives. United States Patent 6,124,269 and PCT application WO
00/62783, published October 26, 2000, disclose certain 2-halo-6-0-substituted ketolide derivatives. United States Patent 6,046,171 and PCT application WO
99/21864, published May 6, 1999, disclose certain 6,11-bridged erythromycin derivatives.
PCT Application WO 03/095466 Al, published November 20, 2003 and PCT Application WO 03/097659 Al, published November 27, 2003 disclose a series of bicyclic erythromycin derivatives.
SUMMARY OF THE INVENTION
The present invention provides a novel class of C6-C 11 bridged oxime erythromycin derivatives which possess antibacterial activity.
In one aspect of the present invention there are provided novel bridged erythromycin compounds represented by the formulae as illustrated below:
A-, 0 Z'X
~ ;,..
O IN 0 p .~' O
W
M-O ,,,,, \\\/
u,wuo o v U
z or their racemates, enantiomers, regioisomers, salts, esters or prodrugs thereof, wherein X and Y are independently selected from the group consisting of: hydrogen, deuterium, halogen, Rl, ORI, S(O)nRj, -NR1C(O)R2, -NRIC(O)NR3R4, -NR1S(O)õR2, -C(O)NR3R4, and -NR3R4;
Each of Rl and R2 is independently selected from the group consisting of:
hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group;
Each of R3 and R4 is independently selected from the group consisting of:
hydrogen, acyl, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted, or unsubstituted heterocyclic group; or can be taken together with the nitrogen atom to which they are attached to form a substituted or unsubstituted heterocyclic or heteroaromatic ring;
or X and Y, taken together with the carbon atom to which they are attached, are selected from the group consisting of: CO, C=CHR1, C=NR1, C=NC(O)Rl, C=NOR1, C=NO(CH2)mRl, C=NNHR1, C=NNHCOR1, C=NNHCONR1R2, C=NNHS(O)nRl, C=N-N=CHR1, C=N-N02, or C=N-ONO;
one of U or V is hydrogen and the other is independently selected from the -0,,,,,", O
G
,O
I
group consisting of: Ri, ORI, OC(O)Rl, OC(O)NR3R4, S(O)õRl, Rt or U and V, talcen together with the carbon atom to which they are attached, are C=O;
one of J or G is hydrogen and the other is selected from: Rl, ORI, or NR3R4;
or, J and G, taken together with the carbon atom to which they are attached, are selected from: C=O, C=NR1, C=NOR1, C=NO(CH2)mRl, C=NNHR1, C=NNHCOR1, C=NNHCONR1R2, C=NNHS(O)õRl, or C=N-N=CHR1;
L is selected from the group consisting of: hydrogen, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group;
M is Rl;
W is NR3R4;
Z is hydrogen, alkyl or halogen;
Rp is hydrogen, hydroxy protecting group or hydroxy prodrug group;
m is an integer; and n is 0, 1, or 2.
A is Zj\ Y
X, P ~ 11 Jv%fv wherein:
Q' is N, CH or CF;
XI is 0, N, NRI, S, or CR5;
Yl is 0, N, NRI, S, CR5, or Se;
Zl is 0, N, NRI, S, or CR5;
R5 is independently selected from hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted heterocyclic group, NR3R4, OH, NHCORI or NHCONH2, and is preferably, NH2 or NHR1.
With the proviso that a compound of Formula I is not selected from compound having the following formula where A, Q, and Z as defined below in the table A.
This application claims the benefit of U.S. Application No. 11/122,251, filed on May 4, 2005 and U.S. Provisional Application No. 60/677,675, filed on May 4, 2005. The entire teachings of the above application(s) are incorporated herein by reference.
TECHNICAL FIELD
The present invention relates to novel semisynthetic macrolides having antibacterial activity and useful in the treatment and prevention of bacterial infections. More particularly, the invention relates to 6-11 bicyclic macrolide, ketolide, and anhydrolide derivatives, compositions containing such compounds and methods for using the same, as well as processes for making such compounds.
BACKGROUND OF THE INVENTION
Macrolide antibiotics play a therapeutically important role, particularly with the emergence of new pathogens. Structural differences are related to the size of the lactone ring and to the number and nature (neutral or basic) of the sugars.
Macrolides are classified according to the size of the lactone ring (12, 14, 15 or 16 atoms). The macrolide antibiotic family (14-, 15- and 16-membered ring derivatives) shows a wide range of characteristics (antibacterial spectrum, side-effects and bioavailability). Among the commonly used macrolides are erythromycin, clarithromycin, and azithromycin. Macrolides possessing a 3-oxo moiety in place of the 3-cladinose sugar are known as ketolides and have shown enhanced activity towards gram-negative bacteria and macrolide resistant gram-positive bacteria. Macrolides possessing a degree of unsaturation between carbons 2 and 3 or between carbons 3 and 4 of the erythromycin macrocycle are known as anhydrolides. The search for macrolide compounds which are active against MLSB-resistant strains (MLSB = Macrolides-Lincosamides-type B Streptogramines) has become a major goal, together with retaining the overall profile of the macrolides in terms of stability, tolerance and pharmacokinetics.
International Application WO 97/42205 of Elliott et al, published November 13, 1997, discloses 3-descladinose-2, 3-anhydroerythromycin derivatives having a cyclic carbamate and cyclic carbazate basic nuciear structure. rurtner aetaiis were also disclosed in J. Med Chein., 41, pp 1651-1659 (1998) and J. Med Chem., 41, pp 1660-1670 (1998) by Elliott et al, and by Griesgraber et al, respectively.
United States Patent 5,444,051 discloses certain 6-0-substituted-3-oxoerythromycin A derivatives. PCT application WO 97/10251, published March 20, 1997, discloses intermediates useful for preparation of 6-0-methyl3-descladinose erythromycin derivatives. United States Patent 5,631,355 discloses certain tricyclic 6-0-methyl3-oxo erythromycin derivatives. United States Patent 5,527,780 discloses certain bicyclic 6-0-methyl-3-oxo erythromycin A
derivatives (Agouridas, ROUSSEL) corresponding to EP application 596802, published May 11, 1994. United States Patents 5,866,549 and 6,075,011, and PCT application WO
00/78773, published December 28, 2000, disclose certain 6-0-substituted erythroinycin derivatives. United States Patent 6,124,269 and PCT application WO
00/62783, published October 26, 2000, disclose certain 2-halo-6-0-substituted ketolide derivatives. United States Patent 6,046,171 and PCT application WO
99/21864, published May 6, 1999, disclose certain 6,11-bridged erythromycin derivatives.
PCT Application WO 03/095466 Al, published November 20, 2003 and PCT Application WO 03/097659 Al, published November 27, 2003 disclose a series of bicyclic erythromycin derivatives.
SUMMARY OF THE INVENTION
The present invention provides a novel class of C6-C 11 bridged oxime erythromycin derivatives which possess antibacterial activity.
In one aspect of the present invention there are provided novel bridged erythromycin compounds represented by the formulae as illustrated below:
A-, 0 Z'X
~ ;,..
O IN 0 p .~' O
W
M-O ,,,,, \\\/
u,wuo o v U
z or their racemates, enantiomers, regioisomers, salts, esters or prodrugs thereof, wherein X and Y are independently selected from the group consisting of: hydrogen, deuterium, halogen, Rl, ORI, S(O)nRj, -NR1C(O)R2, -NRIC(O)NR3R4, -NR1S(O)õR2, -C(O)NR3R4, and -NR3R4;
Each of Rl and R2 is independently selected from the group consisting of:
hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group;
Each of R3 and R4 is independently selected from the group consisting of:
hydrogen, acyl, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted, or unsubstituted heterocyclic group; or can be taken together with the nitrogen atom to which they are attached to form a substituted or unsubstituted heterocyclic or heteroaromatic ring;
or X and Y, taken together with the carbon atom to which they are attached, are selected from the group consisting of: CO, C=CHR1, C=NR1, C=NC(O)Rl, C=NOR1, C=NO(CH2)mRl, C=NNHR1, C=NNHCOR1, C=NNHCONR1R2, C=NNHS(O)nRl, C=N-N=CHR1, C=N-N02, or C=N-ONO;
one of U or V is hydrogen and the other is independently selected from the -0,,,,,", O
G
,O
I
group consisting of: Ri, ORI, OC(O)Rl, OC(O)NR3R4, S(O)õRl, Rt or U and V, talcen together with the carbon atom to which they are attached, are C=O;
one of J or G is hydrogen and the other is selected from: Rl, ORI, or NR3R4;
or, J and G, taken together with the carbon atom to which they are attached, are selected from: C=O, C=NR1, C=NOR1, C=NO(CH2)mRl, C=NNHR1, C=NNHCOR1, C=NNHCONR1R2, C=NNHS(O)õRl, or C=N-N=CHR1;
L is selected from the group consisting of: hydrogen, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group;
M is Rl;
W is NR3R4;
Z is hydrogen, alkyl or halogen;
Rp is hydrogen, hydroxy protecting group or hydroxy prodrug group;
m is an integer; and n is 0, 1, or 2.
A is Zj\ Y
X, P ~ 11 Jv%fv wherein:
Q' is N, CH or CF;
XI is 0, N, NRI, S, or CR5;
Yl is 0, N, NRI, S, CR5, or Se;
Zl is 0, N, NRI, S, or CR5;
R5 is independently selected from hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted heterocyclic group, NR3R4, OH, NHCORI or NHCONH2, and is preferably, NH2 or NHR1.
With the proviso that a compound of Formula I is not selected from compound having the following formula where A, Q, and Z as defined below in the table A.
A--_O Q
O N ON
\
H O HO
õ,nnp0 'o Z
Table A
Compound A Q Z
~JIIL1 =
01 H N NAc H
=
02 NN NAc H
H
03 N~N I/ NH H
H
04 N ~
HZN--~ ~
s ~ NAc H
In one preferred embodiment, A is:
N
wherein XI, and R5 is as defined previously.
O N ON
\
H O HO
õ,nnp0 'o Z
Table A
Compound A Q Z
~JIIL1 =
01 H N NAc H
=
02 NN NAc H
H
03 N~N I/ NH H
H
04 N ~
HZN--~ ~
s ~ NAc H
In one preferred embodiment, A is:
N
wherein XI, and R5 is as defined previously.
In another preferred embodiment, A is:
1~
.nrw wherein Xi is 0, NH or S, and R5 is as defined previously.
In yet another embodiment, A is:
I
N
.n~'u wherein Xi is 0, NH or S, and R5 is as defined previously.
In yet another embodiment, A is:
N
,nnnr wherein R5 is as defined previously.
In yet another embodiment, A is:
p NH2 I
N
,nrvv In one preferred embodiment, A is selected from the compounds shown in Table B.
1~
.nrw wherein Xi is 0, NH or S, and R5 is as defined previously.
In yet another embodiment, A is:
I
N
.n~'u wherein Xi is 0, NH or S, and R5 is as defined previously.
In yet another embodiment, A is:
N
,nnnr wherein R5 is as defined previously.
In yet another embodiment, A is:
p NH2 I
N
,nrvv In one preferred embodiment, A is selected from the compounds shown in Table B.
Table B 12 F
N
Number A- HZN- S\ I
N
<v 13 F
HZN \S\~,~õM
N
02 HzN--/\/ S ~/ 14 H
N
N~
S-N
N H2N V~
03 15 0:0 HZN-N
HzN\ 16 -(N
H
17 N N\
N~ I /
06 p H2N
N~ \ 18 Np HZN
N/ 19 H N~
N
08 HZN~ H2N ~õrv HZN--~~
09 HzN-,N I\ H
~~ /
S 21 N, \
S"N
" D /
HZN-~ ~
\ 22 rNN
'S/ N
11 N~ H
H I ZN O ~
s 23 0 24 ~ ~~ 30 N~
S N
/ 0 25 .N,4110 N N
e ~N ~ 32 N ~
'""~ N ~ ~
=' =
HN-~ /
U N /
HZN--<., N
28 0 ON:j H2N--' O
N N
One preferred compound of the invention has the formula II:
A--_O Q
N
O N 0;~~' HOu,,, HO ~~v' V =,.
O nm0 O
0 o z II
Where in A, Q, and Z are as defined in Table C:
N
Number A- HZN- S\ I
N
<v 13 F
HZN \S\~,~õM
N
02 HzN--/\/ S ~/ 14 H
N
N~
S-N
N H2N V~
03 15 0:0 HZN-N
HzN\ 16 -(N
H
17 N N\
N~ I /
06 p H2N
N~ \ 18 Np HZN
N/ 19 H N~
N
08 HZN~ H2N ~õrv HZN--~~
09 HzN-,N I\ H
~~ /
S 21 N, \
S"N
" D /
HZN-~ ~
\ 22 rNN
'S/ N
11 N~ H
H I ZN O ~
s 23 0 24 ~ ~~ 30 N~
S N
/ 0 25 .N,4110 N N
e ~N ~ 32 N ~
'""~ N ~ ~
=' =
HN-~ /
U N /
HZN--<., N
28 0 ON:j H2N--' O
N N
One preferred compound of the invention has the formula II:
A--_O Q
N
O N 0;~~' HOu,,, HO ~~v' V =,.
O nm0 O
0 o z II
Where in A, Q, and Z are as defined in Table C:
Table C
Number A Q Z
N Dol Ac H
01 g N
HZN--~ ' 02 NAc F
S-N
N x ~
03 NAc H
04 s HZN--{~N NAc H
05 N I ~
NAc H
06 ,~
N ~ NAc H
HZN
N o NAc H
HZN-~
NAc F
09 HZN~S c 0 H
N
HZN--~
NAc H
~
HZN--~~
O H
~
12 N-( / ~
HZNI ~
0 S , NAc H
Number A Q Z
N Dol Ac H
01 g N
HZN--~ ' 02 NAc F
S-N
N x ~
03 NAc H
04 s HZN--{~N NAc H
05 N I ~
NAc H
06 ,~
N ~ NAc H
HZN
N o NAc H
HZN-~
NAc F
09 HZN~S c 0 H
N
HZN--~
NAc H
~
HZN--~~
O H
~
12 N-( / ~
HZNI ~
0 S , NAc H
HZN4S~ I NAc H
~
14 N H N ~~
HzN~ ~S ~
o , 0 H
H N--~ 0 H
z S
H
N
N~ NAc H
~~~~
17 ~
HZN--~ ~
j N NAc H
18 o HZN--~ ~
N ~ 0 H
AH~s ~ I NAc H
N~
N;Xi NAc H
HZN
21 N~
NAc F
HZN
'22 H
c F
N NA
A., ~~~~
H2N_<
N
H NAc H
H2N-<
25 N, ~-SeN /
NAc H
26 r "
C
s H NAc H
i N NAc H
i N I O H
29 ~
's " NAc H
30 clNmN
" NAc H
31 ~
i (/
j " NAc H
32 HN-~ ~ /
//-j " NAc H
N =
,N NAc H
HZN4N ~ N NAc H
35 ~
~N~ I /
"~ NAc H
36 N ~
N~N ~ ~ NAc H
N , ,N ~ NAc H
38 HZN-<"N ~ I NC(O)OCH3 H
O /
39 HZN ~ ~ NH H
N
One preferred compound of the invention has the formula III:
O /
H2N--C ~ I
O I' O RP W
IO
HO C\~ 1 / ==, õO 0 O U
z III
wherein Rp, U, V, W, X, Y, L, and Z are as defined previously.
Another preferred compound of the invention has the formula IV:
o /
H-2N/ ~ I O
N-\
HO O~ O , OP,,, N
\~/
O
z IV
wherein Z and Rp are as previously defined.
Yet another preferred compound of the invention has the formula V:
O
HZN-~
R
lP \ N
HO O~~/ V =
,,.õ~~'0 O
\' O
O
z V
wherein Z and Rp are as defined previously.
In another aspect ot the invention, tnere are proviaeu nuvGi j-Q%,yliuv, mlurvu erythromycin compounds represented by the Formula VI:
B~O Y X
~~.
O ORp W
HO ~~~ II / O
p11111 O
O
'/
O
VI
or any racemates, enantiomers, regioisomers, salts, esters, or prodrugs thereof wherein X, Y, L, W, and Rp are as defined previously;
B is independently selected from hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group.
One preferred compound of Formula VI has the formula VII:
P-N / O
S N
H2N , 000 R N
O N P
HO O
O unnl0 0 O
I\'"
O
N
VII
wherein Rp is as previously defined.
DETAILED DESCRIPTION OF THE INVENTION
Definitions Listed below are definitions of various terms used to describe this invention.
These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.
An "aliphatic group" is non-aromatic moiety that may contain any combination of carbon atoms, hydrogen atoms, halogen atoms, oxygen, nitrogen or other atoms, and optionally contain one or more units of unsaturation, e.g., double and/or triple bonds. An aliphatic group may be straight chained, branched or cyclic and preferably contains between about 1 and about 24 carbon atoms, more typically between about 1 and about 12 carbon atoms. In addition to aliphatic hydrocarbon groups, aliphatic groups include, for example, polyalkoxyalkyls, such as polyalkylene glycols, polyamines, and polyimines, for example. Such aliphatic groups may be further substituted.
The terms "Cl-C3 alkyl," "C1-C6 alkyl," or "Cl-C12 alkyl," as used herein, refer to saturated, straight- or branched-chain hydrocarbon radicals containing between one and three, one and twelve, or one and six carbon atoms, respectively.
Examples of C1-C3 alkyl radicals include methyl, ethyl, propyl and isopropyl radicals; examples of C1-C6 alkyl radicals include, but are not limited to, methyl, ethyl, propyl, propyl, butyl, pentyl, and hexyl radicals; and examples of C1-C12 alkyl radicals include, but are not limited to, ethyl, propyl, propyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl radicals and the like.
The term "substituted alkyl," as used herein, refers to an alkyl, such as a C1-C12 alkyl or C1-C6 alkyl group, substituted by one, two, three or more aliphatic or aromatic substituents.
Suitable aliphatic or aromatic substituents include, but are not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, aliphatic ethers, aromatic ethers, oxo, -NO2, -CN, -CI-CIZ-alkyl optionally substituted with halogen (such as perhaloalkyls), C2-C12-alkenyl optionally substituted with halogen, -C2-C12-alkynyl optionally substituted witli halogen, -NH2, protected amino, -NH -C1-C12-alkyl, -NH -C2-alkenyl, -NH -C2-C12-allcynyl, -NH -C3-C12-cycloalkyl, -NH -aryl, -NH -heteroaryl, -NH -heterocycloalkyl, -dialkylamino, -diarylamino, -diheteroarylamino, -O-C1-C12-alkyl, -O-C2-C12-alkenyl, -O-Cz-C12-alkynyl, -O-C3-C12-cycloalkyl, -0-aryl, -0-heteroaryl, -0-heterocycloalkyl, -C(O)- CI-C12-alkyl, -C(O)- C2-C12-alkenyl, -C(O)- C2-C12-alkynyl, -C(O)-C3-C12-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH2, -CONH- C1-C12-alkyl, -CONH- Cz-C12-alkenyl, -CONH- C2-C12-alkynyl, -CONH-C3-C12-cycloalkyl, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -C02- CI-C12-alkyl, -C02- Ca-C12-alkenyl, -C02- C2-C12-alkynyl, -CO2-C3-Clz-cycloalkyl, -C02-aryl, -C02-heteroaryl, -C02-heterocycloalkyl, -OC02- C1-C12-alkyl, -OC02-C2-C12-alkenyl, -OC02- C2-C12-alkynyl, -OCO2-C3-CIZ-cycloalkyl, -OC02-aryl, -OC02-heteroaryl, -OC02-heterocycloalkyl, -OCONH2, -OCONH- C1-C12-alkyl, -OCONH- C2-C12-alkenyl, -OCONH- C2-C12-alkynyl, -OCONH- C3-C12-cycloalkyl, -OCONH- aryl, -OCONH- heteroaryl, -OCONH- heterocycloalkyl, -NHC(O)- C1-C12-a1ky1, -NHC(O)-C2-C12-alkenyl, -NHC(O)-CZ-Cla-alkynyl, -NHC(O)-C3-C12-cycloalkyl, NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO2- C1-C12-alkyl, -NHCO2- C2-C12-alkenyl, -NHCO2- C2-C12-alkynyl, -NHCO2- C3-Cla-cycloalkyl, -NHC02- aryl, -NHCOZ- heteroaryl, -NHCO2- heterocycloalkyl, NHC(O)NH2, NHC(O)NH- C1-C12-alkyl, -NHC(O)NH-C2-C12-alkenyl, -NHC(O)NH-Ca-C12-alkynyl, NHC(O)NH-C3-C12-cycloalkyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NHZ, NHC(S)NH- Cl-C12-alkyl, -NHC(S)NH-C2-C12-alkenyl, -NHC(S)NH-Ca-C12-alkynyl, -NHC(S)NH-C3-C12-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH2, NHC(NH)NH- Cl-C12-alkyl, -NHC(NH)NH-C2-C12-alkenyl, -NHC(NH)NH-C2-C12-alkynyl, -NHC(NH)NH-C3-C1z-cycloalkyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, NHC(NH)-C1-C12-alkyl, -NHC(NH)-C2-C12-alkenyl, NHC(NH)-C2-C12-alkynyl, -NHC(NH)-C3-C12-cycloalkyl, -NHC(NH)-aryl, -NHC(NH)-heteroaryl, -NHC(NH)-heterocycloalkyl, -C(NH)NH-C1-Cla-alkyl, -C(NH)NH-C2-C12-alkenyl, -C(NH)NH-C2-Cla-alkynyl, -C(NH)NH-C3-Cia-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C1-C12-alkyl, - S(O)-C2-C12-alkenyl, - S(O)-C2-C12-alkynyl, - S(O)-C3-C12-cycloalkyl, - S(O)-aryl, -S(O)-heteroaryl, - S(O)-heterocycloalkyl -SOaNHa, -SO2NH- Cl-Cla-alkyl, -SO2NH- C2-C12-alkenyl, -SO2NH- C2-C12-alkynyl, -SO2NH- C3-C12-cycloalkyl, -SO2NH- aryl, -SO2NH- heteroaryl, -SO2NH- heterocycloalkyl, NHSO2-C1-C12-alkyl, -NHSOa-C2-C1z-allcenyl, - NHSOz-Ca-Cla-alkynyl, -NHSO2-C3-C12-cycloalkyl, -NHSOa-aryl, -NHSOa-heteroaryl, -NHSO2-heterocycloallcyl, -CH2NH2, -CHaSOaCH3, -aryl, -arylalleyl, -heteroaryl, -heteroarylallcyl, -heterocycloalkyl, -C3-C1z-cycloalkyl, polyalkoxyalkyl, polyalkoxy, -methoxymethoxy, -methoxyethoxy, -SH, -S-CI-C12-alkyl, -S-C2-CI2-alkenyl, -S-C2-C12-alkynyl, -S-C3-C12-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl. It is understood that the aryls, heteroaryls, alkyls and the like can be further substituted.
The terms "C2-C12 alkenyl" or "C2-C6 alkenyl," as used herein, denote a monovalent group derived from a hydrocarbon moiety containing from two to twelve or two to six carbon atoms having at least one carbon-carbon double bond by the removal of a single hydrogen atom. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, alkadienes and the like.
The term "substituted alkenyl," as used herein, refers to a"C2-C12 alkenyl"
or "C2-C6 alkenyl" group as previously defined, substituted by one, two, three or more aliphatic substituents.
The terms "C2-ClZ alkynyl" or "C2-C6 alkynyl," as used herein, denote a monovalent group derived from a hydrocarbon moiety containing from two to twelve or two to six carbon atoms having at least one carbon-carbon triple bond by the removal of a single hydrogen atom. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, and the like.
The term "substituted alkynyl," as used herein, refers to a"C2-C12 alkynyl"
or "C2-C6 alkynyl" group as previously defined, substituted by one, two, three or more aliphatic substituents.
The term "Cl-C6 alkoxy," as used herein, refers to a C1-C6 alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom. Examples of C1-Cg-alkoxy include, but are not limited to, inethoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, neopentoxy and n-hexoxy.
The terms "halo" and "halogen," as used herein, refer to an atom selected from fluorine, chlorine, bromine and iodine.
The terms "aryl" or "aromatic," as used herein, refer to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like.
The terms "substituted aryl" or "substituted aromatic," as used herein, refer to an aryl group, as previously defined, substituted by one, two, three or more aromatic substituents.
The term "arylalkyl," as used herein, refers to an aryl group attached to the parent compound via a Cl-C3 alkyl or C1-C6 alkyl residue. Examples include, but are not limited to, benzyl, phenethyl and the like.
The term "substituted arylalkyl," as used herein, refers to an arylalkyl group, as previously defined, substituted by one, two, three or more aromatic substituents.
The terms "heteroaryl" or "heteroaromatic," as used herein, refers to a mono-, bi-, or tri-cyclic aromatic radical or ring having from five to ten ring atoms of which at least one ring atom is selected from S, 0 and N; zero, one, two, three or more ring atoms are additional heteroatoms independently selected from S, 0 and N;
and the remaining ring atoms are carbon, wherein any N or S contained within the ring may be optionally oxidized. Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl, tetrazolyl and the like.
The heteroaromatic ring may be bonded to the chemical structure through a carbon or hetero atom.
The terms "substituted heteroaryl" or "substituted heteroaromatic," as used herein, refer to a heteroaryl group as previously defined, substituted by one, two, three or four aromatic substituents.
The term "alicyclic," as used herein, denotes a monovalent group derived from a monocyclic or bicyclic saturated carbocyclic ring compound by the removal of a single hydrogen atom. Examples include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl.
The term "substituted alicyclic" group as previously defined, substituted by one, two, three or more aliphatic substituents.
The terms "heterocyclic" as used herein, refers to a non-aromatic 5-, 6- or 7-membered ring or a bi- or tri-cyclic group fused system, where (i) each ring contains between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, (ii) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (iii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iv) the nitrogen heteroatom may optionally be quaternized, (iv) any of the above rings may be fused to a benzene ring, and (v) the remaining ring atoms are carbon atoms which may be optionally oxo-substituted.
Representative heterocycloalkyl groups include, but are not limited to, [1,3]dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl, and the like.
The term "substituted heterocyclic," as used herein, refers to a heterocyclic group, as previously defined, substituted by one, two, three or more aliphatic substituents.
The term "heteroarylalkyl," as used herein, refers to a heteroaryl group attached to the parent compound via a Cl-C3 alkyl or C1-C6 alkyl residue.
Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl and the like.
The term "substituted heteroarylallcyl," as used herein, refers to a heteroarylalkyl group, as previously defined, substituted by independent replacement of one, two, or three or more aromatic substituents.
The term "C1-C3-alkylamino," as used herein, refers to one or two Ci-C3-alkyl groups, as previously defined, attached to the parent molecular moiety through a nitrogen atom. Examples of C1-C3-alkylamino include, but are not limited to, methylamino, dimethylamino, ethylamino, diethylamino, and propylamino.
The term "alkylamino" refers to a group having the structure -NH(C1-C12 allcyl) where C1-C12 alkyl is as previously defined.
The term "dialkylamino" refers to a group having the structure -N(C1-C12 alkyl) (C1-C12 alkyl), where CI-C12 alkyl is as previously defined. Examples of dialkylamino are, but not limited to, dimethylamino, diethylamino, methylethylamino, piperidino, and the like.
The term "allcoxycarbonyl" represents an ester group, i.e., an alkoxy group, attached to the parent molecular moiety through a carbonyl group such as methoxycarbonyl, ethoxycarbonyl, and the like.
The term "carboxaldehyde," as used herein, refers to a group of formula -CHO.
The term "carboxy," as used herein, refers to a group of formula -COOH.
The term "carboxamide," as used herein, refers to a group of formula -C(O)NH(CI-C12 alkyl) or -C(O)N(C1-C12 alkyl) (CI-Cla alkyl), -C(O)NH2, -NHC(O)(C1-C12 alkyl), -N(Cl-C1a alkyl)C(O)(C1-C12 alkyl) and the like.
The term "hydroxy protecting group," as used herein, refers to a labile chemical moiety which is known in the art to protect a hydroxyl group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the hydroxy protecting group as described herein may be selectively removed.
Hydroxy protecting groups as known in the art are described generally in T.H.
Greene and P.G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of hydroxyl protecting groups include benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, isopropoxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-furfuryloxycarbonyl, allyloxycarbonyl, acetyl, formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, t-butyl, 2,2,2-trichloroethyl, 2-trimethylsilyl ethyl, 1, 1 -dimethyl-2-propenyl, 3-inethyl- 3 -butenyl, allyl, benzyl, para-methoxybenzyldiphenylmethyl, triphenylmethyl (trityl), tetrahydrofuryl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-triehloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, para-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, and the like. Preferred hydroxyl protecting groups for the present invention are acetyl (Ac or -C(O)CH3), benzoyl (Bz or -C(O)C6H5), and trimethylsilyl (TMS or-Sl(CH3)3)=
The term "protected hydroxy," as used herein, refers to a hydroxy group protected with a hydroxy protecting group, as defined above, including benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups, for example.
The term "hydroxy prodrug group", as used herein, refers to a promoiety group which is known in the art to change the physicochemical, and hence the biological properties of a parent drug in a transient manner by covering or masking the hydroxy group. After said synthetic procedure(s), the hydroxy prodrug group as described herein must be capable of reverting back to hydroxy group in vivo.
Hydroxy prodrug groups as known in the art are described generally in Kenneth B.
Sloan, Prodrugs Topical and Ocular Drug Delivery, (Drugs and the Pharmaceutical Sciences; Volume 53), Marcel Dekker, Inc., New York (1992).
The term "amino protecting group," as used herein, refers to a labile chemical moiety which is known in the art to protect an amino group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the amino protecting group as described herein may be selectively removed.
Amino protecting groups as known in the are described generally in T.H. Greene and P.G.
M. Wuts, Protective Groups in Or ag nic Synthesis, 3rd edition, John Wiley &
Sons, New York (1999). Examples of amino protecting groups include, but are not limited to, t-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, and the like.
The term "protected amino," as used herein, refers to an amino group protected with an amino protecting group as defined above.
The term "acyl" includes residues derived from acids, including but not limited to carboxylic acids, carbamic acids, carbonic acids, sulfonic acids, and phosphorous acids. Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates and aliphatic phosphates.
The term "aprotic solvent," as used herein, refers to a solvent that is relatively inert to proton activity, i.e., not acting as a proton-donor.
Examples include, but are not limited to, hydrocarbons, such as hexane and toluene, for example, halogenated hydrocarbons, such as, for example, methylene chloride, ethylene chloride, chloroform, and the like, heterocyclic compounds, such as, for example, tetrahydrofuran and N-methylpyrrolidinone, and ethers such as diethyl ether, bis-methoxymethyl ether. Such compounds are well lcnown to those skilled in the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of aprotic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick et al., Vol. II, in the Techniques of ChemistrY
Series, John Wiley & Sons, NY, 1986.
The term "protogenic organic solvent" or "protic solvent," as used herein, refers to a solvent that tends to provide protons, such as an alcohol, for example, methanol, ethanol, propanol, isopropanol, butanol, t-butanol, water and the like.
Such solvents are well known to those skilled in the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for exainple. Further discussions of protogenic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A.
Riddick et al., Vol. II, in the Techniques of ChemistrX Series, John Wiley & Sons, NY, 1986.
Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).
The synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.
Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Or ag nic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Or ag nic S
nt~ hesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic S, nt~ hesis, John Wiley and Sons (1995), and subsequent editions thereof.
The term "subject" as used herein refers to an animal. Preferably the animal is a mammal. More preferably the mammal is a human. A subject also refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, fish, birds and the like.
The compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are lcnown in the art and may include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
The compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- , or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forins. Optical isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding resolutions can be found in Jacques, et al., Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 198 1).
When the compounds described herein contain olefinic double bonds, other unsaturation, or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers or cis- and trans- isomers. Likewise, all tautomeric forms are also intended to be included. The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration unless the text so states; thus a carbon-carbon double bond or carbon-heteroatom double bond depicted arbitrarily herein as trans may be cis, trans, or a mixture of the two in any proportion.
As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid or inorganic acid. Examples of pharmaceutically acceptable nontoxic acid addition salts include, but are not limited to, salts of an amino group tormed witn inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid lactobionic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
As used herein, the term "pharmaceutically acceptable ester" refers to esters which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each allcyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
Exainples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
The term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention. "Prodrug", as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of the invention. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al.
(ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, et al., Journal of Drug Deliver Reviews, 8:1-38(1992); Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq.
(1988); Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975); and Bernard Testa & Joachim Mayer, "Hydrolysis In Drug And Prodrug Metabolism: Chemistry, Biochemistry And Enzymology," John Wiley and Sons, Ltd. (2002).
This invention also encompasses pharmaceutical compositions containing, and methods of treating bacterial infections through administering, pharmaceutically acceptable prodrugs of compounds of the invention. For example, compounds of the invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters.
Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in J. Med. Chem. 1996, 39, 10.
Free amines can also be derivatized as amides, sulfonamides or phosphonamides.
All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
As used herein, unless otherwise indicated, the term "bacterial infection(s)"
or "protozoa infections"; includes, but is not limited to, bacterial infections and protozoa infections that occur in mammals, fish and birds as well as disorders related to bacterial infections and protozoa infections that may be treated or prevented by administering antibiotics such as the compounds of the present invention. Such bacterial infections and protozoa infections and disorders related to such infections include, but are not limited to, the following: pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, cystic fibrosis (CF) and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Peptostreptococcus spp. or Pseudomonas spp.;
pharynigitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Clostridium diptheriae, or Actinobacillus haemolyticum; respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae; uncomplicated skin and soft tissue infections, abscesses and osteomyelitis, and puerperal fever related to infection by Staphylococcus aureus, coagulase-positive staphylococci (i.e., S.
epidermidis, S. hemolyticus, etc.), S. pyogenes, S. agalactiae, Streptococcal groups C-F (minute-colony streptococci), viridans streptococci, Corynebacterium spp., Clostridium spp., or Bartonella henselae; uncomplicated acute urinary tract infections related to infection by S. saprophyticus or Enterococcus spp.;
uretliritis and cervicitis; and sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Nesseria gonorrheae; toxin diseases related to infection by S. aureus (food poisoning and Toxic shock syndrome), or Groups A, S. and C streptococci;
ulcers related to infection by Helicobacter pylori; systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by C.
trachomatis, N. gonorrlioeae, S. aureus, S. pneumoniae, S. pyogenes, H.
influenzae, or Listeria spp.; disseminated Mycobacterium avium complex (MAU) disease related to infection by Mycobacterium avium, or Mycobacterium intracellulare;
tuberculosis disease related to infection by Mycobacterium tuberculosis;
gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp. odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by Bordetella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; Skin infection by S. aureus, Propionibacterium acne;
atherosclerosis related to infection by Helicobacter pylori or Chlamydia pneumoniae; or the like.
Bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in animals include, but are not limited to, the following: bovine respiratory disease related to infection by P.
haemolytica., P.
multocida, Mycoplasma bovis, or Bordetella spp.; cow enteric disease related to infection by E. coli or protozoa (i.e., coccidia, cryptosporidia, etc.), dairy cow mastitis related to infection by S. aureus, S. uberis, S. agalactiae, S.
dysgalactiae, Klebsiella spp., Corynebacterium, or Enterococcus spp.; swine respiratory disease related to infection by A. pleuropneumoniae., P. multocida, or Mycoplasma spp.;
swine enteric disease related to infection by E. coli, Lawsonia intracellularis, Salmonella spp., or Serpulina hyodyisinteriae; cow footrot related to infection by Fusobacterium spp.; cow metritis related to infection by E. coli; cow hairy warts related to Infection by Fusobacterium necrophorum or Bacteroides nodosus; cow pink-eye related to infection by Moraxella bovis, cow premature abortion related to infection by protozoa (i.e. neosporium); urinary tract infection in dogs and cats related to infection by E. coli; skin and soft tissue infections in dogs and cats related to infection by S. epidermidis, S. intermedius, coagulase neg. Staphylococcus or P.
multocida; and dental or mouth infections in dogs and oats related to infection by Alcaligenes spp., Bacteroides spp., Clostridium spp., Enterobacter spp., Eubacterium spp., Peptostreptococcus spp., Porphfyromonas spp., Campylobacter spp., Actinomyces spp., Erysipelothrix spp., Rhodococcus spp., Trypanosoma spp., Plasmodium spp., Babesia spp., Toxoplasma spp., Pneumocystis spp., Leishmania spp., and Trichomonas spp. or Prevotella spp. Other bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in accord with the method of the present invention are referred to in J. P.
Sanford at al.,"The Sanford Guide To Antimicrobial Therapy," 26th Edition, (Antimicrobial Therapy, Inc., 1996).
Antibacterial activity studies may be carried out using suitable assays as are known in the art. Susceptibility tests can be used to quantitatively measure the in vitro activity of an antimicrobial agent against a given bacterial isolate.
Compounds are tested for in vitro antibacterial activity by a micro-dilution method.
Minimal Inhibitory Concentration (MIC) is determined in 96 well microtiter plates utilizing the appropriate Mueller Hinton Broth medium (CAMHB) for the observed bacterial isolates. Antimicrobial agents are serially diluted (2-fold) in DMSO to produce a concentration range from about 64 g/ml to about 0.03 g/ml. The diluted compounds (2 l/well) are then transferred into sterile, uninoculated CAIVIHB
(0.2 mL) by use of a 96 fixed tip-pipeting station. The inoculum for each bacterial strain is standardized to 5 x 105 CFU/inL by optical comparison to a 0.5 McFarland turbidity standard. The plates are inoculated with 10 Uwell of adjusted bacterial inoculum. The 96 well plates are covered and incubated at 35 +/- 2 C for 24 hours in ambient air environment. Following incubation, plate wells are visually examined by Optical Density measurement for the presence of growth (turbidity). The lowest concentration of an antimicrobial agent at which no visible growth occurs is defined as the MIC. The compounds of the invention generally demonstrated an MIC in the range from about 64 g/ml to about 0.03 g/ml.
All in vitro testing follows the guidelines described in the Approved Standards M7-A4 protocol, published by the National Committee for Clinical Laboratory Standards (NCCLS).
The invention further provides compositions and methods of treating subjects suffering from an inflammatory condition comprising administering to a subject in need thereof, a therapeutically effective amount of at least one compound of the invention. Specific examples of inflammatory conditions treatable according to the invention include, but are not limited to, scleritis; epi-scleritis;
allergic conjunctivitis; pulmonary inflammatory diseases, particularly CF, asthma, chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and sarcoidosis; procto-sigmoiditis; allergic rhinitis; arthritis;
tendonitis;
apthous stomatitis; and inflammatory bowel disease.
The invention further provides compositions and methods for i) prophylactic treatment of those subjects susceptible to the symptoms CF including pulmonary infection and inflammation associated with CF, ii) treatinent at the initial onset of symptoms of pulmonary infection and inflammation associated with CF, and iii) treatment of ongoing or relapsing symptoms of infection and inflammation associated with CF. In accordance with the invention a compound of the invention, is administered to a subject in need of treatment for CF, in amount sufficient to prevent, diminish or eradicate symptoms of CF including chronic pulmonary inflammation and infection.
The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers or excipients.
As used herein, the term "pharmaceutically acceptable carrier or excipient"
means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminun hydroxide; alginic acid; pyrogen-free water; isotonic saline;
Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the forinulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides.
In addition, fatty acids such as oleic acid are used in the preparation of injectables.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size anca crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalciuin phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
For pulmonary delivery, a therapeutic composition of the invention is formulated and administered to the subject in solid or liquid particulate form by direct administration e.g., inhalation into the respiratory system. Solid or liquid particulate forms of the active compound prepared for practicing the present invention include particles of respirable size: that is, particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs. Delivery of aerosolized therapeutics, particularly aerosolized antibiotics, is known in the art (see, for example U.S. Pat. No. 5,767,068 to VanDevanter et al., U.S. Pat. No. 5,508,269 to Smith et al., and WO 98/43,650 by Montgomery, all of which are incorporated herein by reference). A discussion of pulmonary delivery of antibiotics is also found in U.S. Pat. No. 6,014,969, incorporated herein by reference.
According to the methods of treatment of the present invention, bacterial infections, cystic fibrosis and inflammatory conditions are treated or prevented in a subject such as a human or another animal by administering to the subject a therapeutically effective amount of a compound of the invention, in such amounts and for such time as is necessary to achieve the desired result.
By a "therapeutically effective amount" of a compound of the invention is meant an amount of the compound which confers a therapeutic effect on the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect). An effective amount of the compound described above may range from about 0.1 mg/Kg to about 500 mg/Kg, preferably from about 1 to about 50 mg/Kg. Effective doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject;
the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or contemporaneously with the specific compound employed; and lilee factors well known in the medical arts.
The total daily dose of the compounds of this invention administered to a human or other animal in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In general, treatment regimens according to the present invention comprise administration to a subject in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in single or multiple doses.
The compounds of the formulae described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.1 to about 500 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with pharmaceutically excipients or carriers to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A
typical preparation will contain from about 5% to about 95% active compound (w/w).
Alternatively, such preparations may contain from about 20% to about 80%
active compound.
Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular subject will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the subject's disposition to the disease, condition or symptoms, and the judgment of the treating physician.
Upon improvement of a subject's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Subjects may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
When the compositions of this invention comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
The pharmaceutical compositions of this invention can be administered orally to fish by blending said pharmaceutical compositions into fish feed or said pharmaceutical compositions may be dissolved in water in which infected fish are placed, a method commonly referred to as a medicated bath. The dosage for the treatment of fish differs depending upon the purpose of administration (prevention or cure of disease) and type of administration, size and extent of infection of the fish to be treated. Generally, a dosage of 5 - 1000 mg, preferably 20 - 100 mg, per kg of body weight of fish may be administered per day, either at one time or divided into several times. It will be recognized that the above-specified dosage is only a general range which may be reduced or increased depending upon the age, body weight, condition of disease, etc. of the fish.
Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to one of ordinary skill in the art. All publications, patents, published patent applications, and other references mentioned herein are hereby incorporated by reference in their entirety.
Abbreviations Abbreviations which may be used in the descriptions of the scheme and the examples that follow are:
Ac for acetyl;
AIBN for azobisisobutyronitrile;
Bu3SnH for tributyltin hydride;
CDI for carbonyldiimidazole;
dba for dibenzylidene acetone:
dppb for diphenylphosphino butane;
DBU for 1,8-diazabicyclo[5.4.0]undec-7-ene;
DEAD for diethylazodicarboxylate;
DMAP for dimethylaminopyridine;
DMF for dimethyl formamide;
DPPA for diphenylphosphoryl azide;
EtOAc for ethyl acetate;
EtOH for ethanol;
MeOH for methanol;
Ms for mesylate or O-S02-CF3;
NaN(TMS)2 for sodium bis(trimethylsilyl)amide;
NMMO for N-methylmorpholine N-oxide;
TEA for triethylamine;
THF for tetrahydrofuran;
TPP or PPh3 for triphenylphosphine;
MOM for methoxymethyl;
Boc for t - butoxycarbonyl;
Bz for benzoyl;
Bn for benzyl;
Ph for phenyl;
POPd for dihydrogen dichlorobis(di-tert-butylphosphinito-xP)palladate(II);
TBS for tert-butyl dimethylsilyl; or TMS for trimethylsilyl.
Synthetic Methods The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes that illustrate the methods by which the compounds of the invention may be prepared.
A preferred intermediate for the preparation of compounds represented by formula I is a compound represented by formula VIII as illustrated below Y, X
I
O ltP
W
O O
HO
L, .=.'o ,,,,, ,O
U
Z
VIII
wherein Rp, U, V, W, X, Y and Z are as previously defined.
Schemes 1- 2 describe processes for the preparation of compounds according to the invention.
Compounds of formula VIII, which are useful as the starting materials for the preparation of compounds of the present invention are prepared from erythromycin using the procedures described in U.S. Patent No. 6,878,691 and U.S.
Patent Application Publication No. 2004/0053861, incorporated herein by reference.
Scheme 1 Y, X A-O I' X
O Rp W O_NH2 O ~ XI- O Rp W
0,,,,., HO ' 0 HO
~ 1 ~ .
....q p11 ,q~
O O O õnn O O
acid ,,~'V
O U O
Z Z
VIII (1-2) Scheme 1 illustrates a process of preparing compounds of the present invention by converting the bridged ketone of VIII into an oxime of formula (1-2) using the appropriate substituted hydroxylamine of the formula:
A" O-NH2 where A is as previously defined. This oxime formation can be accomplished, using the appropriate substituted hydroxylamine under either acidic or basic conditions in a variety of solvents. Representative acids include, but are not limited to, hydrochloric acid, phosphoric acid, sulfuric acid, p-toluenesulfonic acid, and pyridinium p-toluene sulfonate and the likes. Likewise, representative bases include, but are not limited to, triethylamine, pyridine, diisopropylethyl amine, 2,6-lutidine, and the likes. Appropriate solvents include, but are not limited to, methanol, ethanol, water, tetrahydrofuran, 1,2-dimethoxyethane, ethyl acetate and the likes. Preferably the reaction is carried out in ethanol using aqueous hydrochloric acid. Reaction temperature is generally, but not limited to, from -20 C to 40 C and the reaction time is froml to 8 hours, preferably the reaction is carried out at 0 C.
Scheme 2 A O YX A-O YX
N . .'.
O lP W
0 O O? w HO O~ HO O~
tO 0 , \ ~f V ~ ~,,,,== \
I,,.,== Iõ==
"OH 4j"0-R
Z Z R = Rl, ORI, OC(O)Rl, (2-1) (2-2) OC(O)NR3R4, S(O)nRl Scheme 2 illustrates the procedure by which compounds of formula (2-1) may be converted to compounds of formula (2-2) by treatment with isocyanates of formula Rl-NCO, acid chlorides of formula Rl-C(O)Cl or Alkyl isocyanates in the present of bases such as, but not limited to, sodium hydride, potassium hydride, potassium tert-butoxide, potassium hydroxide, KHMDS, and the like. The reaction is typically carried out in aprotic solvents such as, but not limited to, THF, DMSO, DMF, or dioxane and the likes. The temperature of the reaction is from 25 C
to 80 C. The preferred reaction time is from 5 to 20 hours.
Alternatively, some of the ester compounds of formula (2-2) can be prepared by treating compounds of formula (2-1) with acids of formula R1-C(O)OH in the presence of bases such as but not limited to Et3N, Pyridine, DMAP and coupling agents such as but not limited to EDC, BOPCI, HATU, and the likes in aprotic solvents such as but not limited to dichloromethane, ethylene chloride, THF, DMF, acetonitrile and the like at a temperature from 25 C to 80 C and the reaction time is from 2 to 24 hours.
Compounds of formula (2-1) also can be treated with with substituted tert-butyl allyl carbonate in the presence of a palladium catalyst and a phosphine additive to give allyl ethers.
Examples The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not limiting of the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents, derivatives, formulations and/or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.
Example 1 ~
H2N-~o ~
N ~ NAc MN ,,~' "I N
HO~~O HO,, ' .
o ~~' ~O O
O O' ~ O
/,--NH2 Step 1 a: N
To a solution of 2-amino-4-methylphenol (157.6g, 1.28mo1) in 1500 ml of EtOH at room temperature, under stirred condition, was added bromocyanogen (135.OOg, 1.28mo1) in about 30 minutes. During the addition, the reaction mixture became warm and water bath was used to cool the reaction to room temperature.
After 5-6 hours, the reaction solvent was evaporated under reduced pressure.
The residue was dissolved in about 1500 ml of EtOAc and washed with the saturated NaHCO3 (1.5 L). The organic layer was separated and dried over anhydrous MgSO4. Removal of solvent and dried by high vacuum gave about 150g of the title compound as pale brown color, which can be used in next step. ESI MS m/e: 149 (M+H)+.
s-N
N
Step lb: 0 A solution of succinic anhydride (141.1 g, 1.41 mol) and 70 g (about 0.47 mol) of compound of step la (70 g, 0.47 mol) in 2500 ml of anhydrous toluene was refluxed for overnight. After that, HATU (100g, 0.26 mol) and 4-methylmorpholine (41.36 ml, 0.376 mol) were added and the resulting mixture was refluxed for 2-hours. TLC showed that the major spot was product (Rf = 0.35, acetone:hexane =
1:2). After reaction was completed, the solvent was evaporated and the residue was dissolved in about 2000 ml of CHZC12. The solution was washed with aqueous NaHCO3. After pH was adjusted to 7-8 and washed with brine, organic phase was separated and dried over MgSO4. Filtration and removal of solvent gave the title compound (98g) as fine white needle crystalline ESI MS m/e: 231 (M+H)+.
~
N
Br ~ /oN~
Step 1 c: o To a solution of the compound of step lb (44.37g, 0.193mo1) in CC14 (1.5 L) was added NBS (41.16g, 0.23mo1) and then the mixture were heated to reflux.
Benzoyl peroxide (0.75g) was added by three times. After refluxing for 24 hours, the reaction was cooled to room temperature and the mixture was diluted with 1.5 L
of CHZC12 , The organic phase was separated and washed with 4 L of saturated NaHCO3 two times to adjust pH to 7-8. Dried over MgSO4 and removal of the solvent under reduced pressure gave the title compound (57.3 g) as slight yellow solid which was used for next step without further purification. ESI MS m/e:
309/311(M+H)+.
o o~
I~ N_ N N
/
Step 1 d: 0 0 To a solution of the compound of step 1c (57.3g, 0.185mo1) in 450 ml of MeCN were added N-hydroxyphanthalimide (60.51g, 0.371mol) and 80 ml of triethylamine. The reaction mixture was stirred at 50 C for 5 hours and cooled to room temperature. The reaction was added water (200 ml) and filtered. The pale yellow solid was collected, washed with100ml of MeOH and ether in the 1:1 ratio.
Dried on vacuum to give the title compound (48 g) as pale solid. ESI MS m/e:
(M+H)+.
~ o HZN-o I ~ N~NHZ
Step le:
A mixture of the compound of step ld (39.1g, 0.1 mol) in 500 ml of 2M
ammonia in methanol was stirred at room temperature for 16 hours and filtered.
The filtrate was concentrated and purified on silica gel (2M NH3 in MeOH:CH2C12 =
5:95) to give the title compound (17g, 95%). ESI MS m/e: 180 (M+H)+.
O
H2N-~~ ~
N,Ac 0N AcN
HO . O''.
O "''O O
O O
Step lf:
To a solution of compound of step id (215 mg, 1.2 mmol) in 15 ml of ethanol was added 1N HCI (2 ml). The mixture was cooled to 0 C and added compound of formula VIII where X and Y taken together with the atom that they are attached is C=N-Ac and U and V taken together with the atom that they are attached is C=O, Z= H, Rp = Ac and W = NMe2 (711 mg, 1 mmol). The mixture was stirred at 0 C for 1 hour and quenched with saturated NaHCO3 (50 ml). Extracted with ethyl acetate (100 ml) and washed with brine (100 ml x 2). Dried over anhydrous Na2SO4 and concentrated to give crude title compound (828 mg, 95%, as a mixture of oximes, oximeE/Z = 4/1), which was used for next step reaction without further purification. ESI MS m/e: 872 (M+H)+.
H, N--~~
o ~ I
N ~ N AC
O~ o O N ''O
HO HO,,, "' O /1,' 'O O
O O
Step l g:
A solution of compound of step lf (828 mg, 0.95 mmol) in 15 ml of methanol was stirred at 60 C for 5 hours. The solvent was removed and the residue was purified on silica gel (2M NH3 in MeOH/ CH2C12 = 5/95) to give the title compound (765mg, 97%, as a mixture of E/Z oximes E/Z - 4/1). The compound was further separated on HPLC to give E-oxime isomer (430 mg) and Z-oxime isomer (110mg).
E-oxime isomer: ESI MS m/e: 830 (M+H)+.
E-oxime isomer: 13C NMR (125 MHz, CDC13): 8 205.9, 191.4, 186.8, 184.7, 178.1, 167.8, 162.1, 153.3, 148.5, 143.0, 134.1, 125.6, 121.9, 116.8, 108.7, 103.0, 79.4, 76.4, 74.6, 70.5, 69.8, 66.1, 63.2, 62.9, 50.8, 40.5, 38.8, 31.2, 28.5, 25.3, 23.8, 21.5, 19.5, 17.8, 15.1, 14.1, 12.8.
Z-oxime isomer: ESI MS m/e: 830 (M+H)+.
Z-oxime isomer: 13C NMR (125 MHz, CDC13): S 206.2, 184.7, 176.9, 169.3, 163.0, 155.9, 148.5, 143.2, 133.6, 121.6, 116.7, 108.5, 103.0, 79.5, 79.0, 76.7, 76.2, 75.8, 70.5, 70.2, 69.7, 66.1, 58.2, 53.7, 51.0, 45.3, 40.5, 39.7, 39.0, 36.9, 28.5, 25.5, 23.4, 21.5, 20.3, 19.6, 17.3, 15.7, 14.5, 12.9, 12Ø
Example 2 O i O
O~,N N
HO OHO ,, O ,''O O
O O
O
N' \
O O AHOO
O '0O
O O
Step 2a:
The title compound of step 2a was prepared according to experimental procedure from U.S. Pat. No. 6,878,691 incorporated herein by reference.
O O\ Ac O '' O
O O
Step 2b:
To a solution of compound of step 2a (711 mg, 1 mmol) in 8 ml of acetonitrile was added 1 N HCI (10 ml) at room temperature. The mixture was stirred at room temperature for 4 hours and was quenched with saturated NaHCO3 (30 ml). Extracted with ethyl acetate (40 ml) and the organic phase was washed with brine (40 m1X2). After dried over anhydrous Na2SO4, the solvent was removed and the residue was purified on silica gel column (hexane: acetone = 1:1) to give the title compound (330 mg, 49%).
O /
HaN--~ ~ ~
z,N .,, HOk/~/ 0 Ac N
~,.
'''v 0 ~''0 0 Step 2c:
To a solution of compound from step 2b (215 mg, 1.2 mmol) in 15 ml of ethanol was added 1N HC1(2 ml). The mixture was cooled to 0 C and added bridged ketone lcetolide, compound of step 2a (670 mg, 1 mmol). The mixture was stirred at 0 C for 1 hour and quenched with saturated NaHCO3 (50 ml).
Extracted with ethyl acetate (100 ml) and washed with brine (100 ml X 2). Dried over anhydrous Na2SO4 and concentrated to give crude title compound (764 mg, 92%, E/Z - 1/1). ESI MS m/e: 831 (M+H)+.
0 i HZN--~ ~ ~
0."
HO H
Y ~
I"~~'0 ~''0 0 Step 2d:
A solution of compound of step 2c (764mg, 0.92 mmol) in 15 ml of methanol was stirred at 60 C for 6 hours. The solvent was removed and the residue was purified on silica gel (2M NH3 in MeOH/ CH2C12 = 5/95) to give the title compound as a mixture of E/Z oxime isomers (690mg, 95%, E/Z - 1/1). The compound was further separated on HPLC to give E-oxime isomer (280 mg) and Z-oxime isomer (230mg).
E-oxime isomer: ESI MS m/e: 789 (M+H)+.
E-oxime isomer: 13C NMR (125 MHz, CDC13): 6 218.5, 205.6, 191.7, 168.0, 162.0, 152.8, 148.6, 143.0, 134.0, 122.1, 117.0, 108.7, 103.3, 79.3, 79.0, 76.5, 75.8, 74.5, 70.5, 69.8, 66.1, 63.0, 61.5, 51.0, 47.0, 46.2, 40.5, 39.5, 39.3, 28.5, 23.5, 21.4, 20.0, 18.6, 18.0, 14.6, 14.2, 12.6, 12.2.
Z-oxime isomer: ESI MS m/e: 789 (M+H)+.
Z-oxime isomer: 13C NMR (125 MHz, CDC13): 8 215.0, 205.7, 169.6, 162.2, 156.2, 149.0, 142.8, 131.4, 124.8, 116.3, 109.7, 102.5, 79.9, 78.7, 76.3, 76.2, 70.5, 69.7, 66.1, 59.2, 50.8, 46.3, 45.7, 40.5, 40.0, 39.1, 28.5, 23.1, 21.6, 19.7, 18.5, 17.2, 14.5, 13.1, 12.9, 11.8.
Example 3.
In accordance with Schemes 1 and 2, the following compounds of the invention having the Formula II were prepared:
A---- O
'4 O N~ O
HO = N
~~ ~ / = ~
~,.Y s V HO,,, ~~. O ,... '',O
O
o = z II
wherein A, Q and Z are defined as in Table I.
TABLE I.
MS (ESI):
Example A- Q Z mlz 13C NMR (125 MHz,CDCI3):S
M+H +
NAc H 205.8,184.7,178.0,167.8, 154.3,153.8,153.0, N ~ 136.0, 134.0,126.7,123.5, 121.5, 103.1, 79.3, ~ 79.2, 76.8, 75.8, 75.5, 74.7, 70.5, 69.7, 66.1, Example 01 S 831 63.1, 62.9, 50.7, 46.2, 40.5, 38.8, 37.2, 31.2, 28.5, 25.3, 23.8, 21.5, 20.3, 19.5, 17.8, 15.1, 14.1 ,~/~N NAc F
Example 02 H2N ~S 864 S-N NAc H
N~
Example 03 832 Example 04 ~S NAc H
HZN ~ 846 N
Example 05 NAc H 205.8, 184.7,178.0,167.8, 153.6,153.0,149.8, /N ~ 140.3, 135.0,126.3,120.5, 110.8,103.0, 79.4, 815 76.8, 76.0, 74.6, 70.5, 69.7, 66.1, 63.1, 62.8, O ~ 53.7, 50.7, 46.2, 40.5, 38.9, 28.5, 25.3, 23.8, 21.5,20.3,19.5,17.8,15.1,14.1,13.6,12.9 Example 06 ,O NAc H
N ~ 830 H N ~~~~
Example 07 H2N NAc H
N~ 830 Example 08 NAc F (selected)205.5, 205.3, 184.2, 165.1, 164.9, 162.4, 153.7,148.8, 142.7, 131.2,124.5,116.2, 109.3,104.1, 99.7, 98.1, 79.7, 76.5, 73.7, 70.6, H2N- 848 69.8, 66.0, 63.1, 62.6, 41.2, 40.5, 39.0, 28.4, o~ 25.3, 24.7, 24.5, 23.2, 21.4, 21.0, 17.5,15.0,14.3,12.6 Example 09 0 H 218.4, 205.6,168.0, 166.3,152.0, 132.1, 131.9, N ~ 126.9, 121.5,119.1, 103.3, 79.3, 78.9, 76.4, HZN--~~ 805 75.9, 74.6, 70.5, 69.8, 66.1, 13.0, 61.5, 50.9, s 47.1, 46.2, 40.5, 39.5, 39.3, 28.5, 23.5, 21.5, 20.1, 18.6, 18.0, 14.6, 14.2, 12.6, 12.2.
Example 10 NAc H 205.9,184.7,178.0, 167.9, 162.2, 153.4, 148.9, 142.6,131.5,124.6,116.2,109.4, 103.1, 79.3, HZN--N 830 76.8, 74.8, 70.5, 66.1, 63.2, 62.9, 50.8, 40.5, o~ 38.8, 28.5, 25.4, 23.8, 21.5, 20.3, 19.6, 17.8, 15.1, 14.1, 12.8.
Example 11 0 H 216.3, 203.6,165.9, 160.1,150.8,146.8, 140.6, 129.1, 122.7,114.1, 107.5, 101.2, 77.2, 76.8, N H2N--~ 789 74.7, 74.4, 73.8, 72.6, 68.4, 67.7, 63.9, 60.8, 59.4, 51.5, 48.9, 45.0, 44.0, 38.3, 37.4, 29.0, 26.3, 21.3, 19.3,18.0, 16.4, 15.9,12.6,12.1 Example 12 NAc H (selected): 205.8, 185.0,178.3,168.2, 161.6, 155.9, 153.4,148.9,133.0,131.6,126.6, 121.2, N-{ ~ 1 889 120.0, 103.0, 79.4, 76.7, 76.2, 70.5, 69.7, 66.0, HZN~ s~ 63.2, 50.8, 46.2, 40.5, 38.8, 28.5, 25.5, 23.7, 0 21.5, 20.2, 19,7, 18.0, 15.4, 14.1, 13.7, 12.7.
Example 13 NAc H (selected): 205.9,184.7,178.0,167.9, 167.4, F 153.9, 153.7,152.0, 140.1,140.0,133.7, 132.9, 132.8, 116.4,112.4,112.3, 103.0, 79.3, 76.7, HZN~N 864 75.6, 74.8, 70.5, 59.7, 66.0, 63.1, 62.9, 50.8, s 46.3, 40.4, 38.8, 28.5, 25.3, 23.7, 21.5, 20.3, 19.6,17.8,15.1, 14.1, 13.7,12.8 Example 14 0 H (selected); 217.9, 205.6,168.9,162.0, 155.5, NN ~ ~ 152.9, 131.8,126.8, 122.1,119.7, 102.8, 9.4, HZN1 ~ 848 79.3, 76.5, 75.1, 70.5, 69.8, 66.1, 63.2, 50.9, o 46.6, 46.3, 40.5, 39.4, 28.5, 23.2, 21.5, 18.2, 17.9,14.2, 14.0, 13.2,12.2.
Example 15 0 H (selected): 218.4, 205.7, 168.1,167.4,154.0, 153.1, 152.0,140.2,140.0, 133.8,133.7,132.8, F 132.7, 116.7,112.7,112.5, 103.3, 79.3, 78.9, 823 76.8, 75.9, 75.8, 74.7, 70.5, 69.8, 66.0, 62.9, H2N-~ ~ 61.5, 51.0, 47.2, 46.2, 40.4, 39.4, 39.3, 28.5, s 23.5, 21.5, 20.1, 18.5,18.0,14.7, 14.2, 12.5, 12.2 Example 16 N, NAc H
N = ~ ~ 829 H N ~~~~
Example 17 o NAc H 205.9, 191.4,186.8,184.7, 178.1,167.8,162.1, ~ 153.3, 148.5,143.0, 134.1,125.6,121.9,116.8, HZN N~ ~ 830 108.7, 103.0, 79.4, 76.4, 74.6, 70.5, 69.8, 66.1, 63.2, 62.9, 50.8, 40.5, 38.8, 31.2, 28.5, 25.3, 23.8, 21.5, 19.5, 17.8, 15.1, 14.1, 12.8.
Example 18 0 H 218.5, 205.6,191.7,168.0,162.0, 152.8, 148.6, O 143.0, 134.0, 122.1, 117.0, 108.7, 103.3, 79.3, H2N-~~ ~ 79.0, 76.5, 75.8, 74.5, 70.5, 69.8, 66.1, 63.0, N~ 789 61.5, 51.0, 47.0, 46.2, 40.5, 39.5, 39.3, 28.5, , 23.5, 21.4, 20.0, 18.6, 18.0, 14.6,14.2,12.6, 12.2.
Example 19 N/ NAc H
AH\s ~ ~ 888 Example 20 H N NAc H
N
H N
Example 21 0 ~ NAc F
N ~ ~ 848 HN
Example 22 N NAc F
, /
N ~ 847 HN
Example 23 N NAc H (selected); 206.2,184.8, 168.6,155.0, 153.8, HZN-~ / 110.0, 103.4, 79.5, 76.7, 75.1, 70.5, 69.8, 66.0, N~ 829 63.2, 63.0, 51.3, 40.5, 38.8, 31.2, 30.0, 28.4, H 25.4, 23.7, 21.8, 20.6, 20.0,17.9, 15.1,14.1, 12.8.
Example 24 N 0 H (selected): 218.5, 206.0, 168.8, 155.1, 153.3, HZN-~ ~ 129.8, 121.1, 103.4, 79.6, 79.1, 76.6, 75.4, N~ 788 70.6, 69.8, 66.0, 62.9, 62.1, 53.7, 51.4, 47.6, H 46.0, 40.5, 39.7, 39.4, 28.4, 23.4, 21.5, 20.4, 18.6, 18.2, 15.3, 14.4, 12.5, 12.2.
Example 25 NAc H 205.8,184.8,178.0,167.9,167.8,159.3,153.5,153 .3,146.3,143.8,143.7,135.0,133.9,1333.3,125.4, 123.7,121.9,120.2,111.1,103.0,79.4,79.2,76.5,7 Cs N ~ 897 6.4,74.8,70.5,69.8,66.1,63.2,62.9,50.8,46.2,40.
/~ 5,38.8,28.5,25.4,23.8,21.5,20.3,19.6,17.8,15.1, 14.1,13.7,12.9.
Example 26 NAc H 205.8, 184.7,178.0,167.8, 153.6,153.0, 149.8, 0 140.3,135.0,126.3, 120.5, 110.8,103.0, 78.4, <\ ~ 815 76.0, 74.6, 70.5, 69.7, 66.2, 63.1, 62.9, 50.7, 46.2, 40.5, 38.8, 28.6, 25.4, 23.8, 21.5, 20.3, 19.5, 17.8, 15.1, 14.1, 13.6, 12.9 Example 27 0 H 218.4, 205.6,168.0,153.0, 149.8,140.3,134.9, O/ 126.5,120.7,110.8,103.1, 79.3, 79.0, 76.1, ~ 775 75.8, 74.6, 70.5, 69.6, 66.2, 63.0, 61.5, 50.9, N~ 47.0, 46.2, 40.5, 39.5, 39.3, 28.9, 23.5, 21.4, 20.0, 18.6,18.0,14.6, 14.3,12.6,12.2 Example 28 NAc H 205.8,184.7,178.0,167.8,157.5,155.1,153.7,150 .5,145.3,141.6,135.9,127.1,123.3,120.4,111.1,1 C ~~ ~ 898 03.0,79.4,76.8,75.8,74.6,70.5,69.7,66.1,63.1,62 s N / .9,50.7,40.5,38.8,29.9,29.5,28.5,25.4,23.8,21.5, 1 20.3,19.5,17.8,15.1,14.1,13.6,12.9.
Example 29 N~ NAc H
Example 30 NAc H
~ ~ 845 N
Example 31 NAc H (selected): 210.1, 184.7,177.9,170.0, 162.4, 153.7,148.5,143.1, 133.9,132.9,121.5,119.6, o ~ 870 116.4, 108.7,102.4, 81.2, 79.7, 76.6, 76.3, 74.5, 70.6, 69.5, 66.2, 62.7, 60.8, 43.7, 40.7, HN~N 40.5, 40.1, 39.3, 37.4, 29.0, 25.3, 22.7,21.6, 21.4, 20.6,19.8,18.3,16.2,14.8, 12.5.
Example 32 HO / NAc H (selected): 206.1,184.9, 178.0,168.1,153.8, ~ 806 150.1,120.4,113.7,103.0, 79.4, 76.7, 70.5, H2N N 69.7, 66.0, 50.9, 40.5, 28.7, 25.4, 23.7, 21.5, 17.8, 17.2, 15.7, 15.1, 14.1, 12.8, 12Ø
Example 33 0 / NAc H
N ~N 816 ll I I
Example 34 NAc H (selected): 205.9,184.8,177.9,167.9,165.1, 157.6,153.8,152.9,140.5,115.5,114.9,102.9, 0 ~ 831 79.3, 76.8, 76.7, 75.1, 70.5, 69.6, 66.1, 63.1, H2N--' ~ 50.9, 40.5, 38.8, 28.7, 25.6, 25.4, 23.8, 21.6, N N 21.5, 20.4,19.6,17.8,17.2,15.2,14.1, 12.8, 12Ø
Example 35 NAc H (selected): 209.9,184.7,177.8,169.9,157.6, 153.9,144.3,133.6,133.3,132.8,131.0,121.1, 119.7,118.1,108.5,107.6, 102.4, 81.0, 79.7, o ~ 910 76.5, 76.0, 74.4, 70.5, 69.5, 66.3, 62.7, 62.6, " <, I i 60.7, 45.1, 43.7, 40.6, 39.3, 29.2, 25.3, 22.9, 21.5, 20.6,19.8,18.2,16.3,14.7, 12.7.
Example 36 N NAc H
Example 37 I NAc H
N /
N ~ 829 N
Example 38 O NC(0)0 H
HZN-~~ CH3 846 205.9,186.4,167.7,163.7,162.4,153.2,148.4,143 .0,134.1,121.8,116.6,108.7,102.9,79.5,78.9,77.
5,76.8,76.4,75.1,74.7,70.5,69.7,66.1,63.2,62.7, 54.1,53.1,50.7,40.5,38.7,32.0,29.5,28.6,23.8,21 .5,20.2,19.3,17.8,14.9,14.1,12.9, Example 39 O NH H
HZN--~~
205.2,169.3,162.8,153.7,148.5,143.1,133.7, 788 121.6, 116.5, 108.8, 103.5, 80.4, 78.8, 78.6, 76.6, 75.9, 70.6, 69.8, 66.1, 64.7, 63.1, 51.6, 47.9, 41.4, 40.5, 38.3, 28.5, 23.0, 21.4, 21.1, 20.1, 17.4,15.8, 14.4, 14.0, 11.8 In accordance with Scheme 1, compounds of the invention having the Formula IX
were prepared:
Q O."A
,o' O
~
YN HO
HO.,.
... '=~O
O
wherein A, Q, and Z are defined as in Table II.
Table II
Example A- Q Z MS (ESI): +sC NMR (125 MHz CDCI3):S
m/z (M+H)+ ' NAc H 815 205.8,184.6, 176.5,169.3,156.2, 153.0, 149.9, 140.3,134.8, 126.6, 120.8, 110.9, Example 01 N> 102.6, 79.6, 79.0, 76.3, 76.2, 70.5, 69.7, 0 66.1, 58.4, 50.9, 45.4, 40.5, 29.9, 28.6, 25.5, 23.4, 21.6, 20.2, 19.7, 17.2, 15.6, 14.4, 12.9, 12.0 0 H 805 215.1, 205.7, 169.6, 166.8, 156.2, 152.1, ):s N'~--NHZ 132.0,126.6, 121.3, 118.9, 102.5, 80.0, Example 02 78.7, 76.3, 76.1, 70.5, 69.7, 66.0, 50.8, 46.3, 45.7, 40.4, 40.0, 39.1, 28.5, 23.1, 21.6, 19.7, 18.5,17.3,14.5,13.1,11.8 0 H 789 215.0, 205.7, 169.6, 162.2, 156.2, 149.0, ):0 N'~--NHZ 142.8, 131.4, 124.8, 116.3, 109.7, 102.5, Example 03 79.9, 78.7, 76.3, 76.2, 70.5, 69.7, 66.1, 59.2, 50.8, 46.3, 45.7, 40.5, 40.0, 39.1, 28.5, 23.1, 21.6,19.7,18.5,17.2,14.5,13.1, 12.9,11.8.
NAc H 864 (selected): 205.9, 184.6, 176.4, 169.4, F 166.7, 156.4, 154.2, 152.2, 140.1, 140.0, N 134.0, 133.9, 133.3, 133.2, 116.6, 116.5, Example 04 '--NH2 112.6, 112.4, 102.6, 79.6, 79.0, 76.2, 75.8, S 75.4, 70.5, 69.7, 66.1, 58.5, 50.9, 45.4, 40.5, 39.0, 28.5, 25.5, 23.3, 21.6, 20.2, 19.7, 17.2, 15.7,14.4,13.0,12Ø
0 H 848 (selected): 216.3, 205.4,169.6, 162.0, N 155.8,149.0,131.9, 127.1,119.6, 102.3, Example 05 ~ I ~"Y NH2 80.0, 79.0, 76.7, 76.3, 76.0, 70.5, 69.7, 66.0, a 59.4, 50.7, 46.3, 45.7, 40.5, 40.1, 39.3, 29.9, 28.6, 23.1, 21.6, 19.8, 18.2,17.4, 14.5, 13.7, 13.0, 11.7.
F 0 H 823 (selected): 215.2, 205.7, 169.6, 167.2, 156.5,154.1,152.1, 140.2,140.1, 134.0, N 133.9, 133.0, 132.9, 116.6, 112.5, 112.3, Example 06 ~NHz 102.5, 76.3, 70.5, 69.7, 66.1, 59.1, 50.9, 46.3, 45.7, 40.5, 39.2, 28.5, 23.1, 21.6, 19.7, 18.5, 17.2, 14.5, 13.2, 12.8, 11.8 PCN ~ NAc H 830 Example 07 NHZ
In accordance with Scheme I, compounds of the invention having the Formula X were prepared:
A "'A
HO O N O N
HO,, o .. '''O
O
0 'oZ 0 x wherein A, X and Z are defined as in Table III.
TABLE III
Example A- x z MS (ESI):
m/z (M+H)+
Example 01 HZN~ ~ ~ NH2 H 790 N ~
Example 4.
g NAc ,, 011 O ~~''' O 0 O NI
Step 4a:
Br S
\ ~/OH
A solution of 5-bromo-2-thiophenecarboxaldehyde (13.08 g, 68.46 mmol) in isopropanol (100 mL) was treated with NaBH4 (1.30 g, 34.23 mmol) at 0 C for 1.5 hours with stirring before HCI (1 M, 60 mL, 60 mmol) was charged. The mixture was stirred for 0.5 hour before being partitioned (ethyl acetate and saturated NaHCO3). The organics were washed with water, brine, and then dried (Na2SO4).
The volatile was removed by evaporation and dried in a vacuum to give the title compound (12.55 g, 95%).
Step 4b:
Bu3Sn S
JoH
Into a solution of the compound of Step 4a (5.02 g, 26.00 mmol) in THF (80 mL) was treated with NaH (95%, 730 mg, 28.9 mmol) at room temperature for 50 minutes with stirring. It was chilled to -78 C before n-BuLi (1.6 M in hexanes, 20 mL, 32 mmol) was charged. The mixture was kept at -78 C for 1 hour before n-Bu3SnC1(17.6 mL, 65 mmol) was introduced. The mixture was warmed up naturally to room temperature and stirred over night. The volatile was evaporated off and the residue was partitioned (ethyl acetate and saturated NaHCO3). The organics were washed with water, brine, and then dried (Na2SO4). Evaporation followed by chromatography (silica, hexanes/ethyl acetate) gave the title compound (4.51 g, 43%).
Step 4c:
O
Br N
a ON
Into a 250 mL round bottom flask was charged 2-amino-6-bromopyridine (25.0 g, 0.144 mol) and phthalic anhydride (21.4g, 0.144 mol). The solid mixture in the open flask (with a slow flow of N2) was heated to 175 C and the temperature was kept there for lhour or until no vapor comes out. It was cooled down to room temperature and vacuumed for 10 hours to give the title compound as a tan solid (100% yield).
Step 4d: ~ S
N I
C:N OH A mixture of the compound from Step 4b (4.50 g, 11.16 mmol), the compound from Step 4c (3.72 g, 12.28 mmol), and Pd(PPh3)4 (645 mg, 0.56 mmol) in PhMe (50 mL) was degassed and heated at 100 C under N2 for 17 hours before being cooled to 0 C. The insoluble was collected by filtration and washed with PhMe to give the title compound (2.90 g). The filtrate and washings were evaporated and the residue was chromatographed (silica, hexanes/ethyl acetate) to give another crop of the title compound (0.20 g).
ESIMS m/e: 337 (M+H)+.
Step 4e:
N \N I ~
CI
O
A suspension of the compound from Step 4d (3.10 g, 9.22 mmol) in methylene chloride (50 mL) was treated with thionyl chloride (3.35 mL, 46.08 mmol) at 0 C. The mixture was warmed up naturally to room temperature and stirred for 16 hours. The volatile was evaporated off. The residue was partitioned (CHaC12/saturated NaHCO3). The organics were washed with water, brine, and then dried (Na2SO4). The volatile was removed by evaporation and dried in vacuo to give the title compound (3.253 g, 100%).
ESIMS m/e: 355/357 (M+H)+.
Step 4f:
o N s N
I / O-N
O
Into a solution of N-hydroxylphthalimide (2.40 g, 14.7 mmol) in DMF (20 mL) was added NaH (95%, 332 mg, 13.8 mmol) at 0 C. It was warmed up to room temperature and stirred for 1 hour. It was added into a solution of the compound from Step 4e (3.25 g, 9.2 mmol) in DMF (25 mL). The mixture was stirred at 40 C
for 16 hours before being cooled to room temperature. It was diluted with saturated NaHCO3 and water. The insoluble was collected by filtration, washed with saturated NaHCO3 and water, and dried to give the title compound (3.930 g, 89%).
ESIMS m/e: 482 (M+H)+.
Step 4g:
/
~N Is A suspension of the compound from Step 4f (1.00 g, 2.08 mmol) in methanolic ammonia (2M, 20 mL, 40 mmol) was heated at 55 C for 2 hours before being cooled to room temperature. The insoluble was filtered off and washed with MeOH. The combined filtrate and washings were evaporated. The residue was added CHZCl2 to dissolve the crude title compound (548 mg) after evaporation.
ESIMS m/e: 222 (M+H)+.
Step 4h:
N,Ac O O Ac ~N~
O "''O O
0 1"'O
NI
A mixture of compound of formula VIII where X and Y taken together with the atom that they are attached is C=N-Ac, U = H, V = OH, Z = H, Rp = Ac and W
= NMe2 (356 mg, 0.50 mmol), 2-pyridylacetic acid hydrochloride (174 mg, 1.0 mmol), 1-(3-dimethylaminopropyl)-3-ethylcabodiimide hydrochloride (EDC-HCI, 192 mg, 1.0 mmol), triethylamine (0.28 mL, 2.0 mmol) and DMAP (10.0 mg) in methylene chloride (5.0 mL) was stirred at room temperature for 22 hours before more 2-pyridylacetic acid hydrochloride (87 mg, 0.5 mmol) and EDC-HCI (192 mg, 1.0 mmol). It was stirred for another 3 hours before being partitioned (ethyl acetate and 10% K2C03). The organics were washed with water, brine, and then dried (Na2SO4). The volatile was removed by evaporation and dried in a vacuum to give a yellow foam (450 mg) as the crude title compound.
ESIMS m/e: 832 (M+H)+.
Step 4i:
/ ~
_N g N,Ac H2N O Ac "'N/
HO 0~,, 'l"O O
O "'O
Into a solution of the crude compound from Step 4g (166 mg, -0.62 mmol) in ethanol (5.0 mL) and HCl (1 M, 2.5 mL) at-5 C was added the crude compound from Step 4h (450 mg, 0.5 mmol at most). After being stirred for one hour, more crude compound from Step 4g (50 mg, -0.18 mmol) was added. The mixture was stirred for another 1 hour before partition (ethyl acetate and saturated NaHCO3).
The organics were washed with water, brine, and then dried (Na2SO4). It was evaporated and the residue was chromatographed (silica, hexanes/acetone) to give the title compound (332 mg, 64%) as a 2:1 mixture.
ESIMS m/e: 1035 (M+H)+.
Step 4j:
/ \ / I
c i_N g NAc H2N O':~,~=~' \N/
~ HO~,, HO Ory Iv '" O O
O N
A solution of the compound from Step 4i (100 mg) in MeOH (3 mL) was stirred at room temperature for 70 hours before evaporation to give the title compound. The two bridged oxime isomers were separated by HPLC.
E-oxime isomer: ESIMS m/e: 993 (M+H)+. 13C NMR (CDC13, 125 MHz): 184.6, 178.0, 172.5, 170.4, 158.0, 153.9,153.2, 151.0, 149.1, 145.4, 141.8, 138.1, 136.6, 127.5, 124.4, 123.7, 122.3, 109.1, 106.7, 103.0, 82.3, 79.4, 78.5, 78.3, 76.4, 75.0, 70.8, 70.5, 69.1, 65.4, 63.1, 62.4, 43.8, 42.7, 40.4, 39.9, 38.3, 36.8, 35.8, 29.7, 29.2, 25.1, 23.2, 21.0, 19.9, 19.1, 17.5, 15.0, 14.3, 12.1, 9Ø
Z-oxime isomer: ESIMS m/e: 993 (M+H)+. 13C NMR (CDC13, 125 MHz): 184.4, 176.6, 173.7, 170.2, 158.0, 156.1, 153.9, 151.1, 149.1, 145.5, 141.2, 138.1, 136.6, 128.0, 124.4, 123.8, 122.3, 109.1, 106.7, 103.0, 83.3, 80.2, 79.0, 77.7, 77.5, 75.8, 70.8, 70.6, 70.5, 69.1, 65.4, 58.7, 43.2, 40.3, 39.1, 38.5, 36.5, 36.0, 29.7, 29.2, 25.2, 22.7, 21.1, 20.1, 19.6, 16.8, 15.4, 14.6, 11.3, 9.1.
Example 5. Compounds with improved antibacterial activities.
Table IV below provides MIC data of species from U.S. Patent No. 6,878,691 and U.S. Patent Application Publication No. 2004/0053 86 1.
The values in the table are minimum inhibition concentration (MIC) and are expressed as ug/mL.
Assays for MIC are described above.
Table IV
S. S. S. S. S. S. S. H.
Com- Structure aureus aureus aureus pneumoniae pneumoniae pyogenes pyogenes influen pound 29213 27660 33591 7701 700906 1323 2912 zae Al 0.25 0.13 >64 0.5 0.25 0.5 8 8 N N,Ac O
HO~ 'N ,=~,"HO, N-O
O
O A2 N 0.5 0.25 >64 0.5 0.25 1 16 16 N
N.Ac HO~ 'N =,O HO N_ O O
A3 N N 0.25 0.25 >64 2 0.13 16 32 8 N N,Ac O
HO~ 'N ,O ..HO N_ O 'O~
O O
A4 ~ ,N 8 64 64 >64 ~ o ~N
HOV OHO
'O 0 O
O "0=., OAc OMe A5 >64 2 64 >64 >64 NH
O'~~=" N
O
HOV oHO,..
O ,,, Oo O "9OH
A6 9' 1 1 16 1 8 2 8 >64 N)\
HO O HO.,, O "O O
O 'O
O IN
Table V provides data for compounds of this invention demonstrating improved microbiological activities against gram negative bacteria and resistant organism. The values in Table V are minimum inhibition concentration and are expressed as ug/mL.
Table V
S. aureus S. aureus S. S. S. S. S. H.
Com- Structure 29213 27660 aureus pneumoniae pneumoniae pyogenes pyogen influen pound 33591 7701 700906 1323 es zae BI H=N~N \ ~ <=0.06 <=0.06 >64 <=0.06 1 0.25 412 23929 S
H O \N t,o Hq N-O O
0.125 <=0.06 >64 0.125 0.5 0.5 2 2 B2 H2N N,Ac O
HO~ N O HO \N~
O O
O
O O
B3 H,N ,N ~ i <=0.06 <=0.06 32 0.125 0.25 0.5 4 2 \
NO~~~..0 H~ ~\[N_ O~
O O
0.125 0.125 32 0.125 0.125 0.5 1 4 B4 N N0 Ac HO~~~ HO N
I :~ A
O O
The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
~
14 N H N ~~
HzN~ ~S ~
o , 0 H
H N--~ 0 H
z S
H
N
N~ NAc H
~~~~
17 ~
HZN--~ ~
j N NAc H
18 o HZN--~ ~
N ~ 0 H
AH~s ~ I NAc H
N~
N;Xi NAc H
HZN
21 N~
NAc F
HZN
'22 H
c F
N NA
A., ~~~~
H2N_<
N
H NAc H
H2N-<
25 N, ~-SeN /
NAc H
26 r "
C
s H NAc H
i N NAc H
i N I O H
29 ~
's " NAc H
30 clNmN
" NAc H
31 ~
i (/
j " NAc H
32 HN-~ ~ /
//-j " NAc H
N =
,N NAc H
HZN4N ~ N NAc H
35 ~
~N~ I /
"~ NAc H
36 N ~
N~N ~ ~ NAc H
N , ,N ~ NAc H
38 HZN-<"N ~ I NC(O)OCH3 H
O /
39 HZN ~ ~ NH H
N
One preferred compound of the invention has the formula III:
O /
H2N--C ~ I
O I' O RP W
IO
HO C\~ 1 / ==, õO 0 O U
z III
wherein Rp, U, V, W, X, Y, L, and Z are as defined previously.
Another preferred compound of the invention has the formula IV:
o /
H-2N/ ~ I O
N-\
HO O~ O , OP,,, N
\~/
O
z IV
wherein Z and Rp are as previously defined.
Yet another preferred compound of the invention has the formula V:
O
HZN-~
R
lP \ N
HO O~~/ V =
,,.õ~~'0 O
\' O
O
z V
wherein Z and Rp are as defined previously.
In another aspect ot the invention, tnere are proviaeu nuvGi j-Q%,yliuv, mlurvu erythromycin compounds represented by the Formula VI:
B~O Y X
~~.
O ORp W
HO ~~~ II / O
p11111 O
O
'/
O
VI
or any racemates, enantiomers, regioisomers, salts, esters, or prodrugs thereof wherein X, Y, L, W, and Rp are as defined previously;
B is independently selected from hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group.
One preferred compound of Formula VI has the formula VII:
P-N / O
S N
H2N , 000 R N
O N P
HO O
O unnl0 0 O
I\'"
O
N
VII
wherein Rp is as previously defined.
DETAILED DESCRIPTION OF THE INVENTION
Definitions Listed below are definitions of various terms used to describe this invention.
These definitions apply to the terms as they are used throughout this specification and claims, unless otherwise limited in specific instances, either individually or as part of a larger group.
An "aliphatic group" is non-aromatic moiety that may contain any combination of carbon atoms, hydrogen atoms, halogen atoms, oxygen, nitrogen or other atoms, and optionally contain one or more units of unsaturation, e.g., double and/or triple bonds. An aliphatic group may be straight chained, branched or cyclic and preferably contains between about 1 and about 24 carbon atoms, more typically between about 1 and about 12 carbon atoms. In addition to aliphatic hydrocarbon groups, aliphatic groups include, for example, polyalkoxyalkyls, such as polyalkylene glycols, polyamines, and polyimines, for example. Such aliphatic groups may be further substituted.
The terms "Cl-C3 alkyl," "C1-C6 alkyl," or "Cl-C12 alkyl," as used herein, refer to saturated, straight- or branched-chain hydrocarbon radicals containing between one and three, one and twelve, or one and six carbon atoms, respectively.
Examples of C1-C3 alkyl radicals include methyl, ethyl, propyl and isopropyl radicals; examples of C1-C6 alkyl radicals include, but are not limited to, methyl, ethyl, propyl, propyl, butyl, pentyl, and hexyl radicals; and examples of C1-C12 alkyl radicals include, but are not limited to, ethyl, propyl, propyl, hexyl, heptyl, octyl, nonyl, decyl, undecyl, dodecyl radicals and the like.
The term "substituted alkyl," as used herein, refers to an alkyl, such as a C1-C12 alkyl or C1-C6 alkyl group, substituted by one, two, three or more aliphatic or aromatic substituents.
Suitable aliphatic or aromatic substituents include, but are not limited to, -F, -Cl, -Br, -I, -OH, protected hydroxy, aliphatic ethers, aromatic ethers, oxo, -NO2, -CN, -CI-CIZ-alkyl optionally substituted with halogen (such as perhaloalkyls), C2-C12-alkenyl optionally substituted with halogen, -C2-C12-alkynyl optionally substituted witli halogen, -NH2, protected amino, -NH -C1-C12-alkyl, -NH -C2-alkenyl, -NH -C2-C12-allcynyl, -NH -C3-C12-cycloalkyl, -NH -aryl, -NH -heteroaryl, -NH -heterocycloalkyl, -dialkylamino, -diarylamino, -diheteroarylamino, -O-C1-C12-alkyl, -O-C2-C12-alkenyl, -O-Cz-C12-alkynyl, -O-C3-C12-cycloalkyl, -0-aryl, -0-heteroaryl, -0-heterocycloalkyl, -C(O)- CI-C12-alkyl, -C(O)- C2-C12-alkenyl, -C(O)- C2-C12-alkynyl, -C(O)-C3-C12-cycloalkyl, -C(O)-aryl, -C(O)-heteroaryl, -C(O)-heterocycloalkyl, -CONH2, -CONH- C1-C12-alkyl, -CONH- Cz-C12-alkenyl, -CONH- C2-C12-alkynyl, -CONH-C3-C12-cycloalkyl, -CONH-aryl, -CONH-heteroaryl, -CONH-heterocycloalkyl, -C02- CI-C12-alkyl, -C02- Ca-C12-alkenyl, -C02- C2-C12-alkynyl, -CO2-C3-Clz-cycloalkyl, -C02-aryl, -C02-heteroaryl, -C02-heterocycloalkyl, -OC02- C1-C12-alkyl, -OC02-C2-C12-alkenyl, -OC02- C2-C12-alkynyl, -OCO2-C3-CIZ-cycloalkyl, -OC02-aryl, -OC02-heteroaryl, -OC02-heterocycloalkyl, -OCONH2, -OCONH- C1-C12-alkyl, -OCONH- C2-C12-alkenyl, -OCONH- C2-C12-alkynyl, -OCONH- C3-C12-cycloalkyl, -OCONH- aryl, -OCONH- heteroaryl, -OCONH- heterocycloalkyl, -NHC(O)- C1-C12-a1ky1, -NHC(O)-C2-C12-alkenyl, -NHC(O)-CZ-Cla-alkynyl, -NHC(O)-C3-C12-cycloalkyl, NHC(O)-aryl, -NHC(O)-heteroaryl, -NHC(O)-heterocycloalkyl, -NHCO2- C1-C12-alkyl, -NHCO2- C2-C12-alkenyl, -NHCO2- C2-C12-alkynyl, -NHCO2- C3-Cla-cycloalkyl, -NHC02- aryl, -NHCOZ- heteroaryl, -NHCO2- heterocycloalkyl, NHC(O)NH2, NHC(O)NH- C1-C12-alkyl, -NHC(O)NH-C2-C12-alkenyl, -NHC(O)NH-Ca-C12-alkynyl, NHC(O)NH-C3-C12-cycloalkyl, -NHC(O)NH-aryl, -NHC(O)NH-heteroaryl, -NHC(O)NH-heterocycloalkyl, NHC(S)NHZ, NHC(S)NH- Cl-C12-alkyl, -NHC(S)NH-C2-C12-alkenyl, -NHC(S)NH-Ca-C12-alkynyl, -NHC(S)NH-C3-C12-cycloalkyl, -NHC(S)NH-aryl, -NHC(S)NH-heteroaryl, -NHC(S)NH-heterocycloalkyl, -NHC(NH)NH2, NHC(NH)NH- Cl-C12-alkyl, -NHC(NH)NH-C2-C12-alkenyl, -NHC(NH)NH-C2-C12-alkynyl, -NHC(NH)NH-C3-C1z-cycloalkyl, -NHC(NH)NH-aryl, -NHC(NH)NH-heteroaryl, -NHC(NH)NH-heterocycloalkyl, NHC(NH)-C1-C12-alkyl, -NHC(NH)-C2-C12-alkenyl, NHC(NH)-C2-C12-alkynyl, -NHC(NH)-C3-C12-cycloalkyl, -NHC(NH)-aryl, -NHC(NH)-heteroaryl, -NHC(NH)-heterocycloalkyl, -C(NH)NH-C1-Cla-alkyl, -C(NH)NH-C2-C12-alkenyl, -C(NH)NH-C2-Cla-alkynyl, -C(NH)NH-C3-Cia-cycloalkyl, -C(NH)NH-aryl, -C(NH)NH-heteroaryl, -C(NH)NH-heterocycloalkyl, -S(O)-C1-C12-alkyl, - S(O)-C2-C12-alkenyl, - S(O)-C2-C12-alkynyl, - S(O)-C3-C12-cycloalkyl, - S(O)-aryl, -S(O)-heteroaryl, - S(O)-heterocycloalkyl -SOaNHa, -SO2NH- Cl-Cla-alkyl, -SO2NH- C2-C12-alkenyl, -SO2NH- C2-C12-alkynyl, -SO2NH- C3-C12-cycloalkyl, -SO2NH- aryl, -SO2NH- heteroaryl, -SO2NH- heterocycloalkyl, NHSO2-C1-C12-alkyl, -NHSOa-C2-C1z-allcenyl, - NHSOz-Ca-Cla-alkynyl, -NHSO2-C3-C12-cycloalkyl, -NHSOa-aryl, -NHSOa-heteroaryl, -NHSO2-heterocycloallcyl, -CH2NH2, -CHaSOaCH3, -aryl, -arylalleyl, -heteroaryl, -heteroarylallcyl, -heterocycloalkyl, -C3-C1z-cycloalkyl, polyalkoxyalkyl, polyalkoxy, -methoxymethoxy, -methoxyethoxy, -SH, -S-CI-C12-alkyl, -S-C2-CI2-alkenyl, -S-C2-C12-alkynyl, -S-C3-C12-cycloalkyl, -S-aryl, -S-heteroaryl, -S-heterocycloalkyl, or methylthiomethyl. It is understood that the aryls, heteroaryls, alkyls and the like can be further substituted.
The terms "C2-C12 alkenyl" or "C2-C6 alkenyl," as used herein, denote a monovalent group derived from a hydrocarbon moiety containing from two to twelve or two to six carbon atoms having at least one carbon-carbon double bond by the removal of a single hydrogen atom. Alkenyl groups include, but are not limited to, for example, ethenyl, propenyl, butenyl, 1-methyl-2-buten-1-yl, alkadienes and the like.
The term "substituted alkenyl," as used herein, refers to a"C2-C12 alkenyl"
or "C2-C6 alkenyl" group as previously defined, substituted by one, two, three or more aliphatic substituents.
The terms "C2-ClZ alkynyl" or "C2-C6 alkynyl," as used herein, denote a monovalent group derived from a hydrocarbon moiety containing from two to twelve or two to six carbon atoms having at least one carbon-carbon triple bond by the removal of a single hydrogen atom. Representative alkynyl groups include, but are not limited to, for example, ethynyl, 1-propynyl, 1-butynyl, and the like.
The term "substituted alkynyl," as used herein, refers to a"C2-C12 alkynyl"
or "C2-C6 alkynyl" group as previously defined, substituted by one, two, three or more aliphatic substituents.
The term "Cl-C6 alkoxy," as used herein, refers to a C1-C6 alkyl group, as previously defined, attached to the parent molecular moiety through an oxygen atom. Examples of C1-Cg-alkoxy include, but are not limited to, inethoxy, ethoxy, propoxy, isopropoxy, n-butoxy, sec-butoxy, tert-butoxy, n-pentoxy, neopentoxy and n-hexoxy.
The terms "halo" and "halogen," as used herein, refer to an atom selected from fluorine, chlorine, bromine and iodine.
The terms "aryl" or "aromatic," as used herein, refer to a mono- or bicyclic carbocyclic ring system having one or two aromatic rings including, but not limited to, phenyl, naphthyl, tetrahydronaphthyl, indanyl, idenyl and the like.
The terms "substituted aryl" or "substituted aromatic," as used herein, refer to an aryl group, as previously defined, substituted by one, two, three or more aromatic substituents.
The term "arylalkyl," as used herein, refers to an aryl group attached to the parent compound via a Cl-C3 alkyl or C1-C6 alkyl residue. Examples include, but are not limited to, benzyl, phenethyl and the like.
The term "substituted arylalkyl," as used herein, refers to an arylalkyl group, as previously defined, substituted by one, two, three or more aromatic substituents.
The terms "heteroaryl" or "heteroaromatic," as used herein, refers to a mono-, bi-, or tri-cyclic aromatic radical or ring having from five to ten ring atoms of which at least one ring atom is selected from S, 0 and N; zero, one, two, three or more ring atoms are additional heteroatoms independently selected from S, 0 and N;
and the remaining ring atoms are carbon, wherein any N or S contained within the ring may be optionally oxidized. Heteroaryl includes, but is not limited to, pyridinyl, pyrazinyl, pyrimidinyl, pyrrolyl, pyrazolyl, imidazolyl, thiazolyl, oxazolyl, isooxazolyl, thiadiazolyl, oxadiazolyl, thiophenyl, furanyl, quinolinyl, isoquinolinyl, benzimidazolyl, benzooxazolyl, quinoxalinyl, tetrazolyl and the like.
The heteroaromatic ring may be bonded to the chemical structure through a carbon or hetero atom.
The terms "substituted heteroaryl" or "substituted heteroaromatic," as used herein, refer to a heteroaryl group as previously defined, substituted by one, two, three or four aromatic substituents.
The term "alicyclic," as used herein, denotes a monovalent group derived from a monocyclic or bicyclic saturated carbocyclic ring compound by the removal of a single hydrogen atom. Examples include, but not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, bicyclo [2.2.1] heptyl, and bicyclo [2.2.2] octyl.
The term "substituted alicyclic" group as previously defined, substituted by one, two, three or more aliphatic substituents.
The terms "heterocyclic" as used herein, refers to a non-aromatic 5-, 6- or 7-membered ring or a bi- or tri-cyclic group fused system, where (i) each ring contains between one and three heteroatoms independently selected from oxygen, sulfur and nitrogen, (ii) each 5-membered ring has 0 to 1 double bonds and each 6-membered ring has 0 to 2 double bonds, (iii) the nitrogen and sulfur heteroatoms may optionally be oxidized, (iv) the nitrogen heteroatom may optionally be quaternized, (iv) any of the above rings may be fused to a benzene ring, and (v) the remaining ring atoms are carbon atoms which may be optionally oxo-substituted.
Representative heterocycloalkyl groups include, but are not limited to, [1,3]dioxolane, pyrrolidinyl, pyrazolinyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, piperidinyl, piperazinyl, oxazolidinyl, isoxazolidinyl, morpholinyl, thiazolidinyl, isothiazolidinyl, quinoxalinyl, pyridazinonyl, tetrahydrofuryl, and the like.
The term "substituted heterocyclic," as used herein, refers to a heterocyclic group, as previously defined, substituted by one, two, three or more aliphatic substituents.
The term "heteroarylalkyl," as used herein, refers to a heteroaryl group attached to the parent compound via a Cl-C3 alkyl or C1-C6 alkyl residue.
Examples include, but are not limited to, pyridinylmethyl, pyrimidinylethyl and the like.
The term "substituted heteroarylallcyl," as used herein, refers to a heteroarylalkyl group, as previously defined, substituted by independent replacement of one, two, or three or more aromatic substituents.
The term "C1-C3-alkylamino," as used herein, refers to one or two Ci-C3-alkyl groups, as previously defined, attached to the parent molecular moiety through a nitrogen atom. Examples of C1-C3-alkylamino include, but are not limited to, methylamino, dimethylamino, ethylamino, diethylamino, and propylamino.
The term "alkylamino" refers to a group having the structure -NH(C1-C12 allcyl) where C1-C12 alkyl is as previously defined.
The term "dialkylamino" refers to a group having the structure -N(C1-C12 alkyl) (C1-C12 alkyl), where CI-C12 alkyl is as previously defined. Examples of dialkylamino are, but not limited to, dimethylamino, diethylamino, methylethylamino, piperidino, and the like.
The term "allcoxycarbonyl" represents an ester group, i.e., an alkoxy group, attached to the parent molecular moiety through a carbonyl group such as methoxycarbonyl, ethoxycarbonyl, and the like.
The term "carboxaldehyde," as used herein, refers to a group of formula -CHO.
The term "carboxy," as used herein, refers to a group of formula -COOH.
The term "carboxamide," as used herein, refers to a group of formula -C(O)NH(CI-C12 alkyl) or -C(O)N(C1-C12 alkyl) (CI-Cla alkyl), -C(O)NH2, -NHC(O)(C1-C12 alkyl), -N(Cl-C1a alkyl)C(O)(C1-C12 alkyl) and the like.
The term "hydroxy protecting group," as used herein, refers to a labile chemical moiety which is known in the art to protect a hydroxyl group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the hydroxy protecting group as described herein may be selectively removed.
Hydroxy protecting groups as known in the art are described generally in T.H.
Greene and P.G. M. Wuts, Protective Groups in Organic Synthesis, 3rd edition, John Wiley & Sons, New York (1999). Examples of hydroxyl protecting groups include benzyloxycarbonyl, 4-nitrobenzyloxycarbonyl, 4-bromobenzyloxycarbonyl, 4-methoxybenzyloxycarbonyl, methoxycarbonyl, tert-butoxycarbonyl, isopropoxycarbonyl, diphenylmethoxycarbonyl, 2,2,2-trichloroethoxycarbonyl, 2-(trimethylsilyl)ethoxycarbonyl, 2-furfuryloxycarbonyl, allyloxycarbonyl, acetyl, formyl, chloroacetyl, trifluoroacetyl, methoxyacetyl, phenoxyacetyl, benzoyl, methyl, t-butyl, 2,2,2-trichloroethyl, 2-trimethylsilyl ethyl, 1, 1 -dimethyl-2-propenyl, 3-inethyl- 3 -butenyl, allyl, benzyl, para-methoxybenzyldiphenylmethyl, triphenylmethyl (trityl), tetrahydrofuryl, methoxymethyl, methylthiomethyl, benzyloxymethyl, 2,2,2-triehloroethoxymethyl, 2-(trimethylsilyl)ethoxymethyl, methanesulfonyl, para-toluenesulfonyl, trimethylsilyl, triethylsilyl, triisopropylsilyl, and the like. Preferred hydroxyl protecting groups for the present invention are acetyl (Ac or -C(O)CH3), benzoyl (Bz or -C(O)C6H5), and trimethylsilyl (TMS or-Sl(CH3)3)=
The term "protected hydroxy," as used herein, refers to a hydroxy group protected with a hydroxy protecting group, as defined above, including benzoyl, acetyl, trimethylsilyl, triethylsilyl, methoxymethyl groups, for example.
The term "hydroxy prodrug group", as used herein, refers to a promoiety group which is known in the art to change the physicochemical, and hence the biological properties of a parent drug in a transient manner by covering or masking the hydroxy group. After said synthetic procedure(s), the hydroxy prodrug group as described herein must be capable of reverting back to hydroxy group in vivo.
Hydroxy prodrug groups as known in the art are described generally in Kenneth B.
Sloan, Prodrugs Topical and Ocular Drug Delivery, (Drugs and the Pharmaceutical Sciences; Volume 53), Marcel Dekker, Inc., New York (1992).
The term "amino protecting group," as used herein, refers to a labile chemical moiety which is known in the art to protect an amino group against undesired reactions during synthetic procedures. After said synthetic procedure(s) the amino protecting group as described herein may be selectively removed.
Amino protecting groups as known in the are described generally in T.H. Greene and P.G.
M. Wuts, Protective Groups in Or ag nic Synthesis, 3rd edition, John Wiley &
Sons, New York (1999). Examples of amino protecting groups include, but are not limited to, t-butoxycarbonyl, 9-fluorenylmethoxycarbonyl, benzyloxycarbonyl, and the like.
The term "protected amino," as used herein, refers to an amino group protected with an amino protecting group as defined above.
The term "acyl" includes residues derived from acids, including but not limited to carboxylic acids, carbamic acids, carbonic acids, sulfonic acids, and phosphorous acids. Examples include aliphatic carbonyls, aromatic carbonyls, aliphatic sulfonyls, aromatic sulfinyls, aliphatic sulfinyls, aromatic phosphates and aliphatic phosphates.
The term "aprotic solvent," as used herein, refers to a solvent that is relatively inert to proton activity, i.e., not acting as a proton-donor.
Examples include, but are not limited to, hydrocarbons, such as hexane and toluene, for example, halogenated hydrocarbons, such as, for example, methylene chloride, ethylene chloride, chloroform, and the like, heterocyclic compounds, such as, for example, tetrahydrofuran and N-methylpyrrolidinone, and ethers such as diethyl ether, bis-methoxymethyl ether. Such compounds are well lcnown to those skilled in the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for example. Further discussions of aprotic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A. Riddick et al., Vol. II, in the Techniques of ChemistrY
Series, John Wiley & Sons, NY, 1986.
The term "protogenic organic solvent" or "protic solvent," as used herein, refers to a solvent that tends to provide protons, such as an alcohol, for example, methanol, ethanol, propanol, isopropanol, butanol, t-butanol, water and the like.
Such solvents are well known to those skilled in the art, and it will be obvious to those skilled in the art that individual solvents or mixtures thereof may be preferred for specific compounds and reaction conditions, depending upon such factors as the solubility of reagents, reactivity of reagents and preferred temperature ranges, for exainple. Further discussions of protogenic solvents may be found in organic chemistry textbooks or in specialized monographs, for example: Organic Solvents Physical Properties and Methods of Purification, 4th ed., edited by John A.
Riddick et al., Vol. II, in the Techniques of ChemistrX Series, John Wiley & Sons, NY, 1986.
Combinations of substituents and variables envisioned by this invention are only those that result in the formation of stable compounds. The term "stable", as used herein, refers to compounds which possess stability sufficient to allow manufacture and which maintains the integrity of the compound for a sufficient period of time to be useful for the purposes detailed herein (e.g., therapeutic or prophylactic administration to a subject).
The synthesized compounds can be separated from a reaction mixture and further purified by a method such as column chromatography, high pressure liquid chromatography, or recrystallization. As can be appreciated by the skilled artisan, further methods of synthesizing the compounds of the formulae herein will be evident to those of ordinary skill in the art. Additionally, the various synthetic steps may be performed in an alternate sequence or order to give the desired compounds.
Synthetic chemistry transformations and protecting group methodologies (protection and deprotection) useful in synthesizing the compounds described herein are known in the art and include, for example, those such as described in R. Larock, Comprehensive Organic Transformations, VCH Publishers (1989); T.W. Greene and P.G.M. Wuts, Protective Groups in Or ag nic Synthesis, 2d. Ed., John Wiley and Sons (1991); L. Fieser and M. Fieser, Fieser and Fieser's Reagents for Or ag nic S
nt~ hesis, John Wiley and Sons (1994); and L. Paquette, ed., Encyclopedia of Reagents for Organic S, nt~ hesis, John Wiley and Sons (1995), and subsequent editions thereof.
The term "subject" as used herein refers to an animal. Preferably the animal is a mammal. More preferably the mammal is a human. A subject also refers to, for example, dogs, cats, horses, cows, pigs, guinea pigs, fish, birds and the like.
The compounds of this invention may be modified by appending appropriate functionalities to enhance selective biological properties. Such modifications are lcnown in the art and may include those which increase biological penetration into a given biological system (e.g., blood, lymphatic system, central nervous system), increase oral availability, increase solubility to allow administration by injection, alter metabolism and alter rate of excretion.
The compounds described herein contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- , or as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forins. Optical isomers may be prepared from their respective optically active precursors by the procedures described above, or by resolving the racemic mixtures. The resolution can be carried out in the presence of a resolving agent, by chromatography or by repeated crystallization or by some combination of these techniques which are known to those skilled in the art. Further details regarding resolutions can be found in Jacques, et al., Enantiomers, Racemates, and Resolutions (John Wiley & Sons, 198 1).
When the compounds described herein contain olefinic double bonds, other unsaturation, or other centers of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers or cis- and trans- isomers. Likewise, all tautomeric forms are also intended to be included. The configuration of any carbon-carbon double bond appearing herein is selected for convenience only and is not intended to designate a particular configuration unless the text so states; thus a carbon-carbon double bond or carbon-heteroatom double bond depicted arbitrarily herein as trans may be cis, trans, or a mixture of the two in any proportion.
As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio. Pharmaceutically acceptable salts are well known in the art. For example, S. M. Berge, et al. describes pharmaceutically acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). The salts can be prepared in situ during the final isolation and purification of the compounds of the invention, or separately by reacting the free base function with a suitable organic acid or inorganic acid. Examples of pharmaceutically acceptable nontoxic acid addition salts include, but are not limited to, salts of an amino group tormed witn inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid lactobionic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include, but are not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydroxy-ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2-naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3-phenylpropionate, phosphate, picrate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p-toluenesulfonate, undecanoate, valerate salts, and the like. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, alkyl having from 1 to 6 carbon atoms, sulfonate and aryl sulfonate.
As used herein, the term "pharmaceutically acceptable ester" refers to esters which hydrolyze in vivo and include those that break down readily in the human body to leave the parent compound or a salt thereof. Suitable ester groups include, for example, those derived from pharmaceutically acceptable aliphatic carboxylic acids, particularly alkanoic, alkenoic, cycloalkanoic and alkanedioic acids, in which each allcyl or alkenyl moiety advantageously has not more than 6 carbon atoms.
Exainples of particular esters include, but are not limited to, formates, acetates, propionates, butyrates, acrylates and ethylsuccinates.
The term "pharmaceutically acceptable prodrugs" as used herein refers to those prodrugs of the compounds of the present invention which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals with undue toxicity, irritation, allergic response, and the like, commensurate with a reasonable benefit/risk ratio, and effective for their intended use, as well as the zwitterionic forms, where possible, of the compounds of the present invention. "Prodrug", as used herein means a compound which is convertible in vivo by metabolic means (e.g. by hydrolysis) to a compound of the invention. Various forms of prodrugs are known in the art, for example, as discussed in Bundgaard, (ed.), Design of Prodrugs, Elsevier (1985); Widder, et al.
(ed.), Methods in Enzymology, vol. 4, Academic Press (1985); Krogsgaard-Larsen, et al., (ed). "Design and Application of Prodrugs, Textbook of Drug Design and Development, Chapter 5, 113-191 (1991); Bundgaard, et al., Journal of Drug Deliver Reviews, 8:1-38(1992); Bundgaard, J. of Pharmaceutical Sciences, 77:285 et seq.
(1988); Higuchi and Stella (eds.) Prodrugs as Novel Drug Delivery Systems, American Chemical Society (1975); and Bernard Testa & Joachim Mayer, "Hydrolysis In Drug And Prodrug Metabolism: Chemistry, Biochemistry And Enzymology," John Wiley and Sons, Ltd. (2002).
This invention also encompasses pharmaceutical compositions containing, and methods of treating bacterial infections through administering, pharmaceutically acceptable prodrugs of compounds of the invention. For example, compounds of the invention having free amino, amido, hydroxy or carboxylic groups can be converted into prodrugs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues is covalently joined through an amide or ester bond to a free amino, hydroxy or carboxylic acid group of compounds of the invention. The amino acid residues include but are not limited to the 20 naturally occurring amino acids commonly designated by three letter symbols and also includes 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma-aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone. Additional types of prodrugs are also encompassed. For instance, free carboxyl groups can be derivatized as amides or alkyl esters.
Free hydroxy groups may be derivatized using groups including but not limited to hemisuccinates, phosphate esters, dimethylaminoacetates, and phosphoryloxymethyloxycarbonyls, as outlined in Advanced Drug Delivery Reviews, 1996, 19, 115. Carbamate prodrugs of hydroxy and amino groups are also included, as are carbonate prodrugs, sulfonate esters and sulfate esters of hydroxy groups. Derivatization of hydroxy groups as (acyloxy)methyl and (acyloxy)ethyl ethers wherein the acyl group may be an alkyl ester, optionally substituted with groups including but not limited to ether, amine and carboxylic acid functionalities, or where the acyl group is an amino acid ester as described above, are also encompassed. Prodrugs of this type are described in J. Med. Chem. 1996, 39, 10.
Free amines can also be derivatized as amides, sulfonamides or phosphonamides.
All of these prodrug moieties may incorporate groups including but not limited to ether, amine and carboxylic acid functionalities.
As used herein, unless otherwise indicated, the term "bacterial infection(s)"
or "protozoa infections"; includes, but is not limited to, bacterial infections and protozoa infections that occur in mammals, fish and birds as well as disorders related to bacterial infections and protozoa infections that may be treated or prevented by administering antibiotics such as the compounds of the present invention. Such bacterial infections and protozoa infections and disorders related to such infections include, but are not limited to, the following: pneumonia, otitis media, sinusitus, bronchitis, tonsillitis, cystic fibrosis (CF) and mastoiditis related to infection by Streptococcus pneumoniae, Haemophilus influenzae, Moraxella catarrhalis, Staphylococcus aureus, Peptostreptococcus spp. or Pseudomonas spp.;
pharynigitis, rheumatic fever, and glomerulonephritis related to infection by Streptococcus pyogenes, Groups C and G streptococci, Clostridium diptheriae, or Actinobacillus haemolyticum; respiratory tract infections related to infection by Mycoplasma pneumoniae, Legionella pneumophila, Streptococcus pneumoniae, Haemophilus influenzae, or Chlamydia pneumoniae; uncomplicated skin and soft tissue infections, abscesses and osteomyelitis, and puerperal fever related to infection by Staphylococcus aureus, coagulase-positive staphylococci (i.e., S.
epidermidis, S. hemolyticus, etc.), S. pyogenes, S. agalactiae, Streptococcal groups C-F (minute-colony streptococci), viridans streptococci, Corynebacterium spp., Clostridium spp., or Bartonella henselae; uncomplicated acute urinary tract infections related to infection by S. saprophyticus or Enterococcus spp.;
uretliritis and cervicitis; and sexually transmitted diseases related to infection by Chlamydia trachomatis, Haemophilus ducreyi, Treponema pallidum, Ureaplasma urealyticum, or Nesseria gonorrheae; toxin diseases related to infection by S. aureus (food poisoning and Toxic shock syndrome), or Groups A, S. and C streptococci;
ulcers related to infection by Helicobacter pylori; systemic febrile syndromes related to infection by Borrelia recurrentis; Lyme disease related to infection by Borrelia burgdorferi; conjunctivitis, keratitis, and dacrocystitis related to infection by C.
trachomatis, N. gonorrlioeae, S. aureus, S. pneumoniae, S. pyogenes, H.
influenzae, or Listeria spp.; disseminated Mycobacterium avium complex (MAU) disease related to infection by Mycobacterium avium, or Mycobacterium intracellulare;
tuberculosis disease related to infection by Mycobacterium tuberculosis;
gastroenteritis related to infection by Campylobacter jejuni; intestinal protozoa related to infection by Cryptosporidium spp. odontogenic infection related to infection by viridans streptococci; persistent cough related to infection by Bordetella pertussis; gas gangrene related to infection by Clostridium perfringens or Bacteroides spp.; Skin infection by S. aureus, Propionibacterium acne;
atherosclerosis related to infection by Helicobacter pylori or Chlamydia pneumoniae; or the like.
Bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in animals include, but are not limited to, the following: bovine respiratory disease related to infection by P.
haemolytica., P.
multocida, Mycoplasma bovis, or Bordetella spp.; cow enteric disease related to infection by E. coli or protozoa (i.e., coccidia, cryptosporidia, etc.), dairy cow mastitis related to infection by S. aureus, S. uberis, S. agalactiae, S.
dysgalactiae, Klebsiella spp., Corynebacterium, or Enterococcus spp.; swine respiratory disease related to infection by A. pleuropneumoniae., P. multocida, or Mycoplasma spp.;
swine enteric disease related to infection by E. coli, Lawsonia intracellularis, Salmonella spp., or Serpulina hyodyisinteriae; cow footrot related to infection by Fusobacterium spp.; cow metritis related to infection by E. coli; cow hairy warts related to Infection by Fusobacterium necrophorum or Bacteroides nodosus; cow pink-eye related to infection by Moraxella bovis, cow premature abortion related to infection by protozoa (i.e. neosporium); urinary tract infection in dogs and cats related to infection by E. coli; skin and soft tissue infections in dogs and cats related to infection by S. epidermidis, S. intermedius, coagulase neg. Staphylococcus or P.
multocida; and dental or mouth infections in dogs and oats related to infection by Alcaligenes spp., Bacteroides spp., Clostridium spp., Enterobacter spp., Eubacterium spp., Peptostreptococcus spp., Porphfyromonas spp., Campylobacter spp., Actinomyces spp., Erysipelothrix spp., Rhodococcus spp., Trypanosoma spp., Plasmodium spp., Babesia spp., Toxoplasma spp., Pneumocystis spp., Leishmania spp., and Trichomonas spp. or Prevotella spp. Other bacterial infections and protozoa infections and disorders related to such infections that may be treated or prevented in accord with the method of the present invention are referred to in J. P.
Sanford at al.,"The Sanford Guide To Antimicrobial Therapy," 26th Edition, (Antimicrobial Therapy, Inc., 1996).
Antibacterial activity studies may be carried out using suitable assays as are known in the art. Susceptibility tests can be used to quantitatively measure the in vitro activity of an antimicrobial agent against a given bacterial isolate.
Compounds are tested for in vitro antibacterial activity by a micro-dilution method.
Minimal Inhibitory Concentration (MIC) is determined in 96 well microtiter plates utilizing the appropriate Mueller Hinton Broth medium (CAMHB) for the observed bacterial isolates. Antimicrobial agents are serially diluted (2-fold) in DMSO to produce a concentration range from about 64 g/ml to about 0.03 g/ml. The diluted compounds (2 l/well) are then transferred into sterile, uninoculated CAIVIHB
(0.2 mL) by use of a 96 fixed tip-pipeting station. The inoculum for each bacterial strain is standardized to 5 x 105 CFU/inL by optical comparison to a 0.5 McFarland turbidity standard. The plates are inoculated with 10 Uwell of adjusted bacterial inoculum. The 96 well plates are covered and incubated at 35 +/- 2 C for 24 hours in ambient air environment. Following incubation, plate wells are visually examined by Optical Density measurement for the presence of growth (turbidity). The lowest concentration of an antimicrobial agent at which no visible growth occurs is defined as the MIC. The compounds of the invention generally demonstrated an MIC in the range from about 64 g/ml to about 0.03 g/ml.
All in vitro testing follows the guidelines described in the Approved Standards M7-A4 protocol, published by the National Committee for Clinical Laboratory Standards (NCCLS).
The invention further provides compositions and methods of treating subjects suffering from an inflammatory condition comprising administering to a subject in need thereof, a therapeutically effective amount of at least one compound of the invention. Specific examples of inflammatory conditions treatable according to the invention include, but are not limited to, scleritis; epi-scleritis;
allergic conjunctivitis; pulmonary inflammatory diseases, particularly CF, asthma, chronic obstructive pulmonary disease (COPD), allergic bronchopulmonary aspergillosis (ABPA), and sarcoidosis; procto-sigmoiditis; allergic rhinitis; arthritis;
tendonitis;
apthous stomatitis; and inflammatory bowel disease.
The invention further provides compositions and methods for i) prophylactic treatment of those subjects susceptible to the symptoms CF including pulmonary infection and inflammation associated with CF, ii) treatinent at the initial onset of symptoms of pulmonary infection and inflammation associated with CF, and iii) treatment of ongoing or relapsing symptoms of infection and inflammation associated with CF. In accordance with the invention a compound of the invention, is administered to a subject in need of treatment for CF, in amount sufficient to prevent, diminish or eradicate symptoms of CF including chronic pulmonary inflammation and infection.
The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of a compound of the present invention formulated together with one or more pharmaceutically acceptable carriers or excipients.
As used herein, the term "pharmaceutically acceptable carrier or excipient"
means a non-toxic, inert solid, semi-solid or liquid filler, diluent, encapsulating material or formulation auxiliary of any type. Some examples of materials which can serve as pharmaceutically acceptable carriers are sugars such as lactose, glucose and sucrose; starches such as corn starch and potato starch; cellulose and its derivatives such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients such as cocoa butter and suppository waxes; oils such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols such as propylene glycol; esters such as ethyl oleate and ethyl laurate; agar; buffering agents such as magnesium hydroxide and aluminun hydroxide; alginic acid; pyrogen-free water; isotonic saline;
Ringer's solution; ethyl alcohol, and phosphate buffer solutions, as well as other non-toxic compatible lubricants such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, releasing agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the composition, according to the judgment of the formulator.
The pharmaceutical compositions of this invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir, preferably by oral administration or administration by injection. The pharmaceutical compositions of this invention may contain any conventional non-toxic pharmaceutically-acceptable carriers, adjuvants or vehicles. In some cases, the pH of the forinulation may be adjusted with pharmaceutically acceptable acids, bases or buffers to enhance the stability of the formulated compound or its delivery form. The term parenteral as used herein includes subcutaneous, intracutaneous, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional and intracranial injection or infusion techniques.
Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions, may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol.
Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides.
In addition, fatty acids such as oleic acid are used in the preparation of injectables.
The injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.
In order to prolong the effect of a drug, it is often desirable to slow the absorption of the drug from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the drug then depends upon its rate of dissolution, which, in turn, may depend upon crystal size anca crystalline form. Alternatively, delayed absorption of a parenterally administered drug form is accomplished by dissolving or suspending the drug in an oil vehicle.
Injectable depot forms are made by forming microencapsule matrices of the drug in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of drug to polymer and the nature of the particular polymer employed, the rate of drug release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the drug in liposomes or microemulsions that are compatible with body tissues.
Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.
Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalciuin phosphate and/or: a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.
Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like.
The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.
Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, eye ointments, powders and solutions are also contemplated as being within the scope of this invention.
The ointments, pastes, creams and gels may contain, in addition to an active compound of this invention, excipients such as animal and vegetable fats, oils, waxes, paraffins, starch, tragacanth, cellulose derivatives, polyethylene glycols, silicones, bentonites, silicic acid, talc and zinc oxide, or mixtures thereof.
Powders and sprays can contain, in addition to the compounds of this invention, excipients such as lactose, talc, silicic acid, aluminum hydroxide, calcium silicates and polyamide powder, or mixtures of these substances. Sprays can additionally contain customary propellants such as chlorofluorohydrocarbons.
Transdermal patches have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.
For pulmonary delivery, a therapeutic composition of the invention is formulated and administered to the subject in solid or liquid particulate form by direct administration e.g., inhalation into the respiratory system. Solid or liquid particulate forms of the active compound prepared for practicing the present invention include particles of respirable size: that is, particles of a size sufficiently small to pass through the mouth and larynx upon inhalation and into the bronchi and alveoli of the lungs. Delivery of aerosolized therapeutics, particularly aerosolized antibiotics, is known in the art (see, for example U.S. Pat. No. 5,767,068 to VanDevanter et al., U.S. Pat. No. 5,508,269 to Smith et al., and WO 98/43,650 by Montgomery, all of which are incorporated herein by reference). A discussion of pulmonary delivery of antibiotics is also found in U.S. Pat. No. 6,014,969, incorporated herein by reference.
According to the methods of treatment of the present invention, bacterial infections, cystic fibrosis and inflammatory conditions are treated or prevented in a subject such as a human or another animal by administering to the subject a therapeutically effective amount of a compound of the invention, in such amounts and for such time as is necessary to achieve the desired result.
By a "therapeutically effective amount" of a compound of the invention is meant an amount of the compound which confers a therapeutic effect on the treated subject, at a reasonable benefit/risk ratio applicable to any medical treatment. The therapeutic effect may be objective (i.e., measurable by some test or marker) or subjective (i.e., subject gives an indication of or feels an effect). An effective amount of the compound described above may range from about 0.1 mg/Kg to about 500 mg/Kg, preferably from about 1 to about 50 mg/Kg. Effective doses will also vary depending on route of administration, as well as the possibility of co-usage with other agents. It will be understood, however, that the total daily usage of the compounds and compositions of the present invention will be decided by the attending physician within the scope of sound medical judgment. The specific therapeutically effective dose level for any particular subject will depend upon a variety of factors including the disorder being treated and the severity of the disorder; the activity of the specific compound employed; the specific composition employed; the age, body weight, general health, sex and diet of the subject;
the time of administration, route of administration, and rate of excretion of the specific compound employed; the duration of the treatment; drugs used in combination or contemporaneously with the specific compound employed; and lilee factors well known in the medical arts.
The total daily dose of the compounds of this invention administered to a human or other animal in single or in divided doses can be in amounts, for example, from 0.01 to 50 mg/kg body weight or more usually from 0.1 to 25 mg/kg body weight. Single dose compositions may contain such amounts or submultiples thereof to make up the daily dose. In general, treatment regimens according to the present invention comprise administration to a subject in need of such treatment from about 10 mg to about 1000 mg of the compound(s) of this invention per day in single or multiple doses.
The compounds of the formulae described herein can, for example, be administered by injection, intravenously, intraarterially, subdermally, intraperitoneally, intramuscularly, or subcutaneously; or orally, buccally, nasally, transmucosally, topically, in an ophthalmic preparation, or by inhalation, with a dosage ranging from about 0.1 to about 500 mg/kg of body weight, alternatively dosages between 1 mg and 1000 mg/dose, every 4 to 120 hours, or according to the requirements of the particular drug. The methods herein contemplate administration of an effective amount of compound or compound composition to achieve the desired or stated effect. Typically, the pharmaceutical compositions of this invention will be administered from about 1 to about 6 times per day or alternatively, as a continuous infusion. Such administration can be used as a chronic or acute therapy. The amount of active ingredient that may be combined with pharmaceutically excipients or carriers to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. A
typical preparation will contain from about 5% to about 95% active compound (w/w).
Alternatively, such preparations may contain from about 20% to about 80%
active compound.
Lower or higher doses than those recited above may be required. Specific dosage and treatment regimens for any particular subject will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health status, sex, diet, time of administration, rate of excretion, drug combination, the severity and course of the disease, condition or symptoms, the subject's disposition to the disease, condition or symptoms, and the judgment of the treating physician.
Upon improvement of a subject's condition, a maintenance dose of a compound, composition or combination of this invention may be administered, if necessary. Subsequently, the dosage or frequency of administration, or both, may be reduced, as a function of the symptoms, to a level at which the improved condition is retained when the symptoms have been alleviated to the desired level. Subjects may, however, require intermittent treatment on a long-term basis upon any recurrence of disease symptoms.
When the compositions of this invention comprise a combination of a compound of the formulae described herein and one or more additional therapeutic or prophylactic agents, both the compound and the additional agent should be present at dosage levels of between about 1 to 100%, and more preferably between about 5 to 95% of the dosage normally administered in a monotherapy regimen.
The additional agents may be administered separately, as part of a multiple dose regimen, from the compounds of this invention. Alternatively, those agents may be part of a single dosage form, mixed together with the compounds of this invention in a single composition.
The pharmaceutical compositions of this invention can be administered orally to fish by blending said pharmaceutical compositions into fish feed or said pharmaceutical compositions may be dissolved in water in which infected fish are placed, a method commonly referred to as a medicated bath. The dosage for the treatment of fish differs depending upon the purpose of administration (prevention or cure of disease) and type of administration, size and extent of infection of the fish to be treated. Generally, a dosage of 5 - 1000 mg, preferably 20 - 100 mg, per kg of body weight of fish may be administered per day, either at one time or divided into several times. It will be recognized that the above-specified dosage is only a general range which may be reduced or increased depending upon the age, body weight, condition of disease, etc. of the fish.
Unless otherwise defined, all technical and scientific terms used herein are accorded the meaning commonly known to one of ordinary skill in the art. All publications, patents, published patent applications, and other references mentioned herein are hereby incorporated by reference in their entirety.
Abbreviations Abbreviations which may be used in the descriptions of the scheme and the examples that follow are:
Ac for acetyl;
AIBN for azobisisobutyronitrile;
Bu3SnH for tributyltin hydride;
CDI for carbonyldiimidazole;
dba for dibenzylidene acetone:
dppb for diphenylphosphino butane;
DBU for 1,8-diazabicyclo[5.4.0]undec-7-ene;
DEAD for diethylazodicarboxylate;
DMAP for dimethylaminopyridine;
DMF for dimethyl formamide;
DPPA for diphenylphosphoryl azide;
EtOAc for ethyl acetate;
EtOH for ethanol;
MeOH for methanol;
Ms for mesylate or O-S02-CF3;
NaN(TMS)2 for sodium bis(trimethylsilyl)amide;
NMMO for N-methylmorpholine N-oxide;
TEA for triethylamine;
THF for tetrahydrofuran;
TPP or PPh3 for triphenylphosphine;
MOM for methoxymethyl;
Boc for t - butoxycarbonyl;
Bz for benzoyl;
Bn for benzyl;
Ph for phenyl;
POPd for dihydrogen dichlorobis(di-tert-butylphosphinito-xP)palladate(II);
TBS for tert-butyl dimethylsilyl; or TMS for trimethylsilyl.
Synthetic Methods The compounds and processes of the present invention will be better understood in connection with the following synthetic schemes that illustrate the methods by which the compounds of the invention may be prepared.
A preferred intermediate for the preparation of compounds represented by formula I is a compound represented by formula VIII as illustrated below Y, X
I
O ltP
W
O O
HO
L, .=.'o ,,,,, ,O
U
Z
VIII
wherein Rp, U, V, W, X, Y and Z are as previously defined.
Schemes 1- 2 describe processes for the preparation of compounds according to the invention.
Compounds of formula VIII, which are useful as the starting materials for the preparation of compounds of the present invention are prepared from erythromycin using the procedures described in U.S. Patent No. 6,878,691 and U.S.
Patent Application Publication No. 2004/0053861, incorporated herein by reference.
Scheme 1 Y, X A-O I' X
O Rp W O_NH2 O ~ XI- O Rp W
0,,,,., HO ' 0 HO
~ 1 ~ .
....q p11 ,q~
O O O õnn O O
acid ,,~'V
O U O
Z Z
VIII (1-2) Scheme 1 illustrates a process of preparing compounds of the present invention by converting the bridged ketone of VIII into an oxime of formula (1-2) using the appropriate substituted hydroxylamine of the formula:
A" O-NH2 where A is as previously defined. This oxime formation can be accomplished, using the appropriate substituted hydroxylamine under either acidic or basic conditions in a variety of solvents. Representative acids include, but are not limited to, hydrochloric acid, phosphoric acid, sulfuric acid, p-toluenesulfonic acid, and pyridinium p-toluene sulfonate and the likes. Likewise, representative bases include, but are not limited to, triethylamine, pyridine, diisopropylethyl amine, 2,6-lutidine, and the likes. Appropriate solvents include, but are not limited to, methanol, ethanol, water, tetrahydrofuran, 1,2-dimethoxyethane, ethyl acetate and the likes. Preferably the reaction is carried out in ethanol using aqueous hydrochloric acid. Reaction temperature is generally, but not limited to, from -20 C to 40 C and the reaction time is froml to 8 hours, preferably the reaction is carried out at 0 C.
Scheme 2 A O YX A-O YX
N . .'.
O lP W
0 O O? w HO O~ HO O~
tO 0 , \ ~f V ~ ~,,,,== \
I,,.,== Iõ==
"OH 4j"0-R
Z Z R = Rl, ORI, OC(O)Rl, (2-1) (2-2) OC(O)NR3R4, S(O)nRl Scheme 2 illustrates the procedure by which compounds of formula (2-1) may be converted to compounds of formula (2-2) by treatment with isocyanates of formula Rl-NCO, acid chlorides of formula Rl-C(O)Cl or Alkyl isocyanates in the present of bases such as, but not limited to, sodium hydride, potassium hydride, potassium tert-butoxide, potassium hydroxide, KHMDS, and the like. The reaction is typically carried out in aprotic solvents such as, but not limited to, THF, DMSO, DMF, or dioxane and the likes. The temperature of the reaction is from 25 C
to 80 C. The preferred reaction time is from 5 to 20 hours.
Alternatively, some of the ester compounds of formula (2-2) can be prepared by treating compounds of formula (2-1) with acids of formula R1-C(O)OH in the presence of bases such as but not limited to Et3N, Pyridine, DMAP and coupling agents such as but not limited to EDC, BOPCI, HATU, and the likes in aprotic solvents such as but not limited to dichloromethane, ethylene chloride, THF, DMF, acetonitrile and the like at a temperature from 25 C to 80 C and the reaction time is from 2 to 24 hours.
Compounds of formula (2-1) also can be treated with with substituted tert-butyl allyl carbonate in the presence of a palladium catalyst and a phosphine additive to give allyl ethers.
Examples The compounds and processes of the present invention will be better understood in connection with the following examples, which are intended as an illustration only and not limiting of the scope of the invention. Various changes and modifications to the disclosed embodiments will be apparent to those skilled in the art and such changes and modifications including, without limitation, those relating to the chemical structures, substituents, derivatives, formulations and/or methods of the invention may be made without departing from the spirit of the invention and the scope of the appended claims.
Example 1 ~
H2N-~o ~
N ~ NAc MN ,,~' "I N
HO~~O HO,, ' .
o ~~' ~O O
O O' ~ O
/,--NH2 Step 1 a: N
To a solution of 2-amino-4-methylphenol (157.6g, 1.28mo1) in 1500 ml of EtOH at room temperature, under stirred condition, was added bromocyanogen (135.OOg, 1.28mo1) in about 30 minutes. During the addition, the reaction mixture became warm and water bath was used to cool the reaction to room temperature.
After 5-6 hours, the reaction solvent was evaporated under reduced pressure.
The residue was dissolved in about 1500 ml of EtOAc and washed with the saturated NaHCO3 (1.5 L). The organic layer was separated and dried over anhydrous MgSO4. Removal of solvent and dried by high vacuum gave about 150g of the title compound as pale brown color, which can be used in next step. ESI MS m/e: 149 (M+H)+.
s-N
N
Step lb: 0 A solution of succinic anhydride (141.1 g, 1.41 mol) and 70 g (about 0.47 mol) of compound of step la (70 g, 0.47 mol) in 2500 ml of anhydrous toluene was refluxed for overnight. After that, HATU (100g, 0.26 mol) and 4-methylmorpholine (41.36 ml, 0.376 mol) were added and the resulting mixture was refluxed for 2-hours. TLC showed that the major spot was product (Rf = 0.35, acetone:hexane =
1:2). After reaction was completed, the solvent was evaporated and the residue was dissolved in about 2000 ml of CHZC12. The solution was washed with aqueous NaHCO3. After pH was adjusted to 7-8 and washed with brine, organic phase was separated and dried over MgSO4. Filtration and removal of solvent gave the title compound (98g) as fine white needle crystalline ESI MS m/e: 231 (M+H)+.
~
N
Br ~ /oN~
Step 1 c: o To a solution of the compound of step lb (44.37g, 0.193mo1) in CC14 (1.5 L) was added NBS (41.16g, 0.23mo1) and then the mixture were heated to reflux.
Benzoyl peroxide (0.75g) was added by three times. After refluxing for 24 hours, the reaction was cooled to room temperature and the mixture was diluted with 1.5 L
of CHZC12 , The organic phase was separated and washed with 4 L of saturated NaHCO3 two times to adjust pH to 7-8. Dried over MgSO4 and removal of the solvent under reduced pressure gave the title compound (57.3 g) as slight yellow solid which was used for next step without further purification. ESI MS m/e:
309/311(M+H)+.
o o~
I~ N_ N N
/
Step 1 d: 0 0 To a solution of the compound of step 1c (57.3g, 0.185mo1) in 450 ml of MeCN were added N-hydroxyphanthalimide (60.51g, 0.371mol) and 80 ml of triethylamine. The reaction mixture was stirred at 50 C for 5 hours and cooled to room temperature. The reaction was added water (200 ml) and filtered. The pale yellow solid was collected, washed with100ml of MeOH and ether in the 1:1 ratio.
Dried on vacuum to give the title compound (48 g) as pale solid. ESI MS m/e:
(M+H)+.
~ o HZN-o I ~ N~NHZ
Step le:
A mixture of the compound of step ld (39.1g, 0.1 mol) in 500 ml of 2M
ammonia in methanol was stirred at room temperature for 16 hours and filtered.
The filtrate was concentrated and purified on silica gel (2M NH3 in MeOH:CH2C12 =
5:95) to give the title compound (17g, 95%). ESI MS m/e: 180 (M+H)+.
O
H2N-~~ ~
N,Ac 0N AcN
HO . O''.
O "''O O
O O
Step lf:
To a solution of compound of step id (215 mg, 1.2 mmol) in 15 ml of ethanol was added 1N HCI (2 ml). The mixture was cooled to 0 C and added compound of formula VIII where X and Y taken together with the atom that they are attached is C=N-Ac and U and V taken together with the atom that they are attached is C=O, Z= H, Rp = Ac and W = NMe2 (711 mg, 1 mmol). The mixture was stirred at 0 C for 1 hour and quenched with saturated NaHCO3 (50 ml). Extracted with ethyl acetate (100 ml) and washed with brine (100 ml x 2). Dried over anhydrous Na2SO4 and concentrated to give crude title compound (828 mg, 95%, as a mixture of oximes, oximeE/Z = 4/1), which was used for next step reaction without further purification. ESI MS m/e: 872 (M+H)+.
H, N--~~
o ~ I
N ~ N AC
O~ o O N ''O
HO HO,,, "' O /1,' 'O O
O O
Step l g:
A solution of compound of step lf (828 mg, 0.95 mmol) in 15 ml of methanol was stirred at 60 C for 5 hours. The solvent was removed and the residue was purified on silica gel (2M NH3 in MeOH/ CH2C12 = 5/95) to give the title compound (765mg, 97%, as a mixture of E/Z oximes E/Z - 4/1). The compound was further separated on HPLC to give E-oxime isomer (430 mg) and Z-oxime isomer (110mg).
E-oxime isomer: ESI MS m/e: 830 (M+H)+.
E-oxime isomer: 13C NMR (125 MHz, CDC13): 8 205.9, 191.4, 186.8, 184.7, 178.1, 167.8, 162.1, 153.3, 148.5, 143.0, 134.1, 125.6, 121.9, 116.8, 108.7, 103.0, 79.4, 76.4, 74.6, 70.5, 69.8, 66.1, 63.2, 62.9, 50.8, 40.5, 38.8, 31.2, 28.5, 25.3, 23.8, 21.5, 19.5, 17.8, 15.1, 14.1, 12.8.
Z-oxime isomer: ESI MS m/e: 830 (M+H)+.
Z-oxime isomer: 13C NMR (125 MHz, CDC13): S 206.2, 184.7, 176.9, 169.3, 163.0, 155.9, 148.5, 143.2, 133.6, 121.6, 116.7, 108.5, 103.0, 79.5, 79.0, 76.7, 76.2, 75.8, 70.5, 70.2, 69.7, 66.1, 58.2, 53.7, 51.0, 45.3, 40.5, 39.7, 39.0, 36.9, 28.5, 25.5, 23.4, 21.5, 20.3, 19.6, 17.3, 15.7, 14.5, 12.9, 12Ø
Example 2 O i O
O~,N N
HO OHO ,, O ,''O O
O O
O
N' \
O O AHOO
O '0O
O O
Step 2a:
The title compound of step 2a was prepared according to experimental procedure from U.S. Pat. No. 6,878,691 incorporated herein by reference.
O O\ Ac O '' O
O O
Step 2b:
To a solution of compound of step 2a (711 mg, 1 mmol) in 8 ml of acetonitrile was added 1 N HCI (10 ml) at room temperature. The mixture was stirred at room temperature for 4 hours and was quenched with saturated NaHCO3 (30 ml). Extracted with ethyl acetate (40 ml) and the organic phase was washed with brine (40 m1X2). After dried over anhydrous Na2SO4, the solvent was removed and the residue was purified on silica gel column (hexane: acetone = 1:1) to give the title compound (330 mg, 49%).
O /
HaN--~ ~ ~
z,N .,, HOk/~/ 0 Ac N
~,.
'''v 0 ~''0 0 Step 2c:
To a solution of compound from step 2b (215 mg, 1.2 mmol) in 15 ml of ethanol was added 1N HC1(2 ml). The mixture was cooled to 0 C and added bridged ketone lcetolide, compound of step 2a (670 mg, 1 mmol). The mixture was stirred at 0 C for 1 hour and quenched with saturated NaHCO3 (50 ml).
Extracted with ethyl acetate (100 ml) and washed with brine (100 ml X 2). Dried over anhydrous Na2SO4 and concentrated to give crude title compound (764 mg, 92%, E/Z - 1/1). ESI MS m/e: 831 (M+H)+.
0 i HZN--~ ~ ~
0."
HO H
Y ~
I"~~'0 ~''0 0 Step 2d:
A solution of compound of step 2c (764mg, 0.92 mmol) in 15 ml of methanol was stirred at 60 C for 6 hours. The solvent was removed and the residue was purified on silica gel (2M NH3 in MeOH/ CH2C12 = 5/95) to give the title compound as a mixture of E/Z oxime isomers (690mg, 95%, E/Z - 1/1). The compound was further separated on HPLC to give E-oxime isomer (280 mg) and Z-oxime isomer (230mg).
E-oxime isomer: ESI MS m/e: 789 (M+H)+.
E-oxime isomer: 13C NMR (125 MHz, CDC13): 6 218.5, 205.6, 191.7, 168.0, 162.0, 152.8, 148.6, 143.0, 134.0, 122.1, 117.0, 108.7, 103.3, 79.3, 79.0, 76.5, 75.8, 74.5, 70.5, 69.8, 66.1, 63.0, 61.5, 51.0, 47.0, 46.2, 40.5, 39.5, 39.3, 28.5, 23.5, 21.4, 20.0, 18.6, 18.0, 14.6, 14.2, 12.6, 12.2.
Z-oxime isomer: ESI MS m/e: 789 (M+H)+.
Z-oxime isomer: 13C NMR (125 MHz, CDC13): 8 215.0, 205.7, 169.6, 162.2, 156.2, 149.0, 142.8, 131.4, 124.8, 116.3, 109.7, 102.5, 79.9, 78.7, 76.3, 76.2, 70.5, 69.7, 66.1, 59.2, 50.8, 46.3, 45.7, 40.5, 40.0, 39.1, 28.5, 23.1, 21.6, 19.7, 18.5, 17.2, 14.5, 13.1, 12.9, 11.8.
Example 3.
In accordance with Schemes 1 and 2, the following compounds of the invention having the Formula II were prepared:
A---- O
'4 O N~ O
HO = N
~~ ~ / = ~
~,.Y s V HO,,, ~~. O ,... '',O
O
o = z II
wherein A, Q and Z are defined as in Table I.
TABLE I.
MS (ESI):
Example A- Q Z mlz 13C NMR (125 MHz,CDCI3):S
M+H +
NAc H 205.8,184.7,178.0,167.8, 154.3,153.8,153.0, N ~ 136.0, 134.0,126.7,123.5, 121.5, 103.1, 79.3, ~ 79.2, 76.8, 75.8, 75.5, 74.7, 70.5, 69.7, 66.1, Example 01 S 831 63.1, 62.9, 50.7, 46.2, 40.5, 38.8, 37.2, 31.2, 28.5, 25.3, 23.8, 21.5, 20.3, 19.5, 17.8, 15.1, 14.1 ,~/~N NAc F
Example 02 H2N ~S 864 S-N NAc H
N~
Example 03 832 Example 04 ~S NAc H
HZN ~ 846 N
Example 05 NAc H 205.8, 184.7,178.0,167.8, 153.6,153.0,149.8, /N ~ 140.3, 135.0,126.3,120.5, 110.8,103.0, 79.4, 815 76.8, 76.0, 74.6, 70.5, 69.7, 66.1, 63.1, 62.8, O ~ 53.7, 50.7, 46.2, 40.5, 38.9, 28.5, 25.3, 23.8, 21.5,20.3,19.5,17.8,15.1,14.1,13.6,12.9 Example 06 ,O NAc H
N ~ 830 H N ~~~~
Example 07 H2N NAc H
N~ 830 Example 08 NAc F (selected)205.5, 205.3, 184.2, 165.1, 164.9, 162.4, 153.7,148.8, 142.7, 131.2,124.5,116.2, 109.3,104.1, 99.7, 98.1, 79.7, 76.5, 73.7, 70.6, H2N- 848 69.8, 66.0, 63.1, 62.6, 41.2, 40.5, 39.0, 28.4, o~ 25.3, 24.7, 24.5, 23.2, 21.4, 21.0, 17.5,15.0,14.3,12.6 Example 09 0 H 218.4, 205.6,168.0, 166.3,152.0, 132.1, 131.9, N ~ 126.9, 121.5,119.1, 103.3, 79.3, 78.9, 76.4, HZN--~~ 805 75.9, 74.6, 70.5, 69.8, 66.1, 13.0, 61.5, 50.9, s 47.1, 46.2, 40.5, 39.5, 39.3, 28.5, 23.5, 21.5, 20.1, 18.6, 18.0, 14.6, 14.2, 12.6, 12.2.
Example 10 NAc H 205.9,184.7,178.0, 167.9, 162.2, 153.4, 148.9, 142.6,131.5,124.6,116.2,109.4, 103.1, 79.3, HZN--N 830 76.8, 74.8, 70.5, 66.1, 63.2, 62.9, 50.8, 40.5, o~ 38.8, 28.5, 25.4, 23.8, 21.5, 20.3, 19.6, 17.8, 15.1, 14.1, 12.8.
Example 11 0 H 216.3, 203.6,165.9, 160.1,150.8,146.8, 140.6, 129.1, 122.7,114.1, 107.5, 101.2, 77.2, 76.8, N H2N--~ 789 74.7, 74.4, 73.8, 72.6, 68.4, 67.7, 63.9, 60.8, 59.4, 51.5, 48.9, 45.0, 44.0, 38.3, 37.4, 29.0, 26.3, 21.3, 19.3,18.0, 16.4, 15.9,12.6,12.1 Example 12 NAc H (selected): 205.8, 185.0,178.3,168.2, 161.6, 155.9, 153.4,148.9,133.0,131.6,126.6, 121.2, N-{ ~ 1 889 120.0, 103.0, 79.4, 76.7, 76.2, 70.5, 69.7, 66.0, HZN~ s~ 63.2, 50.8, 46.2, 40.5, 38.8, 28.5, 25.5, 23.7, 0 21.5, 20.2, 19,7, 18.0, 15.4, 14.1, 13.7, 12.7.
Example 13 NAc H (selected): 205.9,184.7,178.0,167.9, 167.4, F 153.9, 153.7,152.0, 140.1,140.0,133.7, 132.9, 132.8, 116.4,112.4,112.3, 103.0, 79.3, 76.7, HZN~N 864 75.6, 74.8, 70.5, 59.7, 66.0, 63.1, 62.9, 50.8, s 46.3, 40.4, 38.8, 28.5, 25.3, 23.7, 21.5, 20.3, 19.6,17.8,15.1, 14.1, 13.7,12.8 Example 14 0 H (selected); 217.9, 205.6,168.9,162.0, 155.5, NN ~ ~ 152.9, 131.8,126.8, 122.1,119.7, 102.8, 9.4, HZN1 ~ 848 79.3, 76.5, 75.1, 70.5, 69.8, 66.1, 63.2, 50.9, o 46.6, 46.3, 40.5, 39.4, 28.5, 23.2, 21.5, 18.2, 17.9,14.2, 14.0, 13.2,12.2.
Example 15 0 H (selected): 218.4, 205.7, 168.1,167.4,154.0, 153.1, 152.0,140.2,140.0, 133.8,133.7,132.8, F 132.7, 116.7,112.7,112.5, 103.3, 79.3, 78.9, 823 76.8, 75.9, 75.8, 74.7, 70.5, 69.8, 66.0, 62.9, H2N-~ ~ 61.5, 51.0, 47.2, 46.2, 40.4, 39.4, 39.3, 28.5, s 23.5, 21.5, 20.1, 18.5,18.0,14.7, 14.2, 12.5, 12.2 Example 16 N, NAc H
N = ~ ~ 829 H N ~~~~
Example 17 o NAc H 205.9, 191.4,186.8,184.7, 178.1,167.8,162.1, ~ 153.3, 148.5,143.0, 134.1,125.6,121.9,116.8, HZN N~ ~ 830 108.7, 103.0, 79.4, 76.4, 74.6, 70.5, 69.8, 66.1, 63.2, 62.9, 50.8, 40.5, 38.8, 31.2, 28.5, 25.3, 23.8, 21.5, 19.5, 17.8, 15.1, 14.1, 12.8.
Example 18 0 H 218.5, 205.6,191.7,168.0,162.0, 152.8, 148.6, O 143.0, 134.0, 122.1, 117.0, 108.7, 103.3, 79.3, H2N-~~ ~ 79.0, 76.5, 75.8, 74.5, 70.5, 69.8, 66.1, 63.0, N~ 789 61.5, 51.0, 47.0, 46.2, 40.5, 39.5, 39.3, 28.5, , 23.5, 21.4, 20.0, 18.6, 18.0, 14.6,14.2,12.6, 12.2.
Example 19 N/ NAc H
AH\s ~ ~ 888 Example 20 H N NAc H
N
H N
Example 21 0 ~ NAc F
N ~ ~ 848 HN
Example 22 N NAc F
, /
N ~ 847 HN
Example 23 N NAc H (selected); 206.2,184.8, 168.6,155.0, 153.8, HZN-~ / 110.0, 103.4, 79.5, 76.7, 75.1, 70.5, 69.8, 66.0, N~ 829 63.2, 63.0, 51.3, 40.5, 38.8, 31.2, 30.0, 28.4, H 25.4, 23.7, 21.8, 20.6, 20.0,17.9, 15.1,14.1, 12.8.
Example 24 N 0 H (selected): 218.5, 206.0, 168.8, 155.1, 153.3, HZN-~ ~ 129.8, 121.1, 103.4, 79.6, 79.1, 76.6, 75.4, N~ 788 70.6, 69.8, 66.0, 62.9, 62.1, 53.7, 51.4, 47.6, H 46.0, 40.5, 39.7, 39.4, 28.4, 23.4, 21.5, 20.4, 18.6, 18.2, 15.3, 14.4, 12.5, 12.2.
Example 25 NAc H 205.8,184.8,178.0,167.9,167.8,159.3,153.5,153 .3,146.3,143.8,143.7,135.0,133.9,1333.3,125.4, 123.7,121.9,120.2,111.1,103.0,79.4,79.2,76.5,7 Cs N ~ 897 6.4,74.8,70.5,69.8,66.1,63.2,62.9,50.8,46.2,40.
/~ 5,38.8,28.5,25.4,23.8,21.5,20.3,19.6,17.8,15.1, 14.1,13.7,12.9.
Example 26 NAc H 205.8, 184.7,178.0,167.8, 153.6,153.0, 149.8, 0 140.3,135.0,126.3, 120.5, 110.8,103.0, 78.4, <\ ~ 815 76.0, 74.6, 70.5, 69.7, 66.2, 63.1, 62.9, 50.7, 46.2, 40.5, 38.8, 28.6, 25.4, 23.8, 21.5, 20.3, 19.5, 17.8, 15.1, 14.1, 13.6, 12.9 Example 27 0 H 218.4, 205.6,168.0,153.0, 149.8,140.3,134.9, O/ 126.5,120.7,110.8,103.1, 79.3, 79.0, 76.1, ~ 775 75.8, 74.6, 70.5, 69.6, 66.2, 63.0, 61.5, 50.9, N~ 47.0, 46.2, 40.5, 39.5, 39.3, 28.9, 23.5, 21.4, 20.0, 18.6,18.0,14.6, 14.3,12.6,12.2 Example 28 NAc H 205.8,184.7,178.0,167.8,157.5,155.1,153.7,150 .5,145.3,141.6,135.9,127.1,123.3,120.4,111.1,1 C ~~ ~ 898 03.0,79.4,76.8,75.8,74.6,70.5,69.7,66.1,63.1,62 s N / .9,50.7,40.5,38.8,29.9,29.5,28.5,25.4,23.8,21.5, 1 20.3,19.5,17.8,15.1,14.1,13.6,12.9.
Example 29 N~ NAc H
Example 30 NAc H
~ ~ 845 N
Example 31 NAc H (selected): 210.1, 184.7,177.9,170.0, 162.4, 153.7,148.5,143.1, 133.9,132.9,121.5,119.6, o ~ 870 116.4, 108.7,102.4, 81.2, 79.7, 76.6, 76.3, 74.5, 70.6, 69.5, 66.2, 62.7, 60.8, 43.7, 40.7, HN~N 40.5, 40.1, 39.3, 37.4, 29.0, 25.3, 22.7,21.6, 21.4, 20.6,19.8,18.3,16.2,14.8, 12.5.
Example 32 HO / NAc H (selected): 206.1,184.9, 178.0,168.1,153.8, ~ 806 150.1,120.4,113.7,103.0, 79.4, 76.7, 70.5, H2N N 69.7, 66.0, 50.9, 40.5, 28.7, 25.4, 23.7, 21.5, 17.8, 17.2, 15.7, 15.1, 14.1, 12.8, 12Ø
Example 33 0 / NAc H
N ~N 816 ll I I
Example 34 NAc H (selected): 205.9,184.8,177.9,167.9,165.1, 157.6,153.8,152.9,140.5,115.5,114.9,102.9, 0 ~ 831 79.3, 76.8, 76.7, 75.1, 70.5, 69.6, 66.1, 63.1, H2N--' ~ 50.9, 40.5, 38.8, 28.7, 25.6, 25.4, 23.8, 21.6, N N 21.5, 20.4,19.6,17.8,17.2,15.2,14.1, 12.8, 12Ø
Example 35 NAc H (selected): 209.9,184.7,177.8,169.9,157.6, 153.9,144.3,133.6,133.3,132.8,131.0,121.1, 119.7,118.1,108.5,107.6, 102.4, 81.0, 79.7, o ~ 910 76.5, 76.0, 74.4, 70.5, 69.5, 66.3, 62.7, 62.6, " <, I i 60.7, 45.1, 43.7, 40.6, 39.3, 29.2, 25.3, 22.9, 21.5, 20.6,19.8,18.2,16.3,14.7, 12.7.
Example 36 N NAc H
Example 37 I NAc H
N /
N ~ 829 N
Example 38 O NC(0)0 H
HZN-~~ CH3 846 205.9,186.4,167.7,163.7,162.4,153.2,148.4,143 .0,134.1,121.8,116.6,108.7,102.9,79.5,78.9,77.
5,76.8,76.4,75.1,74.7,70.5,69.7,66.1,63.2,62.7, 54.1,53.1,50.7,40.5,38.7,32.0,29.5,28.6,23.8,21 .5,20.2,19.3,17.8,14.9,14.1,12.9, Example 39 O NH H
HZN--~~
205.2,169.3,162.8,153.7,148.5,143.1,133.7, 788 121.6, 116.5, 108.8, 103.5, 80.4, 78.8, 78.6, 76.6, 75.9, 70.6, 69.8, 66.1, 64.7, 63.1, 51.6, 47.9, 41.4, 40.5, 38.3, 28.5, 23.0, 21.4, 21.1, 20.1, 17.4,15.8, 14.4, 14.0, 11.8 In accordance with Scheme 1, compounds of the invention having the Formula IX
were prepared:
Q O."A
,o' O
~
YN HO
HO.,.
... '=~O
O
wherein A, Q, and Z are defined as in Table II.
Table II
Example A- Q Z MS (ESI): +sC NMR (125 MHz CDCI3):S
m/z (M+H)+ ' NAc H 815 205.8,184.6, 176.5,169.3,156.2, 153.0, 149.9, 140.3,134.8, 126.6, 120.8, 110.9, Example 01 N> 102.6, 79.6, 79.0, 76.3, 76.2, 70.5, 69.7, 0 66.1, 58.4, 50.9, 45.4, 40.5, 29.9, 28.6, 25.5, 23.4, 21.6, 20.2, 19.7, 17.2, 15.6, 14.4, 12.9, 12.0 0 H 805 215.1, 205.7, 169.6, 166.8, 156.2, 152.1, ):s N'~--NHZ 132.0,126.6, 121.3, 118.9, 102.5, 80.0, Example 02 78.7, 76.3, 76.1, 70.5, 69.7, 66.0, 50.8, 46.3, 45.7, 40.4, 40.0, 39.1, 28.5, 23.1, 21.6, 19.7, 18.5,17.3,14.5,13.1,11.8 0 H 789 215.0, 205.7, 169.6, 162.2, 156.2, 149.0, ):0 N'~--NHZ 142.8, 131.4, 124.8, 116.3, 109.7, 102.5, Example 03 79.9, 78.7, 76.3, 76.2, 70.5, 69.7, 66.1, 59.2, 50.8, 46.3, 45.7, 40.5, 40.0, 39.1, 28.5, 23.1, 21.6,19.7,18.5,17.2,14.5,13.1, 12.9,11.8.
NAc H 864 (selected): 205.9, 184.6, 176.4, 169.4, F 166.7, 156.4, 154.2, 152.2, 140.1, 140.0, N 134.0, 133.9, 133.3, 133.2, 116.6, 116.5, Example 04 '--NH2 112.6, 112.4, 102.6, 79.6, 79.0, 76.2, 75.8, S 75.4, 70.5, 69.7, 66.1, 58.5, 50.9, 45.4, 40.5, 39.0, 28.5, 25.5, 23.3, 21.6, 20.2, 19.7, 17.2, 15.7,14.4,13.0,12Ø
0 H 848 (selected): 216.3, 205.4,169.6, 162.0, N 155.8,149.0,131.9, 127.1,119.6, 102.3, Example 05 ~ I ~"Y NH2 80.0, 79.0, 76.7, 76.3, 76.0, 70.5, 69.7, 66.0, a 59.4, 50.7, 46.3, 45.7, 40.5, 40.1, 39.3, 29.9, 28.6, 23.1, 21.6, 19.8, 18.2,17.4, 14.5, 13.7, 13.0, 11.7.
F 0 H 823 (selected): 215.2, 205.7, 169.6, 167.2, 156.5,154.1,152.1, 140.2,140.1, 134.0, N 133.9, 133.0, 132.9, 116.6, 112.5, 112.3, Example 06 ~NHz 102.5, 76.3, 70.5, 69.7, 66.1, 59.1, 50.9, 46.3, 45.7, 40.5, 39.2, 28.5, 23.1, 21.6, 19.7, 18.5, 17.2, 14.5, 13.2, 12.8, 11.8 PCN ~ NAc H 830 Example 07 NHZ
In accordance with Scheme I, compounds of the invention having the Formula X were prepared:
A "'A
HO O N O N
HO,, o .. '''O
O
0 'oZ 0 x wherein A, X and Z are defined as in Table III.
TABLE III
Example A- x z MS (ESI):
m/z (M+H)+
Example 01 HZN~ ~ ~ NH2 H 790 N ~
Example 4.
g NAc ,, 011 O ~~''' O 0 O NI
Step 4a:
Br S
\ ~/OH
A solution of 5-bromo-2-thiophenecarboxaldehyde (13.08 g, 68.46 mmol) in isopropanol (100 mL) was treated with NaBH4 (1.30 g, 34.23 mmol) at 0 C for 1.5 hours with stirring before HCI (1 M, 60 mL, 60 mmol) was charged. The mixture was stirred for 0.5 hour before being partitioned (ethyl acetate and saturated NaHCO3). The organics were washed with water, brine, and then dried (Na2SO4).
The volatile was removed by evaporation and dried in a vacuum to give the title compound (12.55 g, 95%).
Step 4b:
Bu3Sn S
JoH
Into a solution of the compound of Step 4a (5.02 g, 26.00 mmol) in THF (80 mL) was treated with NaH (95%, 730 mg, 28.9 mmol) at room temperature for 50 minutes with stirring. It was chilled to -78 C before n-BuLi (1.6 M in hexanes, 20 mL, 32 mmol) was charged. The mixture was kept at -78 C for 1 hour before n-Bu3SnC1(17.6 mL, 65 mmol) was introduced. The mixture was warmed up naturally to room temperature and stirred over night. The volatile was evaporated off and the residue was partitioned (ethyl acetate and saturated NaHCO3). The organics were washed with water, brine, and then dried (Na2SO4). Evaporation followed by chromatography (silica, hexanes/ethyl acetate) gave the title compound (4.51 g, 43%).
Step 4c:
O
Br N
a ON
Into a 250 mL round bottom flask was charged 2-amino-6-bromopyridine (25.0 g, 0.144 mol) and phthalic anhydride (21.4g, 0.144 mol). The solid mixture in the open flask (with a slow flow of N2) was heated to 175 C and the temperature was kept there for lhour or until no vapor comes out. It was cooled down to room temperature and vacuumed for 10 hours to give the title compound as a tan solid (100% yield).
Step 4d: ~ S
N I
C:N OH A mixture of the compound from Step 4b (4.50 g, 11.16 mmol), the compound from Step 4c (3.72 g, 12.28 mmol), and Pd(PPh3)4 (645 mg, 0.56 mmol) in PhMe (50 mL) was degassed and heated at 100 C under N2 for 17 hours before being cooled to 0 C. The insoluble was collected by filtration and washed with PhMe to give the title compound (2.90 g). The filtrate and washings were evaporated and the residue was chromatographed (silica, hexanes/ethyl acetate) to give another crop of the title compound (0.20 g).
ESIMS m/e: 337 (M+H)+.
Step 4e:
N \N I ~
CI
O
A suspension of the compound from Step 4d (3.10 g, 9.22 mmol) in methylene chloride (50 mL) was treated with thionyl chloride (3.35 mL, 46.08 mmol) at 0 C. The mixture was warmed up naturally to room temperature and stirred for 16 hours. The volatile was evaporated off. The residue was partitioned (CHaC12/saturated NaHCO3). The organics were washed with water, brine, and then dried (Na2SO4). The volatile was removed by evaporation and dried in vacuo to give the title compound (3.253 g, 100%).
ESIMS m/e: 355/357 (M+H)+.
Step 4f:
o N s N
I / O-N
O
Into a solution of N-hydroxylphthalimide (2.40 g, 14.7 mmol) in DMF (20 mL) was added NaH (95%, 332 mg, 13.8 mmol) at 0 C. It was warmed up to room temperature and stirred for 1 hour. It was added into a solution of the compound from Step 4e (3.25 g, 9.2 mmol) in DMF (25 mL). The mixture was stirred at 40 C
for 16 hours before being cooled to room temperature. It was diluted with saturated NaHCO3 and water. The insoluble was collected by filtration, washed with saturated NaHCO3 and water, and dried to give the title compound (3.930 g, 89%).
ESIMS m/e: 482 (M+H)+.
Step 4g:
/
~N Is A suspension of the compound from Step 4f (1.00 g, 2.08 mmol) in methanolic ammonia (2M, 20 mL, 40 mmol) was heated at 55 C for 2 hours before being cooled to room temperature. The insoluble was filtered off and washed with MeOH. The combined filtrate and washings were evaporated. The residue was added CHZCl2 to dissolve the crude title compound (548 mg) after evaporation.
ESIMS m/e: 222 (M+H)+.
Step 4h:
N,Ac O O Ac ~N~
O "''O O
0 1"'O
NI
A mixture of compound of formula VIII where X and Y taken together with the atom that they are attached is C=N-Ac, U = H, V = OH, Z = H, Rp = Ac and W
= NMe2 (356 mg, 0.50 mmol), 2-pyridylacetic acid hydrochloride (174 mg, 1.0 mmol), 1-(3-dimethylaminopropyl)-3-ethylcabodiimide hydrochloride (EDC-HCI, 192 mg, 1.0 mmol), triethylamine (0.28 mL, 2.0 mmol) and DMAP (10.0 mg) in methylene chloride (5.0 mL) was stirred at room temperature for 22 hours before more 2-pyridylacetic acid hydrochloride (87 mg, 0.5 mmol) and EDC-HCI (192 mg, 1.0 mmol). It was stirred for another 3 hours before being partitioned (ethyl acetate and 10% K2C03). The organics were washed with water, brine, and then dried (Na2SO4). The volatile was removed by evaporation and dried in a vacuum to give a yellow foam (450 mg) as the crude title compound.
ESIMS m/e: 832 (M+H)+.
Step 4i:
/ ~
_N g N,Ac H2N O Ac "'N/
HO 0~,, 'l"O O
O "'O
Into a solution of the crude compound from Step 4g (166 mg, -0.62 mmol) in ethanol (5.0 mL) and HCl (1 M, 2.5 mL) at-5 C was added the crude compound from Step 4h (450 mg, 0.5 mmol at most). After being stirred for one hour, more crude compound from Step 4g (50 mg, -0.18 mmol) was added. The mixture was stirred for another 1 hour before partition (ethyl acetate and saturated NaHCO3).
The organics were washed with water, brine, and then dried (Na2SO4). It was evaporated and the residue was chromatographed (silica, hexanes/acetone) to give the title compound (332 mg, 64%) as a 2:1 mixture.
ESIMS m/e: 1035 (M+H)+.
Step 4j:
/ \ / I
c i_N g NAc H2N O':~,~=~' \N/
~ HO~,, HO Ory Iv '" O O
O N
A solution of the compound from Step 4i (100 mg) in MeOH (3 mL) was stirred at room temperature for 70 hours before evaporation to give the title compound. The two bridged oxime isomers were separated by HPLC.
E-oxime isomer: ESIMS m/e: 993 (M+H)+. 13C NMR (CDC13, 125 MHz): 184.6, 178.0, 172.5, 170.4, 158.0, 153.9,153.2, 151.0, 149.1, 145.4, 141.8, 138.1, 136.6, 127.5, 124.4, 123.7, 122.3, 109.1, 106.7, 103.0, 82.3, 79.4, 78.5, 78.3, 76.4, 75.0, 70.8, 70.5, 69.1, 65.4, 63.1, 62.4, 43.8, 42.7, 40.4, 39.9, 38.3, 36.8, 35.8, 29.7, 29.2, 25.1, 23.2, 21.0, 19.9, 19.1, 17.5, 15.0, 14.3, 12.1, 9Ø
Z-oxime isomer: ESIMS m/e: 993 (M+H)+. 13C NMR (CDC13, 125 MHz): 184.4, 176.6, 173.7, 170.2, 158.0, 156.1, 153.9, 151.1, 149.1, 145.5, 141.2, 138.1, 136.6, 128.0, 124.4, 123.8, 122.3, 109.1, 106.7, 103.0, 83.3, 80.2, 79.0, 77.7, 77.5, 75.8, 70.8, 70.6, 70.5, 69.1, 65.4, 58.7, 43.2, 40.3, 39.1, 38.5, 36.5, 36.0, 29.7, 29.2, 25.2, 22.7, 21.1, 20.1, 19.6, 16.8, 15.4, 14.6, 11.3, 9.1.
Example 5. Compounds with improved antibacterial activities.
Table IV below provides MIC data of species from U.S. Patent No. 6,878,691 and U.S. Patent Application Publication No. 2004/0053 86 1.
The values in the table are minimum inhibition concentration (MIC) and are expressed as ug/mL.
Assays for MIC are described above.
Table IV
S. S. S. S. S. S. S. H.
Com- Structure aureus aureus aureus pneumoniae pneumoniae pyogenes pyogenes influen pound 29213 27660 33591 7701 700906 1323 2912 zae Al 0.25 0.13 >64 0.5 0.25 0.5 8 8 N N,Ac O
HO~ 'N ,=~,"HO, N-O
O
O A2 N 0.5 0.25 >64 0.5 0.25 1 16 16 N
N.Ac HO~ 'N =,O HO N_ O O
A3 N N 0.25 0.25 >64 2 0.13 16 32 8 N N,Ac O
HO~ 'N ,O ..HO N_ O 'O~
O O
A4 ~ ,N 8 64 64 >64 ~ o ~N
HOV OHO
'O 0 O
O "0=., OAc OMe A5 >64 2 64 >64 >64 NH
O'~~=" N
O
HOV oHO,..
O ,,, Oo O "9OH
A6 9' 1 1 16 1 8 2 8 >64 N)\
HO O HO.,, O "O O
O 'O
O IN
Table V provides data for compounds of this invention demonstrating improved microbiological activities against gram negative bacteria and resistant organism. The values in Table V are minimum inhibition concentration and are expressed as ug/mL.
Table V
S. aureus S. aureus S. S. S. S. S. H.
Com- Structure 29213 27660 aureus pneumoniae pneumoniae pyogenes pyogen influen pound 33591 7701 700906 1323 es zae BI H=N~N \ ~ <=0.06 <=0.06 >64 <=0.06 1 0.25 412 23929 S
H O \N t,o Hq N-O O
0.125 <=0.06 >64 0.125 0.5 0.5 2 2 B2 H2N N,Ac O
HO~ N O HO \N~
O O
O
O O
B3 H,N ,N ~ i <=0.06 <=0.06 32 0.125 0.25 0.5 4 2 \
NO~~~..0 H~ ~\[N_ O~
O O
0.125 0.125 32 0.125 0.125 0.5 1 4 B4 N N0 Ac HO~~~ HO N
I :~ A
O O
The patent and scientific literature referred to herein establishes the knowledge that is available to those with skill in the art. All United States patents and published or unpublished United States patent applications cited herein are incorporated by reference. All published foreign patents and patent applications cited herein are hereby incorporated by reference. All other published references, documents, manuscripts and scientific literature cited herein are hereby incorporated by reference.
While this invention has been particularly shown and described with references to preferred embodiments thereof, it will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the scope of the invention encompassed by the appended claims.
Claims (19)
1. A compound represented by formula:
or their racemates, enantiomers, regioisomers, salts, esters or prodrugs thereof, wherein X and Y are independently selected from the group consisting of: hydrogen, deuterium, halogen, R1, OR1, S(O)n R2, -NR1 C(O)R2, -NR1C(O)NR3R4, -NR1S(O)n R2, -C(O)NR3R4, and -NR3R4;
Each of R1 and R2 is independently selected from the group consisting of:
hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group;
Each of R3 and R4 is independently selected from the group consisting of:
hydrogen, acyl, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted, or unsubstituted heterocyclic group; or can be taken together with the nitrogen atom to which they are attached to form a substituted or unsubstituted heterocyclic or heteroaromatic ring;
or X and Y, taken together with the carbon atom to which they are attached, are selected from the group consisting of: CO, C=CHR1, C=NR1, C=NC(O)R1, C=NOR1, C=NO(CH2)m R1, C=NNHR1, C=NNHCOR1, C=NNHCONR1R2, C=NNHS(O)n R1, C N-N=CHR1, C=N-NO2, or C=N-ONO;
one of U or V is hydrogen and the other is independently selected from the group consisting of: R1, OR1, OC(O)R1, OC(O)NR3R4, S(O)n R1, or U and V, taken together with the carbon atom to which they are attached, are C=O;
one of J or G is hydrogen and the other is selected from: R1, OR1, or NR3R4;
or, J and G, taken together with the carbon atom to which they are attached, are selected from: C=O, C=NR1, C=NOR1, C=NO(CH2)m R1, C=NNHR1, C=NNHCOR1, C=NNHCONR1R2, C=NNHS(O)n R1, or C=N-N=CHR1;
L is selected from the group consisting of: hydrogen, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group;
M is R1;
W is NR3R4;
Z is hydrogen, alkyl or halogen;
R p is hydrogen, hydroxy protecting group or hydroxy prodrug group;
m is an integer; and n is 0, 1, or 2.
A is wherein:
Q' is N, CH or CF;
X1 is O, N, NR1, S, or CR5;
Y1 is O, N, NR1, S, CR5, or Se;
Z1 is O, N, NR1, S, or CR5;
R5 is independently selected from hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted heterocyclic group, NR3R4, OH, NHCOR1 or NHCONH2, and is preferably, NH2 or NHR1.
With the proviso that a compound of Formula I is not selected from the following compound where A, Q, and Z as defined below in the Table A.
or their racemates, enantiomers, regioisomers, salts, esters or prodrugs thereof, wherein X and Y are independently selected from the group consisting of: hydrogen, deuterium, halogen, R1, OR1, S(O)n R2, -NR1 C(O)R2, -NR1C(O)NR3R4, -NR1S(O)n R2, -C(O)NR3R4, and -NR3R4;
Each of R1 and R2 is independently selected from the group consisting of:
hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group;
Each of R3 and R4 is independently selected from the group consisting of:
hydrogen, acyl, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted, or unsubstituted heterocyclic group; or can be taken together with the nitrogen atom to which they are attached to form a substituted or unsubstituted heterocyclic or heteroaromatic ring;
or X and Y, taken together with the carbon atom to which they are attached, are selected from the group consisting of: CO, C=CHR1, C=NR1, C=NC(O)R1, C=NOR1, C=NO(CH2)m R1, C=NNHR1, C=NNHCOR1, C=NNHCONR1R2, C=NNHS(O)n R1, C N-N=CHR1, C=N-NO2, or C=N-ONO;
one of U or V is hydrogen and the other is independently selected from the group consisting of: R1, OR1, OC(O)R1, OC(O)NR3R4, S(O)n R1, or U and V, taken together with the carbon atom to which they are attached, are C=O;
one of J or G is hydrogen and the other is selected from: R1, OR1, or NR3R4;
or, J and G, taken together with the carbon atom to which they are attached, are selected from: C=O, C=NR1, C=NOR1, C=NO(CH2)m R1, C=NNHR1, C=NNHCOR1, C=NNHCONR1R2, C=NNHS(O)n R1, or C=N-N=CHR1;
L is selected from the group consisting of: hydrogen, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group;
M is R1;
W is NR3R4;
Z is hydrogen, alkyl or halogen;
R p is hydrogen, hydroxy protecting group or hydroxy prodrug group;
m is an integer; and n is 0, 1, or 2.
A is wherein:
Q' is N, CH or CF;
X1 is O, N, NR1, S, or CR5;
Y1 is O, N, NR1, S, CR5, or Se;
Z1 is O, N, NR1, S, or CR5;
R5 is independently selected from hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, a substituted or unsubstituted heterocyclic group, NR3R4, OH, NHCOR1 or NHCONH2, and is preferably, NH2 or NHR1.
With the proviso that a compound of Formula I is not selected from the following compound where A, Q, and Z as defined below in the Table A.
2. A compound of Claim 1 wherein A is:
wherein X1 and R5 are as previously defined in Claim 1.
wherein X1 and R5 are as previously defined in Claim 1.
3. A compound of Claim 1 wherein A is:
wherein X1 is O or S, and R5 is as previously defined in Claim 1.
wherein X1 is O or S, and R5 is as previously defined in Claim 1.
4. A compound of Claim 1 wherein A is:
wherein X1 is O or S, and R5 is as previously defined in Claim 1.
wherein X1 is O or S, and R5 is as previously defined in Claim 1.
5. A compound of Claim 1 wherein A is:
wherein R5 is as previously defined in Claim 1.
wherein R5 is as previously defined in Claim 1.
6. A compound of Claim 1 wherein A is:
7. A compound of Claim 1 wherein A is selected from the compounds shown in Table B.
8. A compound of Claim 1 having the Formula II:
wherein A, Q, and Z are as defined in Table C:
Table C
wherein A, Q, and Z are as defined in Table C:
Table C
9. A compound of Claim 1 having the Formula III:
wherein R p, U, V, X, Y, L, W and Z are as previously defined in Claim 1.
wherein R p, U, V, X, Y, L, W and Z are as previously defined in Claim 1.
10. A compound according to Claim 9 having the Formula IV:
wherein R p and Z are as previously defined in Claim 1.
wherein R p and Z are as previously defined in Claim 1.
11. A compound according to Claim 9 represented by Formula V:
wherein R p and Z as previously defined in Claim 1.
wherein R p and Z as previously defined in Claim 1.
12. A compound according to Claim 10 where R p is hydrogen and Z is hydrogen.
13. A compound according to Claim 11 where R p is hydrogen and Z is hydrogen.
14. A pharmaceutical composition comprising a compound of Claim 1 or a pharmaceutically acceptable salt, ester or prodrug thereof, in combination with a pharmaceutically acceptable carrier.
15. A method of treating a bacterial infection in a subject in need of such treatment comprising, administering to said subject a pharmaceutical composition of Claim 14.
16. A method of treating inflammation in a subject in need of such treatment comprising, administering to said subject a pharmaceutical composition of Claim 14.
17. A method of treating cystic fibrosis in a subject in need of such treatment comprising, administering to said subject a pharmaceutical composition of Claim 14.
18. A compound represented by Formula VI:
or any racemates, enantiomers, regioisomers, salts, esters, or prodrugs thereof wherein X, Y, L, W, and R p are as defined previously;
B is independently selected from hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group.
or any racemates, enantiomers, regioisomers, salts, esters, or prodrugs thereof wherein X, Y, L, W, and R p are as defined previously;
B is independently selected from hydrogen, acyl, silane, a substituted or unsubstituted, saturated or unsaturated aliphatic group, a substituted or unsubstituted, saturated or unsaturated alicyclic group, a substituted or unsubstituted aromatic group, a substituted or unsubstituted heteroaromatic group, or a substituted or unsubstituted heterocyclic group.
19. A compound according to Claim 18 represented by Formula VII:
where R p as previously defined in Claim 1.
where R p as previously defined in Claim 1.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US67767505P | 2005-05-04 | 2005-05-04 | |
US11/122,251 US20060252710A1 (en) | 2005-05-04 | 2005-05-04 | 6-11 Bridged oxime erythromycin derivatives |
US11/122,251 | 2005-05-04 | ||
US60/677,675 | 2005-05-04 | ||
PCT/US2006/016882 WO2006119313A2 (en) | 2005-05-04 | 2006-05-02 | 6-11 bridged oxime erythromycin derivatives |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2605295A1 true CA2605295A1 (en) | 2006-11-09 |
Family
ID=37308644
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002605295A Abandoned CA2605295A1 (en) | 2005-05-04 | 2006-05-02 | 6-11 bridged oxime erythromycin derivatives |
Country Status (8)
Country | Link |
---|---|
EP (1) | EP1885737A4 (en) |
JP (1) | JP2008540432A (en) |
AU (1) | AU2006242188A1 (en) |
BR (1) | BRPI0610477A2 (en) |
CA (1) | CA2605295A1 (en) |
MX (1) | MX2007013730A (en) |
TW (1) | TW200716143A (en) |
WO (1) | WO2006119313A2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018201076A2 (en) * | 2017-04-28 | 2018-11-01 | Macrolide Pharmaceuticals Inc. | Macrolides with modified desosamine sugars and uses thereof |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5780605A (en) * | 1997-09-08 | 1998-07-14 | Abbott Laboratories | 6,9-bridged erythromycin derivatives |
US7064110B2 (en) * | 2002-05-13 | 2006-06-20 | Enanta Pharmaceuticals, Inc. | 6-11 bicycle ketolide derivatives |
WO2003095466A1 (en) * | 2002-05-13 | 2003-11-20 | Enanta Pharmaceuticals, Inc. | 6,11 bicyclic erythromycin derivatives |
US6878691B2 (en) * | 2002-05-13 | 2005-04-12 | Enanta Pharmaceuticals, Inc. | 6-11 bicyclic ketolide derivatives |
CA2483678C (en) * | 2002-05-13 | 2010-01-12 | Enanta Pharmaceuticals, Inc. | 6-11 bicyclic ketolide derivatives |
-
2006
- 2006-05-02 MX MX2007013730A patent/MX2007013730A/en not_active Application Discontinuation
- 2006-05-02 EP EP06769971A patent/EP1885737A4/en not_active Withdrawn
- 2006-05-02 WO PCT/US2006/016882 patent/WO2006119313A2/en active Application Filing
- 2006-05-02 JP JP2008510145A patent/JP2008540432A/en active Pending
- 2006-05-02 AU AU2006242188A patent/AU2006242188A1/en not_active Abandoned
- 2006-05-02 CA CA002605295A patent/CA2605295A1/en not_active Abandoned
- 2006-05-02 BR BRPI0610477-0A patent/BRPI0610477A2/en not_active IP Right Cessation
- 2006-05-04 TW TW095115885A patent/TW200716143A/en unknown
Also Published As
Publication number | Publication date |
---|---|
EP1885737A2 (en) | 2008-02-13 |
AU2006242188A1 (en) | 2006-11-09 |
TW200716143A (en) | 2007-05-01 |
JP2008540432A (en) | 2008-11-20 |
MX2007013730A (en) | 2008-01-28 |
WO2006119313A3 (en) | 2007-02-22 |
EP1885737A4 (en) | 2010-11-24 |
WO2006119313A2 (en) | 2006-11-09 |
BRPI0610477A2 (en) | 2010-06-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7384922B2 (en) | 6-11 bridged oxime erythromycin derivatives | |
US7265094B2 (en) | 9N-substituted 6-11 bicyclic erythromycin derivatives | |
US20090209547A1 (en) | C-8 halogenated macrolides | |
US8354383B2 (en) | 6,11-bridged biaryl macrolides | |
US20060252710A1 (en) | 6-11 Bridged oxime erythromycin derivatives | |
EP2203435B1 (en) | 6, 11-bridged biaryl macrolides | |
US7291602B2 (en) | 11,12-lactone bicyclolides | |
US7589067B2 (en) | 6, 11-bridged tricyclic macrolides | |
US7312201B2 (en) | Tetracyclic bicyclolides | |
US7414030B2 (en) | 6-11 Bicyclic erythromycin derivatives | |
US20080027012A1 (en) | Bridged carbamate macrolides | |
US7517859B2 (en) | Spirocyclic bicyclolides | |
US6953782B2 (en) | 11-C-substituted erythromycin derivatives | |
US7622452B2 (en) | C-9 alkenylidine bridged macrolides | |
US7407942B2 (en) | 3,6-bridged 9,12-oxolides | |
CA2605295A1 (en) | 6-11 bridged oxime erythromycin derivatives | |
US20080039406A1 (en) | 3,6-bridged tylosin derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
EEER | Examination request | ||
FZDE | Dead |